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Chapter 1 
Introduction 
Two to six percent of all newborn children have a disorder with a genetic cause (1-3). 
For an increasing number of these diseases, the precise genetic cause is known and 
this can lead to new treatment opportunities (see Appendix A for a basic description 
of the mechanisms of genetic inheritance). However, for most disorders total cure is 
not yet possible. For example, complications in patients with cystic fibrosis can be 
reduced by intensive treatment, but many patients will still die of lung problems 
caused by the disease. For diseases for which cure is not yet possible genetic 
screening might be a (temporary) solution. For example, a genetic screening 
programme in most Western countries is the offer of amniocentesis to pregnant 
women of a specified age (36 years and older in The Netherlands) to detect Down 
syndrome. Women in whom a foetus with Down syndrome is detected can then 
decide to prepare for the birth of an affected child or to avoid its birth by induced 
abortion. A list with examples of tests to detect disorders with a genetic cause or 
component currently offered in The Netherlands is given in Table 1.1. Because of the 
increasing number of genetic diseases that can be detected early, this list will 
probably continue to be extended. 
Table 1.1 Examples of testing for hereditary disorders and risk factors (source: 
Health Council of The Netherlands (4)) 
Disease 
Rhesus haemolytic disease 
Diabetes mellitus 
Down syndrome, neural tube defects or other 
chromosome abnormalities 
Trombocytes blood group 
Carriership of balanced chromosome abnormalities, 
sex-linked diseases or recessive hereditary diseases 
Haemoglobinopathies Of sickle cell disease 
Congenital malformations and neural tube defects 
Phenylketonuria IPKT) and congenital 
hypothyroidism ICHn 
Down syndrome and other chromosomal 
abnormalities 
Carriers hip of balanced chromosome abnormalities, 
sex-linked diseases or recessive hereditary diseases 
Fragile X syndrome 
Target 9roup 
All pregnant women 
All pregnant women 
Pregnant women, demand of the woman 
Pregnant women, on indication 
Pregnant women, on indication 
Certain ethnic groups of pregnant women 
Most pregnant women 
All neonates 
Pregnant women of36 yeats and older 
Women prior to conception, on indication 
Mentally handicapped individuals 
Screening test 
Serological 
Biochemical 
Serum screening (triple test) 
Serological 
Cytogenetic, biochemical, 
DNA testing 
Hb electrophoresis 
Ultrasound 
Biochemical, on heel prick 
Chorionic villus sampling, 
amniocentesis 
Cytogenetic, biochemical, 
DNA testing 
DNA testing 
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Among the diseases for which general population carrier screening is under 
discussion at the moment are cystic fibrosis, one of the most frequent autosomal 
recessive disease with physical problems in Caucasian populations, and fragile X 
syndrome, the most common cause of mental retardation from a single gene defect. 
Screening for carriers of these two diseases is the subject of this thesis. For a 
description of the diseases, see Chapter 2 (cystic fibrosis) and Chapter 6 (fragile X 
syndrome). 
1.1 Screening and test properties 
Screening is the process of sorting out which apparently healthy persons (probably) 
have a given disease or risk factor from those who (probably) do not have the disease 
or risk factor. Its direct purpose thus is to divide the target population into a high-risk 
group (people with a positive test result) and a low-risk group (people with a negative 
test result). The high-risk group is offered a so-called diagnostic test that will 
demonstrate the presence of the disease ('true-positive screening test result') or 
absence of the disease ('false-positive screening test result'). 
The quality of the screening test is described by the terms sensitivity, specificity and 
predictive value (Table 1.2) (5). Sensitivity (or true-positive rate) is the probability that a 
person with the disease will have a positive test result; specificity (or true-negative 
rate) is the probability that a person without the disease will have a negative test 
result. A test is perfect if both sensitivity and specificity are 100 percent. The predictive 
value is the probability that a positive or negative test result turns out to be correct. 
For example, the predictive value of a positive test result gives the probability that a 
person has the disease if he or she has a positive test result. Predictive values do not 
only depend on the sensitivity and specificity of the screening test, but also on the 
prevalence of the disease: if the prevalence of the disease increases, the predictive 
value of a positive test increases and the predictive value of a negative test result 
decreases (5). 
Table 1.2 Classification of screening test results 
Test positive 
Test negative 
Tot,1 
Disorder present Disorder absent Total 
TP (true-positive) FP (f,lse-positive) TP+FP 
FN (false-negative) TN (true-negative) FN+TN 
TP+FN FP+TN TP+FN+FP+TN 
Sensitivity - TP I (TP+FN) 
Specificity ~ TN I (FP+TN) 
Predictive value of a positive test result ~ TP I (TP+FP) 
Predictive value of a negative test result ~ TN I (TN+FN) 
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From a technical point of view most genetic tests only have a very small probability of 
giving an error in the test result. This would mean that if these tests are used for 
screening, the sensitivity and specificity of the screening are almost 100 percent. 
However, many tests can only detect one or a few specific mutations in a gene, while 
several diseases are caused by more than one mutation. For example, cystic fibrosis 
can be caused by hundreds of mutations in one gene (see Chapter 2). This would 
mean that many tests should be performed to detect all these mutations (some of 
which have been detected in only one patient until now) which would make 
screening prohibitively expensive. For this reason, cystic fibrosis screening is aimed at 
the most frequent mutations (for example those few mutations that together already 
account for over 90% of CF cases) so that the sensitivity of screening for cases will not 
be 100%, but only 90%. Fragile X syndrome on the other hand is mostly caused by one 
mutation in a gene, and could therefore have an almost perfect screening test. 
However, in this disease the inheritance pattern from parent to child is peculiar 
(Chapter 6) which leads to a trade-off that has to be made between having a high 
sensitivity or high specificity. For Down syndrome (described in Appendix C) the 
screening test in The Netherlands currently is the age of the mother, since the risk of 
having a foetus with Down syndrome rises with age. Pregnant women of 36 years and 
older (approximately 9% of all pregnant women) are offered prenatal diagnosis. Since 
35% of Down syndrome patients are born to mothers of 36 years or older, screening 
will at most detect 35% of Down syndrome pregnancies (=sensitivity). On the other 
hand, since most women of 36 years and older will have a child without Down 
syndrome, 9% of the women have a false-positive screening test. For this reason, 
serum screening by the triple test is performed in some parts in The Netherlands if the 
woman asks for it. As shown in Appendix C, this screening test has a sensitivity of 67% 
and only 5% of the women will have a false-positive test result. 
1.2 Types of (genetic) screening 
In contrast to what the name suggests, almost no general population screening 
programme tests every member of the population, as for almost all screening 
programmes it is possible to define a group with higher-than-average risk. For 
example, screening for breast cancer is not offered to men and to women at a young 
age because they are at (very) low risk. Screening can be offered standalone (e.g. 
breast cancer screening) or in the form of multiphasic screening where a variety of 
screening tests is used for a variety of diseases on the same occasion (e.g. an annual 
-5-
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Figure 1.1 Points in time where genetic screening can take place 
health check-up or the first visit in pregnancy). The advantage of multiphasic 
screening obviously is that an efficiency effect can be attained when a person is 
screened for several diseases at once and that the woman/couple is bothered only 
one time with screening; the disadvantage is that good information should be given 
to an individual for several diseases and for several screening tests at the same time 
which may be difficult. Information should include the fact that a negative 
(multiphasic) test result does not guarantee a healthy child as people are more 
inclined to think that they will have a healthy child if they are tested negatively for a 
large number for diseases. 
Screening for genetic diseases may take place at various points of time in life (6-8). 
The main points of time are described for cystic fibrosis in Figure 1.1 and are described 
more extenSively in AppendiX B. As this thesis only deals with reproductive screening, 
screening in later life is not considered. There is consensus that an advantage of 
screening prior to pregnancy (preconceptional screening) over screening during 
pregnancy (prenatal screening) is that people have a choice not to conceive children 
after an unfavourable test result. And if they decide to have children, they have more 
time to consider if they want to have prenatal diagnosis, and this may lead to less 
anxiety (9, 10). Furthermore, they can decide to become pregnant by means of 
artificial insemination with donor sperm, egg cell donation or to have pre-
implantation genetic diagnosis. Because it is difficult to reach people who are not yet 
pregnant, a preconceptional consultation centre has been proposed as a new health 
service provision where indiViduals or couples can go to for all questions regarding 
reproduction (11). Alternatively, couples with a child wish can consult their general 
practitioner. 
Specific to genetic diseases is the possibility to test relatives and offspring of detected 
patients and carriers (cascade testing). The advantage of this type of screening is that 
- 6-
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the relatives or offspring of the so-called index case are at much higher-than-average 
risk of having the disease. Furthermore, when they have a relative with the disease, 
they are more or less familiar with the disease. Therefore, they can possibly make a 
better-informed choice concerning screening and reproduction than individuals in 
the general population. A disadvantage of cascade testing is that only relatives of an 
index case are offered screening. Since many children with a genetic disease are born 
in families where the disease has not yet occurred, the parents of these children will 
not have the possibility to have screening. 
1.3 Is genetic screening indicated? 
Genetic (and non-genetic) screening programmes will also have negative effects. For 
example, for each detected disease case (true-positive case) several people without 
the disease will also have a positive screening test result (false-positive cases), at least 
when the specificity of the screening test is less than 100%. All positive cases will 
however have a diagnostic test that in general can cause adverse effects, such as 
miscarriage after prenatal diagnosis. The World Health Organisation has issued ten 
criteria that have to be fulfilled in a screening programme in general (Table 1.3). 
They had especially screening for chronic diseases in mind. However, there are also 
some problems specific to genetic screening. The main difference is that in a genetic 
screening programme aimed at reproduction the screened individual (mostly the 
mother or mother-to-be) is not the individual where the disease will occur (the child 
or child-to-be). Furthermore, genetic screening may also have repercussions for the 
other sibs, the partner and the family members of the screened individual. They can 
Table 1.3 WHO guidelines for screening programmes (source: Wilson and 
Jungner (13)) 
1. The condition sought should be an important health problem 
2. There should be an accepted treatment for patients with recognised disease 
3. Facilities for diagnosis and treatment should be available 
4. There should be a recognisable latent or early symptomatic stage 
5. There should be a suitable test or examination 
6. The telt should be acceptable to the population 
7, The natural history of the condition, including development from latent to declared disease, should be adequately 
understood 
8, There should be an agreed policy on whom to treat as patients 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) shou!d be economically balanced in 
relation to possible expenditure on medical care as a whole 
10. Case-finding should be a continuing process and not a 'once and for all' project 
-7-
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also be affected by the genetic disease or they can be carrier of the disease, and 
perhaps they would have liked not to know it (12). Therefore genetic screening has to 
be dealt with great care. The Dutch State Secretary for Welfare, Health and Cultural 
Affairs requested a report from the Health Council of The Netherlands regarding 
genetic screening. In this report the Health Council described twelve criteria that have 
to be fulfilled before screening is carried out (4). 
1.4 Criteria for genetic screening of the Health Council of 
The Netherlands 
This section lists the criteria of the Health Council Committee in their 1994 report (4) 
and gives a short explanation. 
1. The genetic screening programme must concern a health problem or a condition that 
can lead to a health problem in those being tested, or in their descendants. Unlike the 
WHO guidelines for screening programmes in general, the Health Council 
Committee deliberately avoided stating that screening should focus on important 
public health problems only. This implies that a quantitatively less important 
public health problem that can be detected and treated with simple and harmless 
methods (e.g. PKU) can be screened for using these criteria. 
2. The target population of the screening programme must be clearly defined. The 
identity of the target group must be known before the acceptability and 
desirability of the screening programme can be assessed. 
3. The screening programme should enable participants to become aware of the 
presence or risk of a disorder or carrier status, and to take a decision based on tiwt 
information. This is the primary aim of (genetic) screening. Other potential 
consequences of screening, such as reducing health care costs, will only be 
secondary aims. 
4. Practical courses of action must be open to the participants. For many genetic 
diseases, the 'practical course of action' will primarily be a choice between 
continuation and termination of pregnancy. If an individual with a high-risk 
screening test result does not want any course of action, he/she should generally 
be advised not to have a risky confirmatory test. For example, individuals/couples 
who know in advance that they will not decide for termination of pregnancy 
should be advised not to have invasive prenatal diagnosis since it carries an 
iatrogenic abortion risk (unless the mere knowledge of the disease status of the 
child offsets this risk to them). 
-8-
Introduction 
5. Participation in the genetic screening programme should be voluntary and 
conditional on consent based on good information. This criterion goes without 
comment. 
6. The target group should be supplied witll accurote, comprehensible information. 
Accurate, comprehensible information forms the basis of voluntary consent 
described in the previous criterion. 
7. A test method should be available which is suited to the objective of the screening. 
This criterion also goes without comment. 
8. There should be sufficient facilities for follow-up diagnostics, for carrying out the 
chosen courses of action and for informing and supporting the participants. It is 
evident that there should be sufficient health care facilities. Furthermore, all 
options must be legally allowed, e.g. termination of pregnancy is only allowed 
before 22-24 weeks of pregnancy in The Netherlands. 
9. The procedures used for the storage of medical information alld cellular material must 
incorporate adequate measures to protect both tile personal privacy of the 
participants and their rights regarding their personal data and cellular material. 
Screening programmes have to comply with legal standards such as the Data 
Protection Act (WPR). The procedures to be followed for using body material are 
described in another Health Council report (14). 
10. If scientific research is carried out within the framework of screening, the participants 
should be properly informed about this in advance. Screening is subject to the 
Medical Experiments Bill (WME). 
11. Provision should be made for continuous quality assurance of the effectiveness, 
efficiency and safety of the test procedure and all follow-up procedures, as well as 
information and support given to the participants. Every screening programme 
should always have the best test and the best information possible. However, 
because of the rapid pace of science in genetics this is even more important for 
genetic screening. 
12. The benefits for the participants in the programme should outweigh the 
disadvantages. To support this evaluation, those proposing a screening programme 
must provide information about: 
a. The prevalence of the disease or disorder in the target group. This item goes without 
comment. 
-9-
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b. The natural course of the disorder, and the variation in degrees of severity. The 
information about the natural course of the disorder should contain data about 
average life expectancy, nature and severity of the complications, treatment 
options and the probability of physical or mental handicap. For prenatal screening 
and diagnosis, the information should include the risks of spontaneous abortion 
and foetal death. 
c. The target group and the considerations which led to the choice of the proposed 
target group and the proposed time of testing. In criterion 2 the proposed target 
group is already discussed. In this weighing item, all possible alternatives should 
be given including advantages and disadvantages. If a screening programme 
involves minors, consideration should be given to the question whether 
screening can be postponed to the age where they can decide for themselves. 
d. The specificity, sensitivity and predictive value of the test method and the burden 
which testing imposes on participants. As for all screening programmes, the 
probability of having a true positive or true negative result should be weighed 
against the probability of false positive and false negative results. 
e. The available courses of action if a health problem or carrier status is revealed. This 
item is obviously linked to criterion 4. 
f. The time allowed by the procedure for consideration and possible implementation of 
the selected course of action. The more drastic the courses of action and the more 
latitude for consideration of these options required by the test result, the more 
time should be allowed for choosing the course of action. 
g. The possible psychological, social and other repercussions (both positive and 
negative) of an offer and of participation or non-participation in the screening for the 
person to be tested and for members of their family or for groups within the 
community. The screening offer itself will lead to questions and anxiety for the 
individual, since he/she will be 'forced' to think about the disease. A point of 
concern is the imperative character of the screening offer, where some individuals 
feel themselves forced to accept a screening offer (15). 
h. The likelihood of erroneous results and their possible consequences for participants, 
and the measures taken to limit any harm which such an error might cause. This item 
deals with so-called good practice. 
i. The safeguards for participants against unjustified impediments (as a result of their 
participation or non-participation in the screening programme or follow-up testing) 
to obtain employment or private insurance cover. This item speaks for itself. 
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j. The costs of the screening and of the necessary infrastructure. The considerations of 
the benefits and drawbacks of the above criteria must reveal a clear benefit to the 
participants. If this condition is fulfilled, the costs and savings of the screening 
programme should be assessed to see whether the programme can be justified 
within total health care. 
To see whether the criteria were practical in real life, we performed an assessment of 
the criteria for serum screening for Down syndrome (16). Although this thesis 
primarily concerns screening for cystic fibrosis and/or fragile X syndrome, the 
assessment is presented in Appendix C for illustrative purposes. 
1.5 Economic evaluation 
1.5.1 Types of economic analysis 
The basic economic evaluation is cost analysis. This analysis only takes the costs and 
the induced (economic) savings of the screening programme into account, and can 
therefore be described as a partial form of economic appraisal. In cost-effectiveness 
analysis, the costs of the programme as calculated in a cost analysis are linked to the 
consequences ('effects') of the screening programme. These effects are measured in 
natural or physical units, for example the number of detected people with the disease, 
the number of life-years that are gained as a result of early diagnosis, or the number of 
detected carrier couples. In cost-utility analysis, the effects of the screening 
programme are valued using utility, a measure for the relative preference of an 
individual or group for given health outcomes. The most commonly used measure for 
this type of analysis is costs per quality adjusted life year (QALY) gained. Cost-utility 
analysis is usually performed when programmes target at diseases that do not (only) 
cause mortality but also morbidity, or if the screening programme is aimed to prevent 
mortality but at the expense of some morbidity. For example, screening for prostate 
cancer may possibly prevent mortality, but the treatment of prostate cancer (radical 
prostatectomy) can cause impotence or incontinence, which will influence the quality 
of life. The last type of analysis, cost-benefit analYSiS, is the most radical economic type 
of analysis. In this analysis the effects of the screening programme are valued in 
money terms. It is obvious that valuing effects is very hard and for some effects, e.g. 
knowing earlier of having a certain disease, it may be nearly impossible (but hard-core 
economists will try to reveal your values by asking what you are prepared to pay for 
this earlier knowledge). 
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1.5.2 Points of view 
Some screening programmes will lead to costs for one person or institution, but to 
benefits for others. For example, a screening programme that is financed by the 
Ministry of Health can lead to a smaller number of patients with a disease with 
corresponding lower costs to for example the insurers. Therefore, it is important to 
determine in advance the point of view of an economic analysis. The points of view 
can include (from narrowest to broadest) patients, employers, the provider of the 
screening programme, the Ministry of Health, government and/or society. For most 
screening programmes the societal point of view is the most relevant because 
screening has implications on many sectors in society. Costs in the societal point of 
view do not automatically coincide with the charges and fees paid by the health care 
system. Most of these charges and fees are bargained prices that only have a remote 
relationship with the true costs. These costs, therefore, have to be estimated in a 
different way, namely by measuring each party's investments in manpower, 
equipment and supplies with relevant wages and prices. The resulting costs will differ 
from estimates based on the financial point of view of which the accounts of health 
insurance companies are typical. In that case commercial prices are used, including 
transfer payments such as profits, margins, value-added taxes and royalties. 
1.5.3 Discounting 
Costs and savings of a screening programme will not all occur at the same point in 
time. For example, costs of the screening test(s) itself (occurring at the start of the 
screening) form the largest part of the costs, while a large part of the savings are 
caused by future treatments of the disease which are not needed anymore. 
Furthermore, screening for the same disease can have different target populations 
(pregnant women, couples with a child wish, school children) which lead to different 
time profiles. It is generally accepted that earning an amount of money (EURO or 
Guilder or Dollar) today is preferred over earning the same amount next year because 
it can be put on a bank account where it will 'grow' because of interest. This concept is 
called time preference in economics. For example, if the 'real' interest rate (the 
interest without inflation) is 3% an amount of 1,000 will grow to 1,000 + 1,000 * 3% = 
1,030 in one year. Reversely, the amount of 1,030 of next year can be regarded as 
equivalent to an amount of 1,000 in this year, provided the interest rate is 3%. The 
interest rate in the reverse reasoning is called discount rate and the amounts obtained 
by applying discount rates to future costs and savings are called present values. 
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Among health economists, the rate with which to discount costs is one of the most 
controversial issues at the moment. The most widely used discount rates (which are 
both used in this thesis) are 3% and 5%, but recommendations range from 0% to 10%. 
The most recent and authoritative recommendations are given by a working party 
convened by the US Public Health Service (17-19) and by a working party for the 
British Medical Journal (20). The American party (19) recommends a discount rate of 
3%, but a 5% rate should also be given for at least the next 10 years. The British party 
(20) only indicates that "at present most recommendations seem to vary between 3% 
and 6%, and a common rate in the literature is 5% per year", and emphasises that the 
discount rate should be stated and justified. 
Both working parties recommend discounting health effects and costs by the same 
rate, but the British party adds the suggestion to discount health effects with a lower 
rate for preventive (screening) programmes because the results of some studies seem 
to suggest it (21). Usually, the costs and benefits of a health care programme cover 
the same target population. In an intergenerational setting like genetic screening 
additional arguments apply, and we therefore decided not to discount effects (see 
also Chapter 10, General discussion). 
1.6 The thesis 
This thesis addresses the final criterion of the Health Council report by giving an 
assessment of the effects of screening programmes for carriers of the cystic fibrosis 
gene and/or the fragile X syndrome gene, of the (balance between) costs and savings 
of these screening programmes, and of the cost-effectiveness of these screening 
programmes. The ratio behind first assessing effects and costs of screening 
programmes before assessing the more important other criteria is that screening 
programmes will probably not be introduced in present times anyway if the economic 
balance will be very unfavourable. On the other hand, with a favourable economic 
balance, the decision whether or not to introduce screening will depend on other 
criteria without worry that economic considerations could stop an otherwise 
favourable screening programme. 
The second part of the thesis concerns cystic fibrosis and starts with an introduction of 
the disease and screening. In the two following chapters, both the non hospital costs 
of care and the age-specific and lifetime costs of care of cystic fibrosis are described. 
The part ends with a cost-effectiveness analysis of screening for cystic fibrosis-gene 
carriers. In the next part the disease fragile X syndrome and screening for fragile X 
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syndrome carriers are introduced first, followed by a cost-effectiveness analysis of 
screening for fragile X syndrome carriership. The last chapter of this part describes and 
uses a theoretical simulation model for cascade testing in order to explore its 
effectiveness. A multiphasic screening model is introduced in the last part of this 
thesis, where a combination of screening for cystic fibrosis and fragile X syndrome 
carriers is described. 
For comparison purposes all amounts of money are converted to the new European 
currency EURO (€), where €1.00 is equal to 2.20371 Dutch Guilders, 0.671 Pounds 
Sterling and 1.111 American Dollars. 
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Cystic fibrosis 
I 
I 
2.1 Introduction 
Chapter 2 
Cystic fibrosis 
Cystic fibrosis (CF) was first described in the medical literature in the 1930s (1, 2), and 
turned out to be inherited in an autosomal recessive pattern. In 1985, the CF gene was 
localised on chromosome 7 (3, 4). The cloning of the cystic fibrosis gene in 1989 (5) 
and the development of simple technical methods for the detection of the more 
prevalent mutations (6, 7) have made it possible to test for carriers in the general 
population. 
2.2 The disorder 
Cystic fibrosis is a disease with recurrent pneumonia, disturbances of the digestive 
tract, high sweat sodium concentration, malnutrition and obstructive azoospermia 
(8,9). The disease has a great impact on the length and quality of life and requires a 
relatively high amount of medical care. Care of patients with CF is not only intensive, 
but demands support from relatives, friends, colleagues etc. and interferes with the 
normal daily life both of the patient and relatives. 
Meconium ileus occurs in 10% to 20% of newborns with CF and may be the earliest 
clinical manifestation of the condition (8, 10). Most patients with CF need daily 
physiotherapy and repeated courses of antibiotics to treat pulmonary infections. The 
digestive problem usually results in underweight in children who require a high-
energy diet, with 50% more food than the average child their age. Another 
characteristic of patients with CF is their reduced fertility (11). Although male infertility 
caused by CF is generally recognised, reduced fertility is also characteristic of women 
with CF (11, 12). 
There have been considerable advances in the medical care of individuals with CF, 
including recombinant human DNase that reduces the viscosity of purulent airway 
secretions, heart-lung transplantation, and home therapy (9, 13-17). Current research 
in gene therapy may soon progress to the point of widespread clinical use. This 
progress in treatment will obviously have an impact on the length and quality of a 
patient's life, and will probably have a major influence on the use and type of home 
care. Despite the progress made in clinical management during the last three decades 
- 19-
Chapter 2 
100% 
90% 
80~b - ---------------------~ .. _._~_;~--- ___ ~"__,o_---- ___________________ _ 
'.... .. '. 
70% 
1 60% 
.~ 50%-1 40% 
.. .. ... '. - ... 
- - ~ -------- - - - ------- - - - -'-------- - -'-':::,- ----- ~ ".-.-.-------- - - - ---
" 
--- ____________________________________ ~r~---. 
. . , 
----~':...~.-------
' . 
'. - "-
..... 
--- --- - - - ------- - - - - ----- - - - - ------ - - - ------- - - - .... -.----
-. , 
- - - --
- - - -- - - - - _. - - ----- - - - - ----- - - - - - --- -- - - - - --- -- - - _.- - ---- -_.! •.•• 
-. 
30~6 -------------- ------------------- -------- ------ -- ------
20%·· ...........................................•.......•......... 
10% 
0% .~, .~~~.~~~~ 
o 10 15 20 25 
Age (years) 
30 
Figure 2.1 Survival curve of patients with cystic fibrosis (source: Collee et al. (18j) 
it remains, in most patients, a disease with a limited life expectancy (Figure 2.1). In The 
Netherlands the median cross·sectional survival was 27 years in the period 1985·1990 
(18). Because of likely future improvement in treatment, the real life expectancy for 
children that are born now may be well over 30 years. 
2.3 Genetics 
Cystic fibrosis is one of the most common recessively inherited disorders in Caucasian 
populations. In 1989 the gene that is defective in people with cystic fibrosis was 
discovered (5, 6, 19). This so·called cystic fibrosis transmembrane conductance 
regulator (CFTR) gene codes for a protein that regulates a low·conductance chloride 
channel (20). Many, although not all, of the clinical manifestations of the disease can 
be explained by the lack of this function. Soon after the CF gene was cloned, it was 
realised that screening for carriers would be possible through direct mutation 
detection. 
Since 1989, many different mutations in the CFTR gene have been discovered, and 
some of them have been detected in only one family. Currently more than 
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750 mutations have been identified (CF Genetic Analysis Consortium, 
http://www.genet.sickkids.on.ca/cftr/FuIiTable.html). the most common of which is 
the 6F508 mutation, a three-base deletion in the gene. This mutation, together with a 
further 6-10 non-6F508 mutated genes, account for more than half of the population 
variation in CF mutations worldwide (Table 2.1). Remarkable is the relatively high 
frequency of the A455E mutation in The Netherlands. This mutation is associated with 
a mild form of CF if this mutation is present in one of the two copies of the CF gene 
(21 ). 
Affected individuals have a CFIR gene mutation on both chromosomes number 7, but 
in carriers, who are not affected by the disorder and are healthy, there is only one 
CFIR gene mutation present. Couples in which both partners are carriers have a 1 in 4 
risk with each pregnancy of having an affected child. 
2.4 Prevalence 
As in many genetic conditions, the diagnosis of an infant with CF often is the first clue 
that the genetic trait exists in the family. In fact, more than 80% of individuals with CF 
are born to families with no previous history of the illness (23). 
The birth prevalence of CF in The Netherlands is 1 in 3,600 (24). This means that in The 
Netherlands each year approximately 50 children are born with CF, and the total 
number of patients in The Netherlands is about 1,000. Since the disorder is autosomal 
recessive, the carrier frequency in The Netherlands is 1 in 30 (24, 25). There are 
suggestions that the high frequency of carriers reflects past or present genetic 
Table 2.1 Most frequent mutations in the CFTR-gene (source: CF Genetic Analysis 
Consortium (22) and Halley et al. (21)) 
LlF508 
A455E 
G542X 
1717-1G->A 
R553X 
R1162X 
N1303K 
S1251N 
E60X 
W1282X 
G5510 
Some other mutations 
10tal 
NL North Europe North Amenc. World 
73.6% 
3.5% 
2.09'0 
1.89'0 
1.2% 
1.1% 
1.0% 
1.0% 
1.0% 
0.5% 
0.1% 
2,0% 
88.8% 
70.3% 
0.2% 
2.1% 
0.8% 
0.8% 
0.2% 
1.0% 
not given 
not given 
0.6% 
1.7% 
2,8% 
80.2% 
66.1% 66,0% 
0.3% 0.1% 
2.29'0 2.4% 
0.4% 0.6% 
0.9% 0.7% 
0.2% 0.3% 
1.2% 1.3% 
not given not given 
not given not given 
23% 1.2% 
2.0% 1.6% 
4.2% 2.9% 
79.9% 77.3% 
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advantage (26, 27), for example the gene may protect against cholera or typhoid fever 
which were major killers in the past (27, 28). 
The prevalence of CF carrier status varies widely across different racial and ethnic 
groups, being very common among people in Northern Ireland (carrier prevalence 
1 in 21 and birth prevalence 1 in 1,807) and relatively rare among Orientals (carrier 
prevalence 1 in 150 and birth prevalence 1 in 90,000) (29,30). The carrier prevalence in 
the United States and the United Kingdom is about 1 in 25. 
2.5 Screening and screening test 
2.5.1 Carrier screening 
CFTR mutations can be detected by molecular analysis on material obtained by a 
blood sample, mouthwash or bloods pot (31). Taking a blood sample is the most 
obvious procedure, but medical supervision is necessary when taking the sample. 
With the mouthwash procedure there is no need for medical supervision of sample 
collection and the risk of infection is eliminated. The molecular analysis on material 
obtained by a mouthwash has theoretically an almost perfect sensitivity and 
specificity, apart from laboratory errors (31). This relatively simple detection of CFTR 
mutations makes it possible to consider introducing a screening programme for 
carriers of the cystic fibrosis gene, where the primary aim is to assess carrier status and 
counsel couples whose members are both carrier of a CF gene mutation (32, 33). 
These couples can then be offered further diagnostic possibilities such as prenatal 
diagnosis by chorionic villus sampling or amniocentesis. 
Because of the large number of mutations in the CFTR gene it is not feasible to test all 
individuals for all possible mutations. However, if individuals are tested with a panel of 
probes consisting of the mutations from Table 2.1, 87.3% of the carriers and 76.2% 
(87.3% of 87.3%) of the carrier couples can be detected in The Netherlands. Because of 
the imperfect test sensitivity, couples with one test-positive and one test-negative 
partner have an (increased) risk of 1 in 917 of having an affected child, compared to a 
1 in 3,600 baseline risk. However, these individuals cannot be offered prenatal 
diagnosis. 
Several screening strategies have been suggested (34-37). Of these, prenatal, 
preconceptional, school and neonatal screening can be considered for general 
population screening. For prenatal and preconceptional carrier screening, several 
strategies and definitions exist, and these can be distinguished with regard to the 
testing process and the information process (34, 38-40). Among the strategies are 
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stepwise screening, where one partner (usually the woman) is screened first, and only 
the partners of those found to be carriers will be offered screening. One disadvantage 
of the approach is that it generates anxiety in women identified as carriers. However, 
this anxiety appears to be short-lived and disappears among women whose partners 
test negative (41). In stepwise screening, three test outcomes are possible: both 
partners are test-positive (++ couples), one partner is test-positive and the other test-
negative (+- couples), and one partner is test-negative and the other is not tested 
(-? couples). Another strategy is couple screening, where the couple is treated as an 
entity. Both partners submit a sample simultaneously, and if both are identified as 
carriers the couple is designated as being at high risk and reported as positive. In 
contrast, couples in which one partner is tested positive and one negative are 
designated negative although their risk of an affected infant is higher than the prior 
risk for the general popUlation. One of the arguments for couple screening is that 
unnecessary anxiety can be avoided by identifying couples of mixed carrier status by 
simply treating all couples not at high risk as negative. This caused concern among 
geneticists as it was felt that the results of all genetic testing should be made available 
to those tested and not withheld (42). A compromise has been to make the results 
available on request rather than routinely. Early experience from pilot studies in The 
Netherlands shows that almost all couples want both partners to be tested and to 
obtain individual results (L. Henneman, personal communication). 
Since stepwise screening also aims at the couple, the terminology 'stepwise' and 
'couple' can be confusing. For this reason, the terms single-entry two-step (SETS) 
couple screening and double-entry two-step (DETS) couple screening have been 
proposed (Figure 2.2) (40). In these strategies both partners submit a sample. In 
single-entry two-step screening, one partner is tested first (first step) and if he/she is 
identified as a carrier the second partner is tested. The first partner is tested for the 
L'lF508 and other frequent mutations, while the second partner is tested for a larger 
number of less common mutations (second step). In double-entry two-step couple 
screening, both partners are tested for the L'lF508 and other frequent mutations (first 
step), and the test-negative partner of an identified carrier is tested for a larger 
number of less common mutations (second step). The advantage of DETS over SETS is 
that the remaining risk in couples with two negative partners (-- couples) in the DETS 
strategy is significantly lower than in couples with one test-negative partner and one 
individual that is not tested (-? couples) in the SETS strategy. On the other hand, 
approximately 5% of couples identified in the DETS approach will comprise one test 
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Figure 2.2 Single-entry two-step (SETS) screening and double-entry two-step 
(DETS) CF screening 
positive partner and one test negative partner, compared with 2.5% for single-entry 
two-step screening. For these couples, the risk is not reduced with the current test 
sensitivities, but is higher than the risk in the general population (see Appendix D). 
Several pilot studies of CF carrier screening have been reported and these are 
summarised according to screening strategy (Table 2.2-Table 2.3). Uptake is highest 
for prenatal screening (either stepwise or couple) with a weighted average of 
75 percent. The average uptake of preconceptional screening is 7-9% when 
individuals or couples are invited for screening, 38% and 76% respectively for 
opportunistically offered screening of individuals and couples. Uptake is influenced by 
the method of invitation to screening (opportunistic contact or written or other 
invitation) as well as the setting, with rates as low as 2% reported when the invitation 
is sent by post (43), compared with rates as high as 87% when screening is offered to 
visitors of a family clinic by committed researchers (44) (not shown in the table). Only 
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two studies have been performed using a school setting: uptake was 42% in the 
Canadian study, and 42% and 75% in two high schools in Australia (45,46), 
The most common reason to decline CF carrier screening was unwillingness to 
terminate an affected pregnancy (54, 58, 59), However, once the couple has 
consented to be screened, most affected pregnancies were terminated, The results of 
published prenatal screening studies show that, of the 13 high-risk couples with an 
affected foetus identified as a consequence of screening in early pregnancy, all but 
one chose to terminate that pregnancy, Data for preconceptional screening are not 
available, 
As said earlier, more than 80% of all CF cases are born to families without a history of 
the disease (23), Holloway and Brock calculated that 4-13% of all carriers in Scotland 
would be detected with a hypothetical cascade testing programme, which would 
result in 8-24% of all carrier couples detected (60,61), In contrast, more than 50% of 
carrier couples can be detected by prenatal screening (Appendix D) (40), Therefore, 
Brock (61) concluded that with regard to effectiveness cascade testing should only be 
discussed in combination with general population screening, 
Table 2,2 Summary of studies reporting prenatal screening for CF carriers 
FI~t author Plac. Populalion Number of Coverage Aff.cted Aff.ct.d %d.t.ct.d 
mupl.s (%population pregnancies pregnancies pregnancies 
screened scr.ened) detected tenninated tenninated 
Prenatal stepwise screening 
Harris (47) Manchester NA' t27 NA' 0 0 
Schwartz (48) Copenhagen 7,400 6,599 89% 100% 
Jung (49) Berlin 638 637 100% 100% 
Cuckle (50) York5hire 6,071 3,764 62% NA' NA' NA' 
Miedzybrodzka (51) Aberdeen 1,629 1,475 91% 0 0 
Brock (52) Edinburgh 6,030 4,978 83% 2 2 100% 
Doherty (53) Maine NA' 1,645 NA' 100% 
loader (54) Rochester 5,646 3,334 59% 0 0 
Witt (55) N. California 6,617 5,161 78% 0 0% 
Grody (56) los Angeles 4,739 3,192 67% 100% 
All prenatal stepwise studies 38,770 29,140 75% 7 6 86% 
Prenatal couple screening 
Harns (47) Manchester NA' 117 NA' 0 0 
Miedzybrodzka (51) Aberdeen 361 321 89% 0 0 
Wald (57) Oxford 810 543 67% 0 0 
Brock (52) Edinburgh 16,571 12,566 76% 6 6 100% 
All Erenatal coue1e studies 17,742 13,430 76% 6 6 100% 
'" "NA" means that data are not available; these are omitted in the calculation of totals 
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Table 2.3 Summary of studies reporting preconceptional screening for CF 
carriers 
flmauthor Place Population Number of (overage Method 
couples (% population 
screened ' screened) 
Preconceptional stepwise weening 
Bekker (62) london 3,951 234 6% Invitation 
Bekker (62) london 1,208 556 46% Opportunistic 
Tambor(63) Baltimore 2,713 101 4% Invitation 
Tambor(63) Baltimore 608 143 24% Opportunistic 
Payne (43) South Wales 739 166 22% Invitation 
Payne (43) South Wales 802 303 38% Opportunistic 
All preconceptional stepwise studies 7,403 501 7% Invitation 
All preconceptional stepwise studies 2,618 1,002 38% Opportunistic 
Preconceptional couple screening 
Watlon (44) SW Hertfordlhire 852 87 10% In~tation 
Watlon (44) SW Hertfordlhire 944 714 76% Opportuniltic 
Payne (43) South Wales 135 2 2% In~tation 
Payne (43) South Wales NA' 29 NA' Opportuniltic 
All preconceptional couple studies 987 89 9% Invitation 
All preconceptional couple studies 944 714 76% Opportunistic 
* ~NA" means that data are not available; these are omitted in the calculation of totals 
2.5.2 Neonatal patient screening 
In 1968, Schutt and Isles reported excessive albumin in the meconium of patients with 
meconium ileus due to CF (64). This made neonatal screening for cystic fibrosis 
patients a possibility (65, 66). In 1979 Crossley et al. reported that immunoreactive 
trypsin ORT) was raised in the serum of children with cystic fibrosis (67), Since neonatal 
screening using a dried blood-spot assay for IRT has a high sensitivity and because it 
was widely believed that an early diagnosis would improve outcome, neonatal 
screening programmes were developed in Europe, United States and Australia. The 
sensitivity of the IRT test (85.7%) and the specificity (99.8%) are improved by testing 
for the ~F508 mutation in high-risk bloodspots (sensitivity 95.2%, specificity 99.9%), 
but false positives are still possible (68), Therefore the diagnosis is confirmed by a 
sweat test (69). 
The rationale for neonatal screening to identify affected infants has been questioned. 
It has been argued that evidence is lacking that an early diagnosis will substantially 
improve outcome, While the findings of several studies have suggested that patients 
with CF who are diagnosed early, i.e. before the onset of clinical pulmonary 
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involvement, have a better prognosis than those whose diagnosis was made when 
pulmonary symptoms developed (70-78), all of these studies have some 
methodological problems. 
In an article in the New England Journal of Medicine regarding the only randomised 
controlled trial for neonatal screening so far, Farell et al. concluded that "neonatal 
screening provides the opportunity to prevent malnutrition in infants with cystic 
fibrosis" (79). This article led to an editorial in the same issue that concluded "The 
results of this new study provide further evidence that the time has come for routine 
neonatal screening for cystic fibrosis" (80). However, an editorial in the British Medical 
Journal remarked that there are some methodological issues and concluded that "the 
present evidence is not encouraging and does not warrant any change in policy from 
that suggested by the National Institutes of Health consensus statement (81)", that 
concluded that newborns should not be screened. 
Because the methodology of newborn patient screening is different from general 
population carrier screening, this thesis does not cover newborn patient screening. 
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Chapter 3 
The non hospital costs of care of patients with 
CF in The Netherlands: results of a 
questionnaire 
3.1 Introduction 
Cystic fibrosis (CF) is the most frequent serious autosomal recessive disease in 
Caucasian populations. Characteristics of CF are chronic bronchopulmonary 
infections, pancreatic insufficiency, disturbances of the digestive tract, and high 
sweat-sodium concentration. The birth prevalence of CF in The Netherlands is 1 in 
3,600 (1). This means that in The Netherlands each year approximately 50 children are 
born with CF. The total number of patients in The Netherlands is about 1,000. 
The disease has a great impact on the length and quality of life and consumes a 
relatively high amount of medical care. Treatment starts from the diagnosis and 
continues throughout life, and consists of prescribing additional calories and vitamins 
and fighting the respiratory infections with antibiotics and intensive physiotherapy. 
Care of patients with CF is not only intensive, but demands support from relatives, 
friends, colleagues etc. and interferes with the normal daily life both of the patient 
and relatives (2). 
In a previous study (see Chapter 4), the costs of medical care in the hospital were 
determined by reviewing the medical records of 81 patients (40 males and 41 females) 
of the Beatrix Children's Clinic of the University Hospital Groningen and the 
Leyenburg Hospital in The Hague for the years 1990 and 1991 (3). These hospital 
records contain mainly information regarding medical treatment and appointments, 
and lack data on medical costs outside the hospital, such as physiotherapy, visits to 
the general practitioner and home medication, as well as the costs of nonmedical 
(home) care, such as domestic help, diet, travelling because of CF and special facilities. 
The results of a questionnaire survey to determine these non hospital costs are 
described. 
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3.2 Patients and methods 
We developed a questionnaire containing items about nonhospital medical care, 
domestic help, diet, travelling because of CF, work/school, medication, and devices 
and special facilities at home, work or school. Nonhospital medical care was divided 
into care from general practitioner, physiotherapist and homeopath/acupuncturist. 
The questionnaires were supplied with a number so that a reminder could be sent if 
necessary; the list with numbers and names was destroyed immediately after the 
reminders were sent. 
From the Beatrix Children's Clinic of the University Hospital Groningen, 23 children 
were selected in such a way that all age categories were represented. In the 
Leyenburg Hospital, 50 adult nonterminal patients were selected. These patients or 
their guardian (for children) were asked to fill in the questionnaire on a daily basis for 
4 weeks in May 1993. The questionnaire was returned by 14 Groningen patients 
(average age 10 years; range 1-17 years) and 33 Leyenburg patients with an average 
age of 27 years (range 16-46 years) (Table 3.1). The total response was, therefore, 64% 
(47 out of 73). Data from one (adult) patient were 
not useful because this patient lived abroad. For 
validation purposes, six responding (parents of) 
patients, who had indicated they were willing to 
have a telephone interview, were telephoned and 
the questionnaire was talked through with them. It 
was concluded that the questionnaires were filled in 
carefully and meticulously. Because the 
questionnaire was anonymous, it could not be 
linked to the patient's records; therefore, it was not 
possible to stratify according to severity of disease. 
Table 3.1 Age distribution of 
responders to questionnaire 
Age (years) Responders 
04 ) 
5-9 2 
10-14 6 
15-19 10 
20·24 8 
25-29 6 
30-34 6 
35+ 5 
Total 46 
The average consumption per patient was calculated by dividing the total units 
consumed of that item by the number of respondents. The average costs per patient 
per year were calculated by multiplying the average consumption by 13 (correction 
for a 4 weekly questionnaire period) and mUltiplying this result with the unit costs. If 
possible, unit costs were determined on the basis of insurer allowances. If this was not 
possible, data from the report "Cost calculation in health service research; guidelines 
for practice" (4) were used. The source of financing was nottaken into account. 
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3.3 Results 
The average consumption per item and the costs of non hospital care per year for 
children and adults with CF are presented in Table 3.2 and Table 3.3, respectively. In 
these tables, ranges of consumption and costs are also shown, and the weighted 
average of the consumption and costs for an 'average' patient in The Netherlands, 
where 36% of the patients are adult (aged ~18 years) (J.M. Colfee, personal 
communication). 
Table 3.2 Consumption of non hospital care per year for patients with CF. Values 
are presented as average, and range in parenthesis 
Consumption per year 
Children Adults Weighted average' 
NonhospitaJ medical care 
General practitioner n 0.9 (0-13) 3.7 (0-26) 1.9 
Physiotherapist n 26.0 (0-91) 33.7 (0-260) 28.8 
Homeopath / acupuncturist n 0.9 (0-13) J.3 (0-52) 1.8 
Domestic help h 113 (0-1404) 148 (0-1248) 126 
Diet items for CF n 1.2 (0-3) 1.0 (0-3) 1.1 
Travelling because of CF 857 (120-3192) 4,194 (0-27774) 2,058 
Work, school, absence 
Job contract % total 57 
Part-time % employed 41 
Absence % contract hours 8 (0-65) 18 (0-25) 
Medication prescriptions n 5.6 (1-8) 8.7 (4-16) 6.7 
Pancreatic enzymes 1.1 (H) 0.8 (0-1) 1.0 
Pulmonary medicines 1.3 (0-3) 3.6 (0-7) 2.1 
Vitamins 2.1 (0-5) 1.7 (0·4) 1.9 
Oral antibiotics 0.4 (0-2) 0.4 (0-1) 0.4 
Parenteral antibiotics 0.1 (0-1) 0.3 (0-1) 0.2 
Other medication 0.6 (0-2) 1.9 (0-5) 1.1 
Devices and special facilities at home, work or school % of patients 
Nebulizer 43 88 59 
Home trainer 21 69 38 
Infusion pump 7 13 9 
PEP-mask! 43 16 33 
Special features 0 34 12 
Other 21 31 25 
• per year for a Dutch (f patient 
! positive expiratory pressure mask 
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Table 3,3 Nonhospital costs of care per year for a patient with cystic fibrosis (eF), 
Values are presented as average, and range in parenthesis 
Costs per year (€) 
Chlldre" Adults Weighted 
average'" 
Nonhospital medical care 545 (0-1755) 809 (0-5411) 640 
Domestic help 1,028 (0-12742) 1,342 (0-11326) 1,141 
Diet for Cf 669 (0-2533) 1,084 (0-3937) 818 
Travelling because of CF 245 (34-913) 1,199 (0-7940) 588 
Pancreatic enzymes 2,145 (438-4699) 1,854 (0-4376) 2,040 
Pulmonary medicines 488 (0-2757) 3,045 (0-14299) 1,408 
Vitamins 170 (0-466) 280 (0-1306) 210 
Oral antibiotics 1,237 (0-13316) 2,643 (0-6697) 1,743 
Parenteral antibiotics 217 (0-1559) 1,328 (0-25812) 617 
Other medication 99 (0-435) 1,177 (0-7159) 487 
Devices and special faCilities at home, workor school 101 (0-398) 561 (0-4153) 266 
Total nonhosEital costs of care 6,944 (1065-19852) 15,322 (2473-39751) 9,960 
.. costs per year for Dutch CF patients 
3.3.1 General practitioner, physiotherapist and homeopath/acupuncturist 
One child (7%) and eight adults (25%) consulted their general practitioner (GP) in the 
4 weeks under study for a total of one and nine consultations, respectively. It was, 
therefore, estimated that a CF child has on average 0,9 GP consultations per year and 
an adult 3.7, At a cost per consultation of €15.28, this amounted to €14 per child with 
CF per year and €56 per adult. 
Six children (43%) and 14 adults (44%) indicated that they had visited a 
physiotherapist for 4.7 and 5,9 times per respondent per 4 weeks, respectively. This 
means that a child with CF visited a physiotherapist on average 26 times a year and an 
adult 34 times. The corresponding costs were €501 per year for children and €650 for 
adults, at a cost of €19,29 per consultation, 
Five persons (one child and four adults) consulted a homeopath or acupuncturist, of 
whom one patient had four consultations and one had two. Average consultations 
per year were 0.9 for children and 3.3 for adults. At a cost of €31.76 per consultation, 
this means that consultations with a homeopath or acupuncturist cost €29 per child 
per year and €1 03 per adult. 
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3.3.2 Domestic help 
Fourteen adult patients (44%) responded that they had domestic help for an average 
of 26 hours during the 4 weeks. This corresponds to almost 148 hours per year per 
adult patient. With standardised costs of €9.08 per hour, this amounts to €1,342 per 
adult patient per year. 
Caring for a child with CF costs the parents/guardians a lot of extra time in 
comparison with a child without CF; these costs were only taken into account if the 
parents had some domestic help. Three parents of children with CF (21 %) received 
help from a caretaker or relative for 41 hours on average during the 4 weeks, which 
corresponds to 113 hours domestic help and €1,028 per child per year. 
3.3.3 Diet for CF 
Diet used by patients with CF aims at ameliorating the physical condition of the 
patient. Sixty-three percent (29 out of 46) of all patients indicated that they used a 
supplemental or special diet. Most patients used calorie concentrates: Fortisip" (used 
by 16 patients); Polycal" (12); Nutrison® (s); Nutrilon® (s) and Meritene and Protifar 
(1 each). Furthermore, snacks such as Evergreen", Mars" and Nuts" were used by 
three patients, and other products such as shakes (two patients) and camomile tea, 
celery soup and cream (one patient each). Average costs for a CF-specific diet 
amounted to €669 per yearfor children and €1 ,084 for adults. 
3.3.4 Travelling because of CF 
Almost all respondents, 4S persons (98%), answered that during the 4 weeks they had 
travelled once or more because of CF, children on average 66 km and adults 333 km in 
the 4 weeks. This corresponded to 857 and 4,194 km per patient per year, costing 
€24s and €1, 199 per year at €0.29 per km. 
3.3.5 Work, school and absence 
Fifty-seven percent (17 persons) of the adult patients reported that they held a 
contract of employment, of which almost 50% had a part-time job. During the 
4 weeks, five persons had been absent due to CF for a total of 13 days (104 hours), 
which was 18% of the total contract hours of all 17 patients who had a contract 
(S70 hours). As a comparison, in the general population absence due to sickness in 
The Netherlands in this period was 5.8% for males and 8.9% for females (S). 
Three out of 18 patients (17%) who attended school had been absent for one or more 
days; average absence for these three patients in the 4 weeks was 9 days. This means 
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that a child with CF was on average absent from school for 19.5 days per year. 
National data concerning school absence are not known. 
3.3.6 Medication 
All patients used medication for CF (children on average 5.6 different medicines and 
adults 8.7). For a better overview, medication has been divided into six groups: 
pancreatic enzymes (14 children and 25 adults); pulmonary medicines (8 children and 
29 adults); vitamins (11 children and 25 adults); oral antibiotics (5 children and 
14 adults); parenteral antibiotics (2 children and 9 adults); and other medication 
(6 children and 25 adults). 
The pancreatic enzymes were either pancrelipase (10 children and 23 adults) or 
pancreatin (5 children and 1 adult). Average costs per year amount to €2,145 for 
children and €1,854 for adults. 
In the pulmonary medicines group, many different preparations were used. 
Salbutamol was used most frequently in this group (3 children and 18 adults), 
followed by colistin by nebulization (2 children and 17 adults), and acetylcysteine and 
ipratropium bromide (12 patients each). Other medicines were used less than 
10 times. As mucolytic agent, mercaptoethanesulfonate was recorded 13 times and 
acetylcysteine 12 times. On average, 3.6 different prescriptions were taken by the 
users of pulmonary medicines (children 2.3 and adults 3.9). Average costs amounted 
to €488 per year for children and €3,045 for adults. 
The vitamins A, B, C. D, E and K and multivitamins were prescribed in different 
combinations. The average costs per patient per year amounted to €170 for children 
and €280 for adults. 
In the oral antibiotics group, eight different medicines were indicated in the 
questionnaire. Of these, co-trimoxazole was used most frequently (1 child and 
6 adults). Two patients indicated that they used co-trimoxazole for a fixed period of 
8 months and 3 weeks, respectively. The other patients did not indicate a fixed period 
of use. Ciproxin therapy was used by three patients for an average of 3 weeks per 
patient. Average costs for the oral antibiotics group were €1,237 per year for children 
and €2,643 for adults. 
In the parenteral antibiotics group, three different medicines were noted: flucloxacillin 
(2 children and 7 adults), ceftazidime and tobramycin (both used by one adult). 
Flucloxacillin therapy was used by two patients for 3 weeks and 13 weeks, 
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respectively. Ceftazidime was used as a cure for 3 weeks. Average costs for the group 
parenteral antibiotics were €217 per year for children and €1,328 for adults. 
In the 'other medication' group, 31 users recorded 70 medicines; the most widely 
used were insulin (7 adults, no children), ranitidine and ursodeoxycholic acid (both 
5 adults, no children). Four patients used two homeopathic medicines on average. 
Average costs per patient per year amounted to €99 for children and €1, 177 for 
adults. 
3.3.7 Devices and special facilities at home, work or school 
Three quarters of the respondents (6 children and 28 adults) used a nebulizer with 
(average) cost price of €711. Using an (annuity) amortisation scheme of 10 years and 
an interest rate of 5%, this amounted to €39 per year for children and €140 for adults. 
Almost a quarter of the respondents (6 children and 5 adults) used a positive 
expiratory pressure (PEP)-mask (cost price €1 09), average €13 per child per year and 
€5 per adult. For ameliorating or retaining the physical condition, 22 adult 
respondents and 3 children used a home trainer and/or rowing device (average cost 
price €334), or €5 per child per year and €32 per adult, with an amortisation scheme 
of 10 years. Four adults used an infusion pump at home (3 Cadd-plus and 1 Cadd-1), 
and one child used a Flocare device. Average costs for infusion pumps were €11 per 
child per year and €174 per adult. Other devices were extra diapers (1), vibracan (1), 
ambulant oxygen device (2), lung volume gauge (2) and air cleaner (1): average costs 
per year €32 for children and €81 for adults. Five persons (4 children and 1 adult) did 
not use any device. 
For eight (adult) respondents, a special facility at home or at work had been made, e.g. 
a home trainer, shower and oxygen at work, a personal (handicapped) parking place 
and a shower-seat at home. The costs for an average adult patient with CF were €130 
per year. 
Average costs for devices and special facilities at home, work or school consequently 
amounted to €101 per year for children and €561 per year for adult patients. 
3.4 Discussion 
The disease CF has a great impact on the daily life of the patient and family. In this 
study, it was found that the majority of patients had a special diet and 74% sprayed 
with a nebulizer one or more times a day for about 30 minutes. Almost all patients had 
medical care outside the hospital during the survey period: whereas 43% had visited a 
physiotherapist, it can be assumed that the other 26 patients performed exercises 
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themselves. Total nonhospital costs of CF care in The Netherlands amounted to 
€6,944 per year for children and €15,322 for adults. However, the costs of 
nonhospital care of children should be considered with caution because data from 
only 14 children were collected. 
This study is obviously most relevant to the Dutch situation, but a significant part of it 
could be used to assess costs for other (European) countries as well. Possible 
differences might be the rather low number of consultations with a general 
practitioner (0.9 per year for children and 3.3 for adults) and (reimbursed) visits to a 
physiotherapist (26 times per year for children and 34 times for adults). 
Caring for a family member or friend with CF takes much time and energy. For 
example, almost half of the adult patients had domestic help. These 'direct costs' were 
taken into account in this analysis. On the other hand, caring for a child with CF takes 
more time for parents/guardians than caring for a child without CF. The use of these 
so-called 'indirect costs', mainly production losses, is disputed among economists. 
Therefore, these costs of caring and of absence from work were not included in the 
calculation. 
CF is a disease for which tremendous progress is being made in the field of medical 
care. Some developments have already become reality since the time of our data 
collection, such as recombinant human deoxyribonuclease (DNase) I to decrease the 
viscosity of purulent airway secretions, and the increasing use of (heart-)Iung 
transplantations. Other developments have the possibility of progressing to the point 
of widespread clinical use, such as gene therapy (6-9). This progress in treatment will 
obviously have an impact on the length and quality of a patient's life, and will 
probably have a major influence on the use and type of home care and, thus, on the 
costs of non hospital care. The results of the present analysis should, therefore, be 
updated regularly. 
The results of this analysis have been used in the calculation of the total costs of the 
disease cystic fibrosis (10). For this reason, the medical consumption per age category 
was determined and the nonhospital costs added. These totals were discounted with 
a 5% interest rate and corrected for the survival curve (median age 27 years) of the 
Dutch CF registration (11), which comprises 3,302 observed patient-years. In this way, 
the so-called lifetime costs of CF were determined at €245,901, of which €122,984 
(=50%) were costs made outside the hospital. Considering the cost-effectiveness of, 
for example, continuous intravenous home treatment of airway infections (12), the 
shift from hospital to extramural care could eventually lead to lower costs of the 
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disease. On the other hand, an increase in the number of lung transplantations is 
expected to occur, so that the future total costs of care are difficult to predict. 
The lifetime costs of CF have been used to prospectively evaluate costs of screening 
for carriers of the CF gene (13). A choice for or against genetic screening on the basis 
of economic motives is completely rejected by the authors. Recently, a committee of 
the Dutch Health Council has formulated a set of reasonable criteria for genetic 
screening programmes (14). Cost aspects can playa role in evaluating whether or not 
an otherwise desirable screening programme can be organised, or that costs of 
screening can be prohibitive. The results of our costs study (13) indicate that costs are 
probably not prohibitive for cystic fibrosis screening. 
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Cost of care of patients with cystic fibrosis in 
The Netherlands in 1990-1991 
4.1 Introduction 
Cystic fibrosis is the most common serious autosomal recessive disease in many white 
populations. Despite the progress made in clinical management during the last three 
decades it remains, in most patients, a disease with a limited life expectancy. In The 
Netherlands the median survival is 27 years (1). 
Research on the cost of care of patients with cystic fibrosis is scarce (2-5). Nowadays, 
however, there seems to be an increasing interest in this subject, possibly because of 
the recent discovery of the gene responsible for the disease which creates the 
possibility of population screening for carriers of the cystic fibrosis gene. The cost of 
care analysis presented here is part of a research project in which the costs, effects, 
and savings of screening for carriers of the cystic fibrosis gene in The Netherlands are 
estimated (6). We decided not to use data from the literature because we wanted to 
have age-specific cost estimates using primary data rather than using non-age-
specific data and expert opinions. 
The aim of the cost of care analysis is to estimate the following quantities using data 
collected from medical patient records and a patient questionnaire: (1) the age-
specific medical consumption and medical costs of patients, and a breakdown of 
these costs into costs of hospital care, hospital and nonhospital medication, and home 
care with separate estimates for the (pre)terminal disease stage; (2) the lifetime 
medical costs of a patient by combining age-specific medical costs with recent 
survival figures of the Dutch cystic fibrosis registration (1); and (3) the cost of care of 
cystic fibrosis in The Netherlands by combining age-specific medical consumption 
with the number and age-distribution of patients in The Netherlands (1). 
The estimate of the lifetime costs of medical consumption of patients with cystic 
fibrosis will be used for cost-effectiveness calculations of nationwide screening 
programmes for cystic fibrosis carriers for The Netherlands. 
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4.2 Methods 
The costs of medical consumption of patients with cystic fibrosis were divided into 
costs of hospital care (hospital days, consultations, diagnostic tests), hospital and 
home medication, and home care (visits to a general practitioner, physiotherapy at 
home, help from relatives, diet, travelling expenses, and special aids). 
4.2. 1 Medical consumption 
To determine the cost of hospital care we reviewed the medical records of 81 patients 
(40 men) treated in a cystic fibrosis centre for adults in The Hague and in the 
Groningen University Cystic Fibrosis Centre for Children. We confined ourselves to 
hospital care during the years 1990 and 1991 to reflect recent clinical practice. An 
inventory was made of all admissions to hospital (hospital days, admissions, and 
consultations), visits to outpatient departments (consultations), radiological 
procedures, surgical interventions, laboratory investigations (tests), and other 
activities that were taken in relation to cystic fibrosis. We also made an inventory of all 
medications taken in the hospital and at home. The cohort of patients analysed 
represents approximately 8% of all living patients in The Netherlands. The age 
distribution (median age 13; range 0-37 years) was similar to the age distribution of all 
patients in the Dutch cystic fibrosis registration which covers 3,302 observed patient-
years and has a 75% survival at 17 years and a 50% survival at 27 years (1). 
To gain insight into the medical consumption that is not covered in the medical 
records we asked 73 patients to keep a diary of visits to the general practitioner and 
physiotherapist and travelling expenses for one month. The response rate of this 
questionnaire was 64%. We also questioned the patients about the support received 
from their social environment (for example, relatives), their daily activities and their 
school/work life. 
To check whether the medical consumption estimated from the medical records was 
in accordance with clinical experience, we interviewed several clinicians in charge of 
patients with cystic fibrosis. The results of the patient questionnaire were used to 
validate several data extracted from the patient records. The questionnaire itself was 
validated through interviews with some of the patients (or their parents) who 
completed the diaries. 
The average age-specific medical consumption was obtained by dividing the age-
specific consumption from the patient records and the patient questionnaires by the 
patient-years at risk in the age group concerned. Separate calculations were made for 
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patients in the preterminal or terminal stage, defined as the last two years of life, 
because we expected that their medical consumption would differ significantly from 
the non-(pre)terminal patients. 
4.2.2 Costs 
We estimated the costs from a societal point of view. Costs are measured by 
calculating invested manpower and materials with relevant wages and prices. These 
cost estimates will differ from those resulting from a financial point of view in which 
commercial prices are used including so-called transfer payments - for example, 
profits, margins, tariffs, taxes, royalties (7). Whenever possible we used real costs per 
unit of medical consumption known from other research or estimated by us. If the real 
costs were not known, reimbursements from health care insurers were used 
(Table 4.1). These reimbursements are the prices that insurers pay to hospitals, general 
practitioners, doctors, and other health care providers. The reimbursements are 
mostly settled in some form of negotiation between health care insurers and 
providers (for example, hospitals), and do not necessarily equate with real costs. 
Most patients are treated in specialised cystic fibrosis centres or university hospitals. 
The costs of these hospital days are higher than for general hospitals because of the 
more intensive treatment. The costs of a hospital day include physiotherapy for 
20 minutes a day. Children receive more physiotherapy (on average twice a day for 
30 minutes) than adolescents who can perform their daily exercises mostly on their 
own; we therefore added the cost of 30 minutes physiotherapy to the costs of a 
hospital day for children. 
The average age-specific medical costs are obtained by multiplying the average age-
specific medical consumption by the corresponding unit cost figures. The age-specific 
Table 4.1 Costs of several units of medical consumption by patients with cystic 
fibrosis based on estimates of real costs or on reimbursements 
Unit COlt figure Baled on 
HOlpital day €229.42 Eltimate of real COltl 
Consultation €43.S6 Estimate of real (osts 
Radiograph (average) €J6.81 Reimbursement 
Ultrasound (average) €77.69 Reimbursement 
DopplerultrasQund €62,62 Reimbursement 
CT scan €170.74 Reimbursement 
lung function test €98.16 Reimbursement 
laboratory (weighted average) €9,46 Reimbursement 
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figures were converted into the lifetime average consumption by using the Sum-Limit 
method (8), which corrects for the year-to-year survival of patients with cystic fibrosis. 
To discount these costs we used a 5% discount rate towards the time of birth. Survival 
of patients with cystic fibrosis in The Netherlands was estimated from the Dutch cystic 
fibrosis registration (1). 
4.3 Results 
The average consumption of the most important aspects of hospital care (except 
medication) is presented in Table 4.2. 'Consultations' include all visits of patients to 
the outpatients department. 'Laboratory tests' represent the number of results of 
laboratory investigations (from blood, urine, and stool). 
The estimates of the costs of home medication and home care were based on the 
patient questionnaire. Costs of home care include materials, diet, and travelling 
expenses. On average a patient visited the general practitioner 2.8 times per year and 
the physiotherapist 31 times per year. Of all patients 74% used a nebulizer, 54% a 
hometrainer for daily workouts, 11% an infusion pump, and 24% a positive expiratory 
pressure (PEP) mask. Only 11% did not use any device. For the devices we calculated 
the average yearly costs on an annuity basis. From the questionnaire we also learned 
that 57% of all adults had a paid job and about half of them (47%) had part-time 
contracts. 
The average cost of a patient with cystic fibrosis per year is €16,319. Table4.3 
presents the breakdown of these costs. The total cost of care of cystic fibrosis in The 
Table 4.2 Age-specific average hospital consumption of patients with cystic 
fibrosis per patient per year 
Number of 
Age Patients Hospital Admlllions (onsul- Radio· (Doppler) lung Laborato!)' . 
(years) days tations graphs Ultrasound fundion tests 
scans tests 
0 3 68.8 2.5 13.7 65 05 0.0 146.8 
1-4 11 7.2 0.4 6.4 25 0.1 0.2 575 
5-9 11 5.9 05 5.7 2.6 03 5.8 64.8 
10-14 21 4.9 0.4 53 23 0.4 7.9 87.1 
15-19 18 22.4 0.9 6.5 4.4 1.0 10.4 134.2 
20-24 9 52,6 1.6 7.4 8,8 0,9 73 216,2 
25-29 2 25.1 1.9 8,9 4,9 0,5 2.4 128.2 
30-34 5 6,5 0.7 8,2 3.1 0.7 43 141,8 
35+ 1 0,0 0,0 4,0 1,0 0,0 2,8 36,0 
All 81 18,5 0,9 6,9 4,0 05 53 116,5 
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Table 4.3 Average cost of care (per patient per year) of patients with cystic 
fibrosis in 1991 
(Olt Percentage 
Hospital (are 
€6.900 42% 
Medication €6.084 37% 
Home care €3,335 20% 
Tot,1 €16,319 100% 
Netherlands in 1991 is estimated to be €16.3 million, which is approximately 0.07% of 
the total health care budget in The Netherlands. This figure is obtained by multiplying 
the average costs per year with the number of patients (estimated at 1,000 patients). 
The cost of age-specific hospital care, medication, and home care is presented in 
Figure 4.1. The five year moving average is obtained by averaging the costs of the 
index year with the costs of the two preceding and the two following years. We have 
to keep in mind that from age 25 onwards our estimates are based on a relatively 
small group of patients (age 25 years, n=8). 
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Figure 4.1 Average cost of care of patients with cystic fibrosis per year of age 
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A relatively high medical consumption occurs in the first year of life because the 
diagnostic process takes place in the first year of life in most (57%) patients (1). The 
increase in average costs after the age of 15 is mainly due to frequent antibiotic 
treatment and hospital days (Table 4.4) due to exacerbations or complications. 
Among the Dutch patients older than 31 years a relatively high proportion is 
diagnosed at an older age. Those patients have milder pulmonary disease, are less 
likely to suffer from pancreatic insufficiency or diabetes mellitus, and have 
consequently lower than average cost of care (9). The high values of the average costs 
at age 25 and 30 shown in Figure 4.1 are caused by two patients who underwent a 
lung transplantation (cost €122,521). 
In order to arrive at the costs in The Netherlands we totalled the average cost per year 
of life up to the age of 35, which amounted to €919,464. When survival is taken into 
consideration, the lifetime costs of a patient with cystic fibrosis are €612,570. If we 
discount the lifetime costs to the time of birth using a discount rate of 5%, which is 
common in cost-effectiveness studies, they amount to €245,901. 
The difference in costs between the average medical consumption of patients aged 
15 and older who are not in the (pre)terminal phase and the average medical 
consumption of patients in the (pre)terminal stage amounts to €39,794 which is 71 % 
of the costs of the (pre)terminal stage (Table 4.4). This difference is due to the large 
number of hospital days, radiographs, Doppler studies and laboratory tests that are 
required. It is noteworthy that there is no big difference between the average cost of 
care of all patients (€16,319) and the cost of care for patients olderthan 15 years who 
are not in the (pre)terminal phase (€16,609). This can be explained by the relatively 
small number of patients in the (pre)terminal phase (n~8) and the relatively low costs 
of patients under the age of 15 (€11,608). 
Table 4.4 Average medical consumption (per patient per year) of patients with 
cystic fibrosis aged 15 or older not in the (pre)terminal stage compared with the 
average consumption of patients in the (pre)terminal stage 
Numb<rof 
Hospital Admissions Consul- Radlo- (Ooppler) Lung Laborato!)' Average 
days tatlons graphs ultrasound function tests medical 
scans tests consumption 
cost 
15+ years 10.9 0.8 6.5 3.0 0.3 8.7 76.3 €16,609 
(Pre)terminal 106,0 2.7 7.9 15,9 5.4 5.5 575,5 €56,404 
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4.4 Discussion 
Our model of age-specific medical consumption seems plausible and the approach is 
also applicable to other countries. The lifetime costs of €245,901 differ from other 
estimates. The OTA report estimates the lifetime costs of a patient with cystic fibrosis 
for 1989 at €107,959 (3). This figure is obtained by discounting the average direct 
medical costs (average per year €8,405) by 5% per year and correcting for survival in 
the USA. The difference between the OTA estimate and ours is probably due to 
primary data collection in our research (instead of using expert estimates). Ginsberg 
et al. estimate the excess lifetime costs of patients to be €194,1 01 (4), which comes 
closest to our research. Although they made age-specific estimates of the costs, they 
did not always use data from real patients, and this may be the reason for the 
difference from our estimate. 
All other known research on costs of cystic fibrosis differentiates between mild, 
moderate, and severe patients (2, 5). Robson et al. calculated costs to be between 
€4,177 and €29,852 per year with an average of €12,328 for an adult patient (2). 
From our calculations the costs of an adult patient (aged 15 or over), excluding home 
care costs (for comparability), are €21,650.ln Denmark these costs were €58,291 for 
three year old patients, €54,802 for 12 year old patients, and €97,398 for a 20 year old 
patient (5). Our calculations for these patients are, respectively, €8,362 for patients of 
three years of age, €9,406 for patients aged 12, and €46,867 for those aged 20. These 
differences could again be the result of the use of expert estimates in the Danish 
study instead of using primary patient data. 
Cystic fibrosis is a disease in which tremendous progress is being made in medical 
care. Some developments such as recombinant human DNase I to decrease the 
viscosity of purulent airway secretions, an increasing use of (heart-)lung 
transplantations, and home therapy have already become a reality since the time of 
this review, while others such as gene therapy have a possibility of progressing to the 
point of widespread clinical use (10-13). Although some of these developments can 
be very economical-for example, home therapy-most new developments are 
costly (14-18). Moreover, this progress in treatment will have an impact on the length 
and quality of a patient's life so that the cost of care for patients with cystic fibrosis will 
probably rise. 
The indirect costs of patients have not been taken into consideration in this study. 
Indirect costs are mainly the result of production losses because patients (or their 
carers) are unable to work full time. Although American studies have tried to estimate 
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these costs (for example, Pauly estimated the total cost for the cystic fibrosis 
population per year at €66 million (19)), the use of such a method is disputed among 
economists. The so-called costs of 'replacement' have also not been calculated and 
can only be calculated if a child born with cystic fibrosis was foregone and replaced by 
a child not affected with cystic fibrosis. 
The daily costs of patients with cystic fibrosis such as diet appear to be relatively 
stable. The additional costs of, for example, frequent admission to the hospital, and 
treatment with intravenous antibiotics fluctuate and depend on the age of the patient 
and stage of the disease. It is to be expected that daily costs will remain stable in the 
future, but additional costs will increase due to expensive new treatment and care 
provision. Because of better treatment and new medication, the lifetime cost of care 
will probably increase (higher medical consumption). This will lead to an ever 
increasing cost-savings balance of screening, as long as the growth in the costs of 
screening is lower than the growth in the lifetime costs of cystic fibrosis. 
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Costs, effects, and savings of screening for 
cystic fibrosis gene carriers 
5.1 Introduction 
Cystic fibrosis (CF) is the most frequent serious autosomal recessive disease in white 
populations. Characteristics of CF are chronic bronchopulmonary infections, 
pancreatic insufficiency, disturbances of the digestive tract, and high sweat sodium 
concentration. The disease has a great impact on the length and quality of life and 
causes a comparatively high medical consumption (1, 2). Treatment starts from the 
diagnosis and continues throughout life, and consists of prescribing additional 
calories, vitamins and pancreas enzymes, and fighting the respiratory infections with 
antibiotics and intensive physiotherapy. 
In 1989, the gene responsible for cystic fibrosis was cloned (3-5). Nowadays, more 
than 600 mutations of this CFTR gene are known (CF Genetic Analysis Consortium). Of 
these, the 50-called 6F508 mutation, a three-base deletion in a part of the gene, is by 
far the most common in Western Europe, while a limited number of other mutations 
accounts for more than half of the non-6F508 mutated genes (6, 7). These mutations 
can be detected by polymerase chain reaction analysis with, apart from laboratory 
errors, a perfect sensitivity and specificity. This makes it possible to consider 
introducing a screening programme for carriers of the CF gene, where the primary aim 
is to detect carrier status and counsel couples whose members are both carrier of a CF 
gene mutation 50 that they can make deliberate decisions about reproduction. 
Screening for CF gene carriers is under debate in many countries. There are health 
related, psychosocial, ethical, legal, and economic consequences associated with CF 
gene carrier screening, as with other genetic screening programmes. In The 
Netherlands, the Dutch Health Council recently formulated criteria for genetic 
screening programmes intended to ensure systematic assessment of such 
programmes before their introduction (8). The last criterion states that if the positive 
consequences clearly outweigh the negative consequences, costs and savings of the 
screening programme should be calculated and checked in view of a fair distribution 
of resources within the total area of the health services. We started a prospective 
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evaluation to determine the cost-savings balance of CF screening and related the 
costs to effect measures. If the economic balance will turn out to be unacceptably 
unfavourable, CF screening is not warranted anyhow. If, on the other hand, the 
economic balance is favourable, decision making can concentrate on the crucial non-
economic aspects. 
Several screening strategies have been suggested (9-12) and are being or have been 
analysed in a pilot study (13-21). Of these, prenatal, preconceptional, school, and 
neonatal screening can be considered for general population screening. For the 
prenatal and preconceptional screening strategies we considered both single-entry 
and double-entry two-step couple screening (see below). Analogously to Morris and 
Oppenheimer (22), we did not consider cascade screening (screening of relatives of 
patients) in this analysis, because the approach is completely different from general 
population screening. Furthermore, Holloway and Brock (23) have shown that cascade 
testing is not very effective, as only between 8% and 24% of all carrier couples would 
be detected if cascade testing were restricted to up to the second cousin level. 
We calculated the costs, effects, and savings of the screening strategies and compared 
them with a situation in which there is no CF gene carrier screening. For a one year 
screening period, we simulated the effects on individuals and couples under certain 
assumptions concerning reproductive decision making. Although our main analysis 
uses population genetic figures and cost estimates for The Netherlands, other 
combinations of assumptions can be analysed as well with our model. In this paper, 
we will only analyse other carrier frequencies as they may occur in other countries. 
5.2 Methods 
We developed a simulation model for a screening programme for CF gene carriers. We 
prospectively evaluated four different screening strategies taking the Dutch situation 
as an example: prenatal screening, preconceptional screening, school screening, and 
neonatal carrier screening. For each screening strategy we calculated the expected 
costs, effects, and savings for a one year screening period. CF related costs and 
savings that occur after that year were taken into account using a five percent annual 
discount rate (24). 
To see by what extent the cost-savings balance depends on our assumptions, we 
conducted two threshold analyses. In a single-variable threshold analysis, we 
determined for selected assumptions the maximal or minimal value of that 
assumption for which savings equal costs. In a multi-variable threshold analysis, we 
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varied these assumptions simultaneously and determined at what percentage change 
in all assumptions savings equal costs. Furthermore, we examined the influence of the 
CF gene carrier prevalence on the cost-savings balance. After a brief explanation of 
the screening strategies, we describe the assumptions and parameters that we used in 
our analysis. 
5.2.1 Screening strategies 
Prenatal screening 
In the prenatal screening strategy, pregnant women and their partners are screened 
as early in their pregnancy as possible so that chorionic villus sampling may still be 
possible in case both are carriers. Prenatal screening is the only form of screening in 
which prevention of pregnancy is not possible. Only for the future children all 
reproductive options are open. Because almost all women who suspect to be 
pregnant consult a general practitioner or midwife, it is relatively easy to integrate this 
form of CF gene screening in the existing health care system. Observed participation 
rates in the UK range from 62% to 91 % (18, 25-27). 
Preconceptional screening 
Preconceptional screening concerns couples who consider having a child and want to 
receive information about their carrier status. The screening result is known before 
the (potential) reproduction so that all reproductive options are open to the carrier 
couples, for example, accepting the risk of giving birth to a CF child, having prenatal 
diagnosis possibly followed by induced abortion, refraining from having (more) 
children, adoption, artificial insemination with donor sperm or egg cell donation and 
pre-implantation diagnosis. For most countries (including The Netherlands) an 
important obstacle to preconceptional screening is the absence of a preconceptional 
consultation system. Observed participation rates in the UK range from 4% to 87%, 
and depend very much on the way people are approached (13, 14, 28). 
School screening 
In the school screening strategy, acquisition of the testing material (for example, 
mouth washes) can take place within the school environment. For minimising the 
time between screening and (potential) reproduction, pupils in the last year of 
compulsory education (at the age of 16 in The Netherlands) should be offered the test. 
From a social-genetic perspective, this type of screening also offers a good 
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opportunity for teaching genetics. Good information is important because school 
screening takes place in a rather unstable stage of life, possibly leading to 
stigmatisation. Studies in Italy and Canada on thalassaemia and Tay-Sachs disease 
screening, and for CF carrier screening in Australia and Canada show that school 
screening is feasible (21, 29-31). Observed participation rates for screening in high 
schools range from 42% to 75% (21, 31). 
Neonatal screening 
In the neonatal carrier screening strategy, the target population consists of newborn 
children who are tested in the first months after birth. As almost all newborns are 
already tested on PKU/CHT by a blood spot, CF gene screening can easily be 
integrated into the existing screening programme. If a newborn child turns out to be a 
carrier the target population can be extended to the parents, and if both turn out to 
be a carrier they can use this information in making further reproductive choices. 
However, there are also disadvantages for this strategy. Firstly, screening for curable 
diseases (PKU/CHT) which has a routine character will be combined with screening for 
carriership of a (still) incurable disease (CF). Secondly, the information regarding 
carriership only becomes relevant to the newborn for reproductive decisions after 20 
to 30 years. This necessitates considerable efforts for retaining this information that 
can be helped by, for example, a computer database or an individual health passport. 
Single-entry versus double-entry in prenatal and preconceptional screening 
In the school and neonatal screening strategies, single persons are screened. For 
prenatal screening and preconceptional screening however, we deal with couples and 
the test can be offered with single or with double-entry (27, 32-34). We assumed that 
in the single-entry two-step screening framework (SETS), one partner is tested initially 
for carriers hip of the ilF508 mutation only. In case he/she is a carrier, the sample of the 
second partner will be searched for a total of 17 mutations. For the double-entry two-
step screening framework (DETS), we assumed that the mouth wash sample of both 
partners is initially tested for the ilF508 mutation and that the sample of the negative 
partner in case of a positive/negative couple is searched for the other 16 mutations 
(32). We have assumed that testing material will be directly obtained from both 
partners, even in the SETS framework. In this way, the partner who is not tested 
initially does not have to make extra arrangements to be tested in case his/her partner 
is shown to be a carrier. For the school and neonatal screening programmes, we 
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assumed that for cost considerations the individuals are tested only for the 8FS08 
mutation (see also the discussion). 
5.2.2 Prevalence 
The prevalence of CF gene carriers varies between populations; in The Netherlands it 
is one in 30 (35). The 8FS08 mutation is identified in 73.6 percent of all CF genes and 
16 other mutations account for 11.9 percent (36). It is therefore possible to identify 
85.5 percent of all mutations with a 17 mutations screening test. As a comparison, the 
prevalences in the United Kingdom and the United States are 1 :25 to 1 :28, while the 
8F508 mutation accounts for 70-77 percent of all CF genes and five to 11 other 
mutations for 15-20 percent, depending on racial and ethnic background (37, 38). 
In The Netherlands, the presence of autosomal and sex chromosome abnormalities is 
checked for routinely when chorionic villi are analysed for CF. Therefore we took these 
abnormalities into account, with a prevalence at time of prenatal diagnosis of 1 :500 
for both autosomal and sex chromosome abnormalities (39). 
5.2.3 Target populations 
We assumed that the target population of prenatal screening consists of couples who 
are pregnant with their first child. We used the number of firstborn children, 85,030 in 
1995 in The Netherlands (40), but corrected for the probability of spontaneous 
abortion between the time of screening and time of birth (3.5% for low-risk 
pregnancies (41)), leading to a target of 88,241 couples (see first line ofTable 5.1). For 
preconceptional screening, the number of firstborn children was corrected with a 10% 
probability of a couple remaining infertile (42), so that the target of preconceptional 
screening consists of 94,478 couples. The target population of school screening 
consists of 183,060 people of 16 years (43). We assumed that 90% of them will form a 
couple that wants a child, and 10% of these couples remain infertile (44). For neonatal 
screening, the target population consists of all 190,513 children that were born in 
1995 (40), again it is assumed that 90% of them will form a couple that wants a child 
and that 10% of these remain infertile (44). 
We assumed that in all screening strategies, 84.9% of the people with a firstborn child 
will have a second child after 2.9 years on average (40, 44). For computational 
simplicity, we ignore in our calculations births of children who are third born or more. 
This assumption will obviously not have effects on the costs per detected carrier 
couple, but will lead to a conservative estimate of the cost-savings balance. 
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Table 5.1 Assumptions that differ between CF gene screening strategies: size of 
target population, coverage, information preservation, and costs 
Screening strategy 
Prenatal PreconceQtional School Neonatal 
Size of target population 88,241 94,478 183,060 190,513 
(overage of screening 90% 50% 85% 95% 
Information preservation 100% 100% 90% 70% 
Mass information costs €lS7,23S €262,OS8 €209,646 €lS7,2J5 
Individual information costs €2.72 
€U6 €0.68 €U6 
Or2anlsation costs €10.38 €10.38 €10.38 €O.OO 
5.2.4 Coverage and information preservation 
As discussed in the description of the strategies, the coverage that may be achieved is 
probably highest for neonatal screening, somewhat lower for prenatal screening, and 
again somewhat lower for school screening; we set these values at 95%, 90% (18, 27), 
and 85% (45), respectively. For preconceptional screening, coverage depends very 
much on the existence of a preconceptional consultation system and on the way in 
which people are approached (13, 14); we took 50% coverage as baseline value. 
In the Tay-Sachs disease prevention programme in Montreal, Zeesman et al. (30) 
found that after eight years 90% of the screened pupils were able to retrieve the test 
result regarding carriership. Because the time between testing and possible use of the 
carrier information for school screening is of the same order of magnitude (12 years in 
our analysis), we took this value for the information retention rate of school screening. 
For neonatal screening, the time between testing and possible use of the information 
equals 28 years in our analysis, leading to a lower retention rate. Moreover, carrier 
status information has to be passed from the parents to the screened child at some 
time. For these reasons we presumed an information retention rate of 70% for 
neonatal screening. Furthermore, we assumed that individuals who have not retained 
their test information will not be retested. We summarise the estimates for coverage 
and information preservation in the second and third row ofTable 5.1. 
5.2.5 Other assumptions 
Furthermore, to assess the consequences of CF gene screening, we had to make a 
number of assumptions concerning reproduction and use of prenatal diagnosis. In the 
published pilot carrier screening studies that actually tested persons, 95% of all 
detected carrier couples opted for prenatal diagnosis and 92% of all affected foetuses 
were aborted subsequently (25-27, 46-51). However, these figures were based on very 
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small numbers, and the attenders in these pilot studies might be a selected group that 
is favourably biased towards screening, prenatal diagnosis, and abortion. Therefore, 
we decided to take somewhat more conservative estimates and presumed that 15% 
of the detected carrier couples refrain from having (more) children (52), that 85% of 
the carrier couples make use of prenatal diagnosis, that in 80% of diagnosed affected 
foetuses parents make the choice for selective abortion, -and that prenatal diagnosis 
carries an attributable risk of iatrogenic abortion of 0.75% (53). Furthermore, we took 
into account spontaneous abortions. Most of the assumptions were subjected to a 
sensitivity analysis. 
5.2.6 Economic factors 
The costs of screening can be divided in three aspects: the costs of spread of 
information before the screening-for instance by mass media and leaflets-, the 
costs of the organisation of the screening and the testing itself, and the costs of 
aftercare. We estimated the costs from a societal point of view: costs are measured by 
calculating invested manpower and materials with relevant wages and prices. 
Resulting figures will differ from those obtained when using a purely financial point of 
view, where commercial prices of, for example, kits are used, including so-called 
transfer payments (for example, profits, margins, tariffs, taxes, royalties) (54). We 
regarded as economic savings the precluded lifetime medical costs of patients who 
will be born less as a result of the screening programme. Because costs of diagnosis 
and treatment of CF occur at a later point in time than the actual screening, they were 
recalculated to the (present) value in the year of screening using an annual discount 
rate of five percent (24). 
Costs of information 
We divided the information costs into two parts (see Table 5.1): the mass information 
costs that depend on the target group-for example, costs of mass media 
campaigns-and the individual information costs that are proportional to the number 
of individuals or couples-for instance costs of leaflets. 
Van der Maas et aI., studying the costs and effects of mass screening for breast cancer 
in The Netherlands, obtained €262,058 for the mass information costs and €1.36 for 
individual information (costs adjusted for inflation between 1990 and 1996) (55). As 
we may regard the way of information provision in the preconceptional screening 
strategy as somewhat analogous to that for the breast cancer screening programme, 
we took these values as baseline cost estimates for the preconceptional screening 
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programme. Because of its easy integration in the existing health care system, we set 
the mass information costs for prenatal and neonatal screening lower at 60% of the 
value for preconceptional screening and we took the school mass information costs at 
80% because of the integration in the school setting. 
The individual information costs are likely to be highest for prenatal screening 
because of the direct consequences and emotional sequelae of the test outcome. 
Therefore we estimated them as twice the costs of individual information for 
preconceptional screening at €2.72, which is comparable to the costs used by Cuckle 
et al. (26). We set the individual information costs lowest for school screening at 50% 
of the value of preconceptional screening. The individual information costs to the 
parents in the neonatal screening strategy were set at the same value as the costs in 
the preconceptional screening strategy. 
Costs of testing 
Costs of testing can be subdivided into costs of acquisition of the sample of an 
individual or couple, shipment of the samples to a laboratory, DNA extraction, DNA 
analysis, reporting of the results, and costs for the screenee. The so-called 
organisation costs of acquisition, shipment, and administration were estimated at 
€10.38 per couple for prenatal, preconceptional, and school screening. Organisation 
costs for neonatal screening were ignored because the CF test is assumed to 
supplement the already existing screening programme for PKU/CHT in The 
Netherlands; therefore costs of acquisition, shipment, and reporting of the results will 
not change or change only very slightly if a screening test is added to the PKUICHT 
programme. Estimates of the costs of DNA testing for mUltiple mutations in the 
United Kingdom range from €34 to €45 (22, 26, 56). In our analysis, we took the cost 
estimate of Cuckle et al. (€37.89) (26) for the multiple mutations test. The t-F508 
mutation analysis can be performed with a comparatively cheap in house polymerase 
chain reaction, and is done in much larger quantities than the multiple mutations 
tests. Therefore we assumed that the cost of DNA testing for the t-F508 mutation only 
would cost only a quarter of the multiple mutations test (€9.47). For the costs for the 
screenee, we took the costs of travelling by public transport and the costs of 
production loss (one hour for travelling to the screening, waiting time, and the time of 
screening) (57), totalling €6.57. 
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Costs of further diagnosis and treatment 
Aftercare consists of counselling carrier couples and positive/negative couples and, 
depending on the choice of the couple, prenatal diagnosis for detected carrier 
couples and eventually, depending on the couples decision, abortion of an affected 
foetus. For counselling we took the costs of a qualified nurse in a clinical genetics 
centre, assuming that counselling a carrier couple takes one hour (22) and counselling 
a positive/negative couple takes a half hour. At an hourly wage of €19.06 and an 
overhead percentage of 40%, counselling costs to the clinical genetics centre are 
€26.68 for a carrier couple and €13.34 for a positive/negative couple. For the carrier 
couple, we added 15 minutes of waiting time and the costs of public transport to the 
counselling costs, totalling €10.50 for positive/positive couples and €7.88 for 
positive/negative couples (57). The costs of prenatal diagnosis, selective abortion, 
early spontaneous abortion, late spontaneous abortion, and iatrogenic abortion were 
based on Dutch reimbursements between health care providers, government, and 
insurance companies: €1,270.58, €221.01, €69.23, €444.36, and €69.23 respectively 
(58,59). 
Lifetime costs of a CF patient 
By means of an examination of the medical records of 81 patients (40 men, 
41 women) and a patient questionnaire among 73 patients (2), we estimated the age 
specific cost of illness of a CF patient. We converted this cost of illness into the 
average lifetime excess costs of care of a CF patient by adjusting for the survival 
figures of CF patients and discounting at five percent (1). The lifetime excess costs of 
care of a CF patient in The Netherlands were in this way estimated to be €273,967 
(corrected for inflation). 
5.3 Results 
Lowest total costs of screening are achieved with single-entry preconceptional 
screening, and with neonatal screening (upper part of Table 5.2). The costs of the 
other strategies are much higher. The double-entry two-step (DETS) frameworks for 
preconceptional and prenatal screening have much higher costs than their single-
entry counterparts (SETS), because the number of tests performed is almost twice as 
high. 
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Table 5.2 Costs, effects, and savings per year for a CF gene screening programme 
Costs ofinformation* 
Costs of testing* 
Costs of aftercare* 
Total costs of screening* 
Detected carrier couples 
Costs per detected carrier couple" 
Number of avoided patients 
Costs per avoided patient* 
Net economic savings 
(53\'iog5 minus costs)* 
Screening strategy 
Prenatal Preconceptional 
SETSt DETSt SETSt DETSt 
€438,OOQ €438,OOQ €431,OOO €431,OOQ 
€3,074,OOO €4,386,OOQ €2,107,000 €2,895,OOQ 
€166,OOQ €229,000 €84,000 €122,OOQ 
€3,679,OOO €5,053,000 €2,621,000 €J,448,OOQ 
56 63 33 38 
€66,000 €80,000 €79,OOO €92,000 
18 21 10 12 
€205,OOQ €247,OOQ €258,000 €298,OOQ 
€1,561,OOQ €869,000 €221,OOQ -€2JS,000 
* costs and savings are rounded to €l,OOO 
t SETS=single-entry two~step couple screening 
DETS=double-entry two-step couple screening 
School Neonatal 
€300,000 €465,000 
€3,096,000 €1,999,000 
€93,000 €186,000 
€3,489,000 €2,651,000 
361 1121 
€97,000 €24,000 
8 1J§ 
€421,OOQ €206,OOO 
-€2,11S,OOQ -€224,000 
t number of couples whose members both have retained their carrier information until their reproductilJe period 
§ induding seven patients born less because parents are shown to be a carrier couple due to their first carrier child being 
detected 
With regard to the number of detected carrier couples, neonatal screening performs 
best (112 carrier couples detected), If testing of parents of diagnosed carrier newborns 
(which is an extra possibility of neonatal screening only) would not be included in the 
calculations, double-entry prenatal screening detects most carrier couples 
(63 couples), As expected, double-entry screening detects more carrier couples than 
single-entry screening (63 compared with 56 couples for prenatal screening), The 
costs per detected carrier couple are by far lowest for neonatal screening, because its 
organisation costs are set at zero, The SETS versions of prenatal and preconceptional 
screening perform much better than the DETS versions, for example, €66,OOO and 
€80,OOO, respectively for prenatal screening, 
When we want to carry the economic analysis of the screening programmes further, 
we need to calculate the number of patients that are born less as a result of the 
screening programme (third part of Table 5,2), This number is defined as the number 
of patients not born because the (would be) parents decide to refrain from having 
(more) children or to have an induced abortion in case of an affected foetus, In the 
neonatal screening strategy, some patients are born less because the first child is 
detected carrier, and in the follow-up his/her parents appear to be a carrier couple 
and decide to refrain from further children, The DETS framework of prenatal screening 
results in the highest number (21 patients) of avoided patients, Because we assumed 
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that individuals who have not retained their test information are not retested, school 
screening does not result in many avoided patients (eight patients). In the neonatal 
screening strategy, seven patients are born less because the first child is detected 
carrier. The number of avoided patients in the preconceptional screening strategy is 
rather small because of its low coverage. 
The net economic savings (savings minus costs) are 'positive for both prenatal 
screening strategies and the single-entry version of preconceptional screening. The 
costs of double-entry preconceptional, school, and neonatal screening are higher 
than the economic savings, mainly because of the high polymerase chain reaction 
screening costs, which account for more than 25% of the total costs of these 
screening programmes. Maximum net economic savings are obtained in the SETS 
version of prenatal screening (€1.6 million). 
5.3.1 Threshold analysis 
We calculated for selected parameters the values for which savings exactly equal costs 
while keeping all other parameters at their baseline values (Table 5.3). Even if carrier 
couples never refrain from having more children, prenatal screening and SETS 
preconceptional screening have a favourable cost-savings balance. The savings of 
DETS preconceptionalscreening would be higher than its costs if more than 29% of all 
carriers would refrain from having children, while an unrealistic 96% of all carriers 
should refrain to achieve higher savings than costs for neonatal screening. Even if all 
carrier couples would refrain from having children, costs exceed savings for school 
screening. 
For the prenatal screening programmes, the fraction of the carrier couples that will 
use prenatal diagnosis can decrease to 74% or less before costs exceed savings, and 
for SETS preconceptional screening the threshold is 78%. If more than 95% of all 
carriers would have prenatal diagnosis, even DETS preconceptional screening and 
neonatal screening would have higher savings than costs, while costs always exceed 
savings for school screening, even if all couples will use prenatal diagnosis. The 
threshold values for the fraction that decides to have an affected foetus aborted are 
similar to the thresholds for the fraction of the carrier couples that will use prenatal 
diagnosis, because these two parameters act 'multiplicatively' on the number of 
avoided patients. 
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Table 5.3 Single· and multi·variable threshold analyses. The table gives the 
threshold value for which costs of screening equal savings. Between 
parentheses: the ratio of threshold to baseline value. Costs and savings are 
discounted at 5% per year 
Screening strategy 
Prenatal Preconceptlonal School Neonatal 
SETS' OETS' SETS' OETS' 
Single-variable threshold analysis 
Fraction of the carrier couples that will refrain t t t 29% 
* 
96% 
from having a child (baseline: 15%) x1.92 x6.41 
Fraction of the carrier couples that will use 63% 74% 78% 93% 
* 
95% 
prenatal diagnosis (baseline: 85%) xO.74 xO.87 xO.92 x1.09 x1.12 
Fraction of the affected foetuses that will be 54% 67% 71% 87% 
* 
89% 
selectively aborted (baseline: 80%) ,0.67 xO.84 xO.89 x1.09 x1.12 
Coverage of screening 25% 40% 37% 66% t 
* ,0.27 xO.44 xO.74 x1.32 
Information preservation 77% 89% 94% I t 94% 
,0.77 xO.89 ,0.94 x1.35 
Costs of individual information €19.21 €12.16 €3.65 I t €0.J4 
x7.05 x4.46 x2.68 xO.25 
Cost of M508 mutations test (baseline €9.41) €25.79 €14.65 €lJ.Ol €7.62 t €7.83 
Cost of multiple mutations test (baseline €37.89) €103.16 €58.59 €52.04 €30.48 €31.33 
x2.72 x1.55 x1.37 xO.80 ,0.83 
Multi-variable threshold analysis§ 8% 4% 2% -3% t -3% 
* SETS - Single-entry two-step couple screening, DETS - double-entry two-step couple screening 
t for every value of the parameter, savings exceed costs 
t for every value of the parameter, costs exceed savings 
§ all parameter values can simultaneously decrease by this percentage (respective increase for costs of individual information 
and costs of testing) before costs will exceed savings 
Coverage of screening does not influence the cost-savings balance very much 
because a large part of the costs are so-called variable costs that are proportional to 
coverage. However, savings in the DETS preconceptional screening strategy would be 
higher than its costs if a coverage higher than 66% is attained. Even if all people 
would be screened, costs of school and neonatal screening are higher than the 
savings. Attaining a high enough information preservation is rather important, as the 
costs exceed savings for SETS preconceptional screening and prenatal screening if 
many people would forget the test results. If an information preservation of more 
than 94% would be reached, savings of neonatal screening would be higher than the 
costs. For school screening and DETS preconceptional screening, costs are always 
higherthan savings. 
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Because the costs of individual information do not form a large part of total costs, 
these costs do not influence the cost-savings balance very much: the costs can be 
more than two times higher before costs exceed savings for the prenatal and 
preconceptional SETS screening strategies. Even if the costs of individual information 
would be zero, costs exceed savings for school screening and DETS preconceptional 
screening. 
Costs of testing form a large part of total screening costs, ranging from 24% in 
prenatal SETS screening to 48% in neonatal screening. For prenatal screening and 
SETS preconceptional screening, costs will be higher than savings only if the costs of 
tests rise by more than 37%. However, if the costs of the tests could be lowered by 
approximately 20% all screening strategies (except school screening) would have a 
positive cost-savings balance. 
In the multi-variable threshold analysis, we determined by what percentage the 
parameter values mentioned in the single-variable threshold analysis could 
deteriorate simultaneously from the baseline values before costs exceed savings (see 
the last line of Table 5.3). As an increase in the parameter values (except for costs of 
information and costs of testing) leads to higher savings or lower costs, or both, we 
decreased these values by a given percentage, while we increased the costs by that 
same percentage. The conclusion of this multi-variable threshold analysis is that the 
parameter values for the prenatal screening programmes can deteriorate 4% or more, 
and the values for SETS preconceptional screening 2%. On the other hand, the 
parameter values of DETS preconceptional screening and neonatal screening should 
improve 3% before savings exceed costs, while school screening will never have a 
favourable cost-savings balance. 
5.3.2 Other CF gene carrier prevalences 
As the CF gene carrier prevalence varies between countries, we calculated the net 
economic savings for carrier prevalences between one in 35 and one in 25 (Figure 5.1). 
Using this figure, readers can determine the net economic savings in their country or 
situation, provided the costs structure is similar to the one we used. 
As expected, the cost-savings balance worsens for all strategies if the carrier 
frequency is lower, but single-entry prenatal screening remains the best strategy from 
a costs point of view. The costs in this strategy will exceed the savings only if the 
carrier frequency is lower than 1 :36. If the carrier frequency is higher than 1 :28, both 
DETS preconceptional screening and neonatal screening will have a favourable cost-
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Figure 5.1 Net economic savings per year for six CF gene screening strategies for 
different CF gene frequencies 
savings balance. This means that, other things being equal, prenatal, preconceptional, 
and neonatal screening would have higher savings than costs in countries (for 
example, UK and USA) where the CF gene carrier frequency is higher than one in 25. 
School screening will only have higher savings than costs with a theoretical carrier 
frequency of 1 :18. 
5.4 Discussion 
Using a decision analytic model we found that there are no economic objections 
against prenatal screening and single-entry preconceptional screening for carriers of 
the CF gene when we take costs of care of CF patients into account. For double-entry 
preconceptional screening, neonatal screening, and school screening, costs are higher 
than savings. In a sensitivity analysis, this conclusion remained valid for prenatal and 
single-entry preconceptional screening programmes for a wide range of other 
plausible assumptions. For double-entry preconceptional screening and neonatal 
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screening programmes, a favourable cost-savings balance can only be obtained if 
uptake of screening, prenatal diagnosis or induced abortion would be higher than our 
assumptions, or if the costs of testing would be lowered by 20%. School screening will 
never have a favourable cost-savings balance. 
We investigated if the poor performance of the neonatal and school screening 
strategies could be improved upon by testing all persons for 17 CF mutations. In this 
scenario more carrier couples are detected and more CF patients are avoided than in 
the baseline scenario, but the increased savings of the avoided patients does not 
offset the higher costs of screening. Consequently, this scenario has a worse cost-
savings balance than the baseline scenario. 
Although our model is primarily quantified for the Dutch situation of CF gene 
screening, it can be adapted for use in other countries or even for other autosomal 
recessive genetic diseases by changing the relevant parameter values. For example, 
because the carrier frequency in the United Kingdom is higher (1 in 2S) than in The 
Netherlands (37), screening for CF gene carriers has a better cost-savings balance, 
provided the costs structure, and especially the relative magnitude of costs and 
savings, is similar to the Dutch situation. Using the 1 in 25 prevalence of CF gene 
carriers, we calculated a cost per detected carrier couple of €47,000 for prenatal SETS 
and €56,000 for DETS. These results are much higher than those of Cuckle et al. (26), 
who calculated a cost per detected carrier couple of €24,000 for sequential prenatal 
screening (SETS in our notation) and €27,000 for couple screening (almost similar to 
DETS). An explanation is that they took a 100% uptake of prenatal diagnosis and 
induced abortion and did not include costs of further diagnosis and treatment. Morris 
and Oppenheimer (22) concluded that sequential prenatal screening costs €45,000 
per detected carrier couple and couple screening €44,000. These costs are somewhat 
lower than ours because we took the costs of further diagnosis and treatment into 
account. 
It should be borne in mind that, even when savings exceed costs, financing a 
screening programme for CF gene carriers is not straightforward, because the 
screening budget has to be made available now, while the savings of the programme 
will only appear later. Moreover, savings may be realised in different budgets than the 
costs of screening are made, so that a conflict of interests may arise. 
The reader should note that CF is a disease for which advances in medical treatment 
are or will (probably) be made, for example, lung transplantation and introduction of 
gene therapy (60, 61). This progress in treatment will most probably have an impact 
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on the length and quality of life of a CF patient (62). Whether lifetime costs of CF for 
such a patient will increase or decrease remains to be seen. And when-hopefully-
treatment improves the life of CF patients even more, screening for CF gene carriers 
will be a thing of the past. 
The present paper focussed deliberately on cost aspects. There is much more to be 
discussed in genetic screening than costs. Economic considerations should not be the 
primary goal of any screening programme, but a careful cost analysis and a discussion 
of cost-effectiveness and the cost-savings balance as reported in this paper, is an 
essential part of a full evaluation. Prenatal and single-entry preconceptional CF 
screening have from an economic point of view roughly comparable and reassuring 
cost prospects. When other aspects are also considered, single-entry preconceptional 
screening, which has a slightly worse cost-savings balance, possibly has to be 
preferred because with that strategy all reproductive options are still open for a carrier 
couple. Lack of participation will not be irreparable when prenatal screening is used as 
a 'safety net' for pregnant couples who did not attend the preconceptional screening 
programme. 
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Part 3 
Fragile X syndrome 

6.1 Introduction 
Chapter 6 
Fragile X syndrome 
The first pedigree with clear familial X-linked mental retardation was reported in 1943 
by J.P. Martin and J. Bell (1). They described a family in which eleven mentally retarded 
sons from two generations had been born from normally intelligent mothers, and 
concluded that the mental defect was due to a sex-linked recessive gene. 
Furthermore, they noted that in two known instances relatively slight mental 
retardation had occurred in females and suggested that in these two the causal 
mutation was incompletely recessive. Using metaphases of cells from patients with 
X-linked mental retardation, Lubs (2) was the first to describe a fragile site near the 
end of the long arm of the X chromosome, that appears as an unstained gap or break 
at a defined point on the X chromosome; therefore the disorder is named fragile X 
syndrome. Only a part of the patients show this fragile site in a part of their cells; this 
complicated the diagnosis of fragile X syndrome for a long time. In 1991, the gene 
responsible for fragile X syndrome was sequenced and cloned (3). It was shown that in 
almost all cases a large increase in the length of a part of this gene causes fragile X 
syndrome (see '6.3 Genetics'). Therefore, a distinction is generally made between 
normal (normal repeat length), premutation (a small increase in repeat length) and full 
mutation (a large increase in repeat length). 
6.2 The disorder 
Mental retardation is the most prominent feature of fragile X syndrome. 10 in most 
males with fragile X syndrome is below 70 (mean 10 approximately 40), and decreases 
with age in many patients (4). Eighty percent of all affected males have one or more of 
the following dysmorphic features: high forehead, large prominent ears, big jaw, 
macroorchidism, hyperextensibility of joints, and high-pitched, jocular speech (5-7). 
Not every patient shows all the physical symptoms, which are generally more 
apparent after childhood. Behavioural abnormalities include hand flapping and biting, 
excessive shyness (avoidance of eye contact), hyperactivity, and some have autistic 
features (6). Although it is most unusual for men with fragile X syndrome to have 
children, there are some exceptions described in literature (8-11); however the 
-79-
Chapter 6 
presence of the full mutation in these patients has not been confirmed by DNA 
testing. 
Approximately sixty percent of females with a full mutation has some mental 
retardation, and the degree of this retardation is on average less than in males (12-14). 
The behaviour problems are milder and fewer and the dysmorphic features less 
obvious (15, 16). In fragile X carrier females of normal intelligence there is an increase 
in psychiatric symptoms, particularly schizophrenia-spectrum disorders (17, 18). 
Premutations are not associated with a clinical phenotype (19, 20) and are found in 
female carriers and so-called normal transmitting males. Both full mutation and 
premutation women have similar numbers of pregnancies as non-carrier women, and 
the sex ratio of the children does not differ from those of normal women (21, 22). 
Furthermore, the survival of both full mutation and premutation carriers is the same 
as for the general population. 
6.3 Genetics 
The fragile X syndrome is the most common cause of mental retardation caused by a 
single gene defect and is associated with a fragile site, designated FRAXA, on the long 
arm of the X chromosome at Xq27.3 (23). The molecular basis for the syndrome 
usually is a large expansion of a repetitive CGG triplet sequence located in the 
5' untranslated region of the fragile X gene, FMRl (3, 24-28). In rare cases (less than 
5%), the syndrome is due to either a deletion of part or all of the FMRl gene (29-36) or 
a point mutation within an RNA binding domain (37, 38). The phenotype of these 
individuals is indistinguishable from those with a large expansion; therefore it appears 
that absence of functioning FMRl protein causes fragile X syndrome. 
The length of the CGG repeat varies in the normal population (polymorphism) from 6 
to 52 repeats with a mode of 30 and is stable on transmission (24, 39-42). Alleles that 
are not stable upon transmission can be divided into premutation alleles and full 
mutation alleles. Premutation alleles range from 43 to 200 repeats and exhibit 
instability, usually resulting in increases in repeat number in the offspring (25, 42-45). 
The most important risk factor for the instability of the pre mutation allele is the sex of 
the transmitting parent (46, 47). If a father transmits a premutation to his daughter, 
the premutation size usually increases or decreases by less than 10 repeats; males 
with a premutation are called normal transmitting males (48,49). These premutations 
may however become unstable in their daughter's offspring (24, 50, 51). These 
findings explain the phenomenon known as the 'Sherman paradox' in which 
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penetrance of mental impairment is lower in the daughters of transmitting males than 
in their granddaughters (48). No well-defined boundary exists between the normal 
and premutation state. The term 'grey zone' has been used to describe this region of 
repeat numbers between approximately 45 and 55 repeats, which includes large 
normal and small premutation alleles. 
In fragile X syndrome patients the CGG repeat is amplified beyond 200 copies (full 
mutation) (24) and the concomitant hypermethylation of the preceding CpG island 
represses the transcription of FMR1 (55-57). This results in the absence of the FMR1 
protein (FMRP) leading to the fragile X phenotype (58, 59). Full mutations are always 
derived from full mutations or from maternal premutations, with the rate of transition 
being directly related to the maternal repeat length (Figure 6.1, Table 6.1). The 
smallest premutation size in a mother that expanded to a full mutation reported in 
the literature was 59 triplets (54). Published expansion risks from premutation to full 
mutation are almost certainly biased upwards, since they are obtained by analysing 
families that are detected by an index fragile X syndrome patient. They should 
therefore be used with caution if applied to general population screening where 
pre mutations might be somewhat more stable (60). 
Approximately 15-20% of patients (so-called mosaics) has a full mutation in the 
majority of their cells, but carry a premutation in a small number of cells (12, 25, 47, 55, 
57,61). These patients exhibit variation in the DNA methylation, but in general do not 
appear to be less severely affected than patients with a full mutation (12). For this 
reason we consider in the analyses described in this thesis mosaics as belonging to 
the full mutation group. 
Table 6.1 Probabilities of transmitting a full mutation to their offspring by 
premutation women 
No. of CGG (epeats Fu Heitz Yu Snow Shennan Turner Valsanen Fisch Nolin Totalt 
(24) (50) (51) (39) (22) (52) (53) (43)' (54) 
N=63 N=131 N=89 N=75 N=24 N=2S4 N=79 N=l84 N=393 N=l,lS4 
-69 8% 10% 20% 67% 56% 36% 18% 21% 32% 
70-79 71% 47% 27% 28% 50% 56% 85% 39% 63% 50% 
80-89 82% 69% 56% 79% 80% 78% 100% 77% 68% 72% 
90-99 100% 90% 56% 100% 100% 78% 100% 89% 92% 87% 
100-109 100% 93% 56% 100% 100% 78% 100% 91% 100% 91% 
110-119 100% 100% 789'0 100% 100% 87% 100% 100% 97% 95% 
120-129 100% 96% 100% 87% 100% 100% 100% 97% 
130- 100% 94% 87% lOo~6 95% 96% 92% 
Total 70% 77% 69% 65% 88% 76% 62% 67% 80% 75% 
• includes pedigrees from Fu (24). Snow (39) 
t data from fu (24). Snow (39) not included since they are included in Fisch (43) 
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Figure 6.1 Proportion of offspring with a full mutation from premutation 
women, obtained by a logistic regression analysis. The closed circles represent 
the midpoints of the premutation categories in Table 6.1 
In the normal population, one AGG triplet interrupts the CGG string every eight to 
twelve eGG repeats on average (41, 42, 44, 45, 62, 63). In premutation alleles the 
stretch of so-called pure eGGs (no interspersion of AGGs) is increased. Because it is 
postulated that the threshold for instability is about 34-38 pure eGGs (44), the risk for 
fragile X 'grey-zone' alleles to expand appears to depend on the absence of stabilising 
AGG repeats (45, 64). 
Because affected males rarely reproduce, a very high mutation rate has been 
suggested to maintain the frequency of the disorder (65). If this would have been the 
case, variation between different ethnic groups would be minimal. However, no new 
mutations have been described for fragile X syndrome (51, 66-68). Actually, founder 
effects have now been identified through the demonstration of linkage 
disequilibrium, so that varying prevalence figures are to be anticipated in different 
ethnic populations (45, 68-74). For example, the broad geographical distribution of 
the 153-196 fragile X haplotype all over Finland indicates that it is of ancient origin 
Fragile X syndrome 
and that it was most likely present in the founder population of Finland about 100 
generations ago (71, 75). As an alternative for founder chromosomes it has been 
suggested that this might be because certain haplotypes have a larger number of 
CGG repeats which might make them more mutable, and thus more likely to give rise 
to a premutation or full mutation (72, 76). The data of Buyle et al. (68) suggest that a 
founder effect of the fragile X mutation also exists in the Belgian and Dutch 
populations. 
A four-allele model, which describes the CGG expansion process, postulates four 
distinct allele states based on overall length (75). In this model. the normal (N) allele 
with fewer than approximately 40 repeats is stable, the intermediate (5) allele with 
approximately 40-60 repeats is prone to conversion at a low rate to the unstable 
premutation (Z) allele with approximately 60-200 repeats, which in turn has a high 
likelihood of conversion to the full mutation (L) allele. This four-allele model has been 
generalised to nine alleles (77) and to n alleles by using empirically derived risk figures 
(78). However, because it is difficult to determine which of the 5 alleles are likely to be 
unstable by CGG repeat length determination, it has not been practical to apply these 
models clinically to determine accurately the risk of expansion for intermediate alleles 
detected within the 'grey zone'. Fisch et al. (79), using different CGG repeat numbers 
as cut-off criteria between general and premutation populations, concluded that no 
members from either the general or the premutation popUlation were misclassified in 
their study if a cut-off of 55 CGG repeats was used, while one (out of 939) individuals 
from the general popUlation would be misclassified as being from the premutation 
population if a cut-off of 50 CGG repeats would be used. 
6.4 Prevalence 
6.4. 1 Fragile X syndrome and full mutations 
The two biggest studies on the prevalence of fragile X syndrome were performed in 
England and Australia (80, 81). Webb et al. (80) carried out a clinical and cytogenetic 
study of 219 boys and 104 girls between 11 and 16 years of age who attended schools 
for the educationally handicapped or who were in residential accommodation in 
Coventry, England, and detected 16 boys and 10 girls with fragile X syndrome. 
Children who had a specific cause of mental retardation in their record were not 
included in the study. Correcting for parents who did not agree that their child was 
tested, and assuming that no patient was missed, they estimated the frequency of 
fragile X syndrome to be 1 in 1,360 for males and 1 in 2,073 for females. In that same 
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year, Webb et al. (82) gave an update on the previous study and presented a 1 in 9S2 
prevalence of the fragile X mental retardation syndrome for all school age children. 
After the discovery of a non-pathological fragile site at Xq27.2 (FRAXD, the 'common 
fragile site') (83), which may be confused with the mental retardation fragile site at 
Xq27.3 (FRAXA, the 'rare fragile site'), Webb et al. reanalysed their data and concluded 
that they mistakenly diagnosed 2 patients for sure and two patients probably as being 
FRAXA. Therefore they adjusted the prevalences to 1 in 1,039, approximately the same 
for both sexes (84). In 1991, after the cloning of the FMRl gene, they retested the 
school children with molecular analysis (85). Fragile X syndrome was excluded in 13 of 
the children, so that the estimated frequency of fragile X syndrome dropped to 1 in 
2,197. 
Turner et al. (81) also cytogenetically tested children between 5 and 18 years in special 
schools and special classes in Sydney, Australia, and also screened persons of all ages 
who resided in institutions, day activity centres and sheltered workshops. Again, 
persons who had a recognised cause of mental retardation were excluded from the 
study, and the figures were corrected for persons who refused screening. They 
detected 28 male fragile X syndrome patients out of 599 tested and 12 female 
patients out of 322 tested, leading to a 1 in 2,610 frequency for males and 1 in 4,221 
for females. 
In 1996, Turner, Webb et al. updated the prevalence figures of their respective studies 
(94). They retested all boys who were identified by cytogenetic tests as having 
fragile X syndrome by molecular analysis and corrected the prevalence figures to 1 in 
4,090 for Coventry (originally 1 in 952) and 1 in 4,350 for Sydney (originally 1 in 2,610). 
Since these estimates were almost similar, the authors concluded that "a more realistic 
figure based on molecular analysis is 1 in 4,000". 
Since (almost) all male persons with a full mutation have fragile X syndrome (12), the 
prevalence of full mutations among males is the same as the prevalence of fragile X 
syndrome males, namely 1 in 4,000. There are no reasons to assume that the 
prevalence offull fragile X mutations would be different in females than in males as 
the paternally derived X chromosome does not show a full mutation. However, only 
59% of females with a full fragile X mutation are mentally retarded (12), so that the 
prevalence of fragile X syndrome mentally retarded females is 1 in 4,000 times 59%, 
which is apprOXimately 1 in 7,000. 
In The Netherlands, de Vries et al. screened a representative sample of 3,352 
individuals in schools and institutes for the mentally retarded (95). Assuming the same 
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prevalence in participating and non-participating individuals, they estimated a 
fragile X syndrome prevalence of 1 in 6,045 boys (95% confidence interval: 1 in 9,981 
to 1 in 3,851), which is just not significantly lower than the consensus estimate of 
Turner et al. (94). 
6.4.2 Premutations 
With regard to premutations, the situation is not so clear-cut. There are a few small-
scale studies performed that determined pre mutation prevalences ranging from 0 in 
227 females to 1 in 197 (Table 6.2). The largest study performed on the normal 
popUlation is that of Rousseau et al. (88). In this study, 41 premutation alleles were 
found in 10,624 persons from an unselected popUlation, leading to a premutation-
frequency of 1 in 259. Furthermore, using this premutation frequency and assuming 
that the risk of expansion of a premutation allele was the same as that in fragile X 
families (50), the authors of that study calculated a fragile X syndrome prevalence of 
1 in 2,381 (42/100,000) in the French Canadian population, which is 68% higher than 
the consensus estimate of Turner, Webb et al. (94). However, there are indications of 
founder effects in the French Canadian population (96), so that the premutation 
frequency obtained from this population should be used with caution for other 
populations. Furthermore, Sherman speculated that women who are cognitively 
impaired were not included in this study, so that Rousseau et al. only estimated the 
frequency of pre mutation carrier females and did not attempt to determine the 
frequency of full mutation carrier females. Therefore, an estimate with regard to the 
premutation prevalence in an un selected population without founder effects would 
be 68% lower, which is 1 in 435. It is this figure that is used throughout the analyses 
performed in this thesis. 
6.5 Screening and screening test 
The cloning of the fragile X syndrome gene in 1991 has created a discussion whether a 
DNA screening programme for premutation and full mutation carriers in the general 
population should be investigated in a pilot study or even implemented (60, 97-103). 
The main goal of general population carrier screening is to identify premutation and 
full mutation carriers and thereby give them the possibility of an informed 
reproductive choice. For example, they can decide to become pregnant and to have 
prenatal diagnosis by DNA sampling of a chorionic villus sample or amniocentesis 
sample. 
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Table 6.2 Prevalence of premutations (~55 eGG-repeats) in females and males in 
the general population 
Ye" Fem.le M.le 
Snow et.1. (39) 1993 1/197 0/50 
Arin.mi et.1. (86) 1993 0/227 0/370 
Reis"t .1. (87) 1994 1/561 0/416 
Rousseau et.1. (88) 1995 41/10,624 
Brown et.1. (89) 1996 6/2,500 
D.wson et .1. (90) 1995 2/735 3/778 
Spence (91) 1996 3/745 
Eichler et.1. (92) 1995 0/406 
Holden et.1. (93) 1995 1/1,000 
Tot.1 54/15,589 413,020 (1/289) (1/755) 
Southern blot analysis is used for screening since the cloning of the gene (24, 25, 47, 
104,105). It detects premutations and full mutations (25, 28, 47), gives information 
about methylation (47) and, if the right probe is used, detects deletions in the FMRl 
gene (106). However, Southern blot does not give a precise estimation of the number 
of eGG repeats (107) and misses some small pre mutations. Moreover, especially 
important for a general population screening programme, Southern blot is very 
labour-intensive and thus expensive at €67 in The Netherlands (108), takes a lot of 
time before the test result is known (2 weeks or more), and demands relatively large 
amounts of DNA, 
peR on the other hand gives a rather accurate estimation of the number of eGG 
repeats (24, 40) and does not miss small premutations. Furthermore, it gives a quick 
test result (1-2 days), is less expensive at €21 in The Netherlands (108) and does not 
need a large amount of DNA. On the other hand, peR does not give information about 
methylation status and has its limitations in detecting deletions in the FMRl gene, The 
most important disadvantage with regard to general population screening is that peR 
can not detect very large premutations and full mutations (109), so that it can not 
discriminate between women with two X chromosomes of the same number of eGG 
repeats and women with a combination of one normal-size X chromosome and one 
large premutation or full mutation. The two groups of women, approximately 40% of 
all women (40), subsequently have to be retested with Southern blot analysis. 
There are several arguments against general population carrier screening, An 
important argument (99, 102), acknowledged also by proponents of screening, is the 
inability to predict the intellectual status of a female foetus with a full mutation, since 
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only approximately 60% of these has some mental retardation (12-14). Methylation 
gives some indication about the degree of mental retardation, but is not a perfect 
prognostic value. This makes the decision whether or not to terminate a pregnancy of 
a female foetus with a full mutation very difficult and requires delicate counselling 
(110). The results from seven studies show that more than S7% of the pregnancies of 
female foetuses with a full mutation detected by prenatal diagnosis are terminated 
(111). Another problem is the inability to determine between large normal alleles (that 
can not expand to a full mutation) and small premutation alleles ('grey zone' alleles 
that can expand to a full mutation). Generally, opponents of general population 
screening point out that the complicated inheritance pattern of fragile X syndrome 
necessitates appropriate follow-up counselling (102). The advocates of general 
population screening on the other hand point out that this counselling is available in 
genetics clinics, so that population screening can be offered appropriately (100). 
The American College of Medical Genetics (102) does not recommend population 
screening, except as part of a well-defined clinical research protocol. However, the 
College gave guidelines that the following special populations could be tested: 
patients with some form of mental retardation and/or features that are prominent of 
fragile X syndrome; patients with a family history of fragile X syndrome or 
undiagnosed mental retardation (cascade testing); foetuses of known carrier mothers. 
Screening persons in institutions who do not have a definite diagnosis for their mental 
retardation has been done since a long time. First, the testing was done by 
cytogenetic detection of the fragile site in lymphocytes. After the cloning of the 
fragile X syndrome gene this was replaced by Southern blot analysis and PCR. 
Provided the tests are done with 'good laboratory practice', DNA testing for fragile X 
syndrome has an almost 100% sensitivity and specificity (47). Even opponents of 
patient screening acknowledge that "many parents of affected males who have had to 
trudge back and forth to their general practitioners trying to convince them that there 
is something wrong with their child" would benefit from neonatal patient screening 
(112). These patients can then be 'used' as so-called index patients to test relatives 
and give them an informed choice (cascade testing). 
In Chapter 7 of this thesis, we analyse the cost, effects and savings of general 
population preconceptional, prenatal and school screening programmes for fragile X 
syndrome carriers, and in Chapter 8 we describe the effectiveness of cascade testing 
for fragile X syndrome. We would like to stress again that the most important 'gain' of 
screening is not the economic gain because less fragile X syndrome patients are born. 
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As Modell et al. (113) (cited by Turner et al. (114)) observed: "accepted affected 
children (born because informed parents decided not to have prenatal diagnosis or 
not to terminate an affected pregnancy) are a benefit not a cost". 
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Chapter 7 
Explorative study of costs, effects and savings 
of screening for female fragile X premutation 
and full mutation carriers in the general 
population 
7.1 Introduction 
The fragile X syndrome is the commonest cause of mental retardation from a single 
gene defect. It is transmitted in an X-linked semi-dominant fashion, with females 
being typically more mildly affected than males (1). Affected males may show 
suggestive physical features (the Martin-Bell phenotype), consisting of long face and 
ears, rather coarse features and macroorchidism. However, the phenotype may go 
unnoticed and cannot be relied upon to make the diagnosis. The dysmorphic features 
in females with frayile X syndrome are less obvious (2). 
The syndrome is characterised by the amplification of a eGG repeat present in the 5' 
untranslated region of the FMR1 gene (3-6). The length of the eGG repeat varies in the 
normal population from 6 to 52 repeats and is stable on transmission (7). Premutation 
alleles ranging from 43 to 200 repeats exhibit instability, usually resulting in increases 
in repeat number in the offspring. Premutations are not associated with a clinical 
phenotype and are found in female carriers and so-called normal transmitting males. 
In fragile X syndrome patients, the eGG repeat is amplified beyond 200 copies (full 
mutation) and the concomitant hypermethylation of the preceding epG island 
represses the transcription of FMR1 (8). This results in the absence of the FMR1 protein 
leading to the fragile X syndrome phenotype (9, 10). 
The cloning of the gene and the knowledge of the inheritance pattern of the fragile X 
syndrome make it possible to consider a screening programme for premutation and 
full mutation carriers in the general population (11-18). Several general-population-
based screening strategies have been suggested for genetic diseases and are being or 
have been analysed in a pilot study (19). Of these, prenatal, preconceptional, and 
school screening can, on technical grounds, also be considered for general population 
fragile X screening. Neonatal carrier screening cannot be considered for general 
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population screening because Southern blot analysis on a blood spot does not appear 
to be feasible. 
The primary aim of a fragile X screening programme is to detect carrier status and 
counsel women who are carriers of a pre mutation or full mutation so that they have 
an informed choice about reproduction, but there are also many health-related, 
psychosocial, ethical, legal and economic consequences. In The Netherlands, the 
Dutch Health Council has recently provided a number of criteria for genetic screening 
programmes intended to ensure systematic assessment of such programmes before 
their introduction (20). The last criterion in this report states that if the favourable 
non-economic consequences for the participants clearly outweigh the unfavourable 
consequences, costs and effects of the screening programme should be calculated 
and checked in view of a fair distribution of resources within the total area of the 
health service. We started a prospective evaluation of the cost-savings balance of 
screening for fragile X carriers to determine whether there are economic arguments to 
decide against a screening programme and what kind of programme is the most 
favourable one from an economic point of view. Also, we relate costs to effect 
measures. The methodology of this evaluation has also been used for an evaluation of 
the costs, effects and savings for screening for carriers of the cystic fibrosis gene (21). 
7.2 Materials and methods 
We developed a decision-analytic model for a screening programme for fragile X 
female premutation and full mutation carriers. We divided the premutation categories 
according the number of CGG repeats using 55 CGG repeats as a cut-off between 
general population and premutation alleles (22): CGG repeats between 55 and 59, 
60-69,70-79,80-89 and 90-200 CGG repeats. We made two full mutation categories: 
full mutation with and without mental retardation. 
We prospectively evaluated three different screening strategies taking the Dutch 
situation as an example: prenatal screening, preconceptional screening, and school 
carrier screening. For each screening strategy we calculated the expected costs, 
effects and savings for a l-year screening period. Fragile X-related effects, costs and 
savings that occur later were taken into account using a 3% annual discount rate for 
the costs and savings; effects were not discounted. For comparison, we also calculated 
results of a maximum yield scenario in which we set information preservation and 
uptake of screening, prenatal diagnosis and induced abortion at 100%. Because 
prenatal and preconceptional screening are probably more desirable than school 
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screening, we will discuss these two strategies in more detail in the 'Results' section. 
The knowledge about and experience with fragile X screening is not very large. 
Therefore a relatively large number of assumptions have to be made in our analysis. 
For this reason, we conducted a sensitivity analysis to assess the stability of the results 
of our analysis. In this analysis, we varied the values of selected assumptions while 
keeping all other parameters at their baseline values. We also varied the values of all 
selected assumptions simultaneously in a multi-variable sensitivity analysis. After a 
brief explanation of the screening strategies, we describe the assumptions and 
parameters that we used in our analysis (Table 7.1). 
7.2. 1 Screening strategies 
Prenatal screening 
In the prenatal screening strategy, a pregnant woman is screened as early in her 
pregnancy as possible so that chorionic villus sampling (CV5) is still possible in case 
she is a detected carrier. Prenatal screening provides a suitable gateway for genetic 
screening because questions concerning familial disease often arise in early 
pregnancy. Furthermore, it is relatively easy to integrate this form of fragile X 
screening in the existing health care system because almost all women who suspect 
to be pregnant consult a general practitioner or midwife. Prenatal screening is the 
only form of screening in which not all reproductive options are possible: the carrier 
couple can obviously not decide to refrain from conceiving children, to adopt a child 
or to have egg cell donation. Furthermore, the reproductive choices that are still 
possible (accepting the risk of giving birth to a fragile X syndrome child or having 
prenatal diagnosis possibly followed by induced abortion) have to be made in a 
relatively short time span. Only for subsequent children all reproductive options are 
open. 
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Table 7.1 Assumptions used in the analysis offragile X carrier screening 
Fragile X prevalences 
Females with premutation 
Males with premutation 
Probabilities 
1:435 
1:871 
Females with full mutation 
Males with full mutation 
Probability of a new premutation 0% 
Probability of a ba(k~mutation from premutation size to normal size 0% 
FuJI-mutation boys with mental retardation 10096 
FuH~mutation girls with mental retardation 59% 
Probability of a couple being unIVantedly childless 10% 
Probability of a couple being deliberately childless 10% 
Autosomal chromosome abnormalities at birth 1:500 
Sex chromosome abnormalities at birth 1:500 
Recurrence risk of chromosome abnormalities 1,50% 
Iatrogenic abortion after OJS 0.75% 
No amplification of PCR 10% 
1 DNA band at PCR 40% 
Southern blot fails 10% 
Costs 
DNA~extra(tion 
Costs for the screenee 
PCR test 
Southern blot 
Counselling a carrier 
Prenatal diagnosis 
€7.96 
€7.00 
€21.27 
€66.68 
€101.0J 
€1,270.58 
Induced abortion 
Early spontaneous abortion 
late spontaneous abortion 
Iatrogenic abortion 
Discount rate for costs 
1:4,000 
1:4,000 
€221.01 
€69.1J 
€444.J6 
€69.2l 
3% 
Screenlng--depeodent parameters Prenatal Preconceptlonal 
Target group size 
(overage of people without fragile X mental retardation 
(overage of people with fragile X mental retardation 
(overage of people who were not screened for their 1>1 chUd 
Information retention 
Mass information costs 
Personal information costs 
Organisation costs 
Parameters depending on carrier status of the screened 
Norm 
Persons who refrain from having children 0% 
Uptake of prenatal diagnosis 0% 
Paramet", depending on the status ofthe foetus 
Norm or PM 
Early spontaneous abortion 
Late spontaneous abortion 
Uptake ofinduced abortion 
Costs of care of patient 
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1.95% 
1.55% 
0% 
€O 
100,000 
75% 
37.5% 
25% 
100% 
€J14,470 
€5.45 
€17.2J 
Premutation 
15% 
75% 
FMboys 
1.95% 
1.55% 
90% 
€847,472 
100,000 
50% 
25% 
25% 
100% 
€524,116 
€2.72 
€17.1J 
Full mutation 
15% 
75% 
FMgiris Aut.abn. 
1.95% 21.21% 
1.55% 19.70% 
45% 95% 
€472,1J2 €66J,854 
Sex.abn. 
6.15% 
2.79% 
75% 
€O 
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Precanceptional screening 
Preconceptional screening concerns women who consider having a child and want to 
receive information about their carrier status. The screening result is known prior to 
the (potential) reproduction so that all reproductive options are open to the carriers. 
Since some women need time to psychologically accept that they are carrier (23), 
many people advocate preconceptional screening rather than prenatal screening. In 
most countries (including The Netherlands), a major obstacle to preconceptional 
screening is the absence of a preconceptional consultation system, so that a high 
coverage of screening is unlikely. Furthermore, coverage will probably depend on the 
way in which people are approached, as has been shown for cystic fibrosis carrier 
screening (24-26). 
School screening 
In the school screening strategy, acquisition of the testing material can take place 
within the school environment. To minimise the time between screening and 
(potential) reproduction, pupils in the last year of compulsory education (in The 
Netherlands at the age of 16) should be offered the test. Studies in Italy and Canada 
on thalassaemia and Tay-Sachs disease screening show that school screening for 
carriership of genetic diseases is feasible (27, 28). From a community-genetic 
perspective, this type of screening can offer an opportunity for teaching genetics, but 
this has also been questioned (29). One concern is the lack of confidentiality of test 
results. Furthermore, good information is important because school screening takes 
place at a rather unstable stage of life and might lead to stigmatisation. 
7.2.2 Target populations and coverage 
Premutation and full mutation males never pass a full mutation X chromosome to 
their children. Because the aim of a fragile X screening programme is to inform carriers 
who are at risk of having a fragile X syndrome child, only women are the target of 
screening. 
In The Netherlands, 189,521 children were born in 1996 of whom 85,792 were 
firstborns (30). The average age of a primigravida is 28.9 years; the mean interval 
between two subsequent pregnancies is 2.9 years (30). In our calculations, we work for 
ease of interpretation with a simplified stable population of 1 00,000 couples. 
We corrected for the probability of spontaneous abortion between the time of 
screening and time of birth (see below). If applicable, we corrected with a 10% 
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probability of a couple being infertile (31) and assumed in the school screening 
strategy that 90% of females will later form a couple that wants a child (32). 
Furthermore, we assumed that in all screening strategies 85% of the people with a 
firstborn child will have a second child after 3 years on average (32, 33). For 
computational simplicity, we ignore in our calculations the birth of children who are 
third born or more. This assumption will obviously not have effects on the costs per 
detected carrier couple, but will lead to a conservative estimate of the cost-savings 
balance. 
As discussed in the description of the strategies, coverage is probably highest for 
prenatal screening and somewhat lower for school screening. For preconceptional 
screening, coverage depends very much on the existence of a preconceptional 
consultation system and on the way in which people are approached (24, 26). As 
(arbitrary) basic assumptions, we set the coverage values at 75% for prenatal 
screening and 50% for preconceptional and school screenings. For the coverage of 
women with fragile X syndrome, we took half of these baselines, as several studies 
have shown that they participate less in screening programmes (34, 35). For people 
who did not attend screening for their first child, we took an attendance rate for the 
second child of 25% for people without fragile X syndrome and 12.5% for people with 
fragile X syndrome. 
7.2.3 Information preservation 
In the Tay-Sachs disease prevention programme in Montreal, Zeesman et al. (28) 
found that after 8 years 90% of the screened pupils Were able to retrieve the test 
result regarding carriership. Because the time between testing and possible use of the 
carrier information for school screening is of the same order of magnitude (12-13 
years in our analysis), we took this value for the information retention rate of school 
screening. Although there is also a time lag between screening and use of information 
in the preconceptional screening strategy (1 year in our analysis), we assumed an 
information retention rate of 100% for this strategy. Furthermore, we assumed that 
someone who has not retained the carrier information will not be retested. 
7.2.4 Tests 
The samples of people in the target group are tested with a polymerase chain reaction 
(PCR) test that takes approximately 8 hours. In about 10% of the samples no 
amplification will occur so that a repeat PCR test has to be performed (G. Pals, 
personal communication). In 40% of the samples, the PCR test will show only one 
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band, either because a person has two alleles of the same size or two alleles that differ 
by only one CGG repeat, or because a person has one normal-size allele and one long 
DNA sequence (large premutation or full mutation) which escapes detection in the 
PCR test (36). In these cases, Southern blot analysis is performed which will fail for 
technical reasons in 10% of the cases so that a repeat Southern blot is needed (G. Pals, 
personal communication). In the model we presume that after these tests the number 
of CGG repeats or the presence of a full mutation is known with certainty and that 
both PCR and Southern blots are performed on one blood sample. 
If the woman is pregnant and decides to have prenatal diagnosis, CVS is performed at 
10-12 weeks gestation. The sample is examined in the same way as the sample of the 
woman with PCR and Southern blot. In addition to these tests, the villi are routinely 
tested for maternal contamination and for chromosomal abnormalities. We presumed 
a 100% sensitivity and specificity of the DNA tests. In The Netherlands, karyotyping of 
the foetus is offered to women of advanced maternal age (36 years and older), and 
approximately 50% of the women make use of this offer (37). Since approximately 
88% of the births are from women younger than 36 years (30), only a small percentage 
of pregnant women will have karyotyping of the foetus. Because of this, and because 
triple marker screening for Down syndrome and neural tube defects is not actively 
being offered in The Netherlands, the number of detected foetuses with chromosome 
abnormalities mentioned in this article can almost completely be accredited to the 
fragile X screening programme. 
7.2.5 Prevalence, risk and recurrence 
The prevalence of both males and females with a full mutation has been estimated as 
1 :4,000 by Turner et al. (38). In The Netherlands, de Vries et al. (39) screened a 
representative sample of 3,352 individuals in schools and institutes for the mentally 
retarded. They estimated a fragile X syndrome prevalence of 1 in 6,045 boys (95% 
confidence interval: 1 in 9,981 to 1 in 3,851). Since the 1:4,000 estimate is based on 
larger groups and since this estimate is contained in the confidence interval of de 
Vries et aI., we used the 1 :4,000 prevalence. 
In the largest general popUlation-screening programme to date, Rousseau et al. (40) 
detected 41 women with 55 CGG repeats or more among 10,624 women. They 
estimated a frequency of full mutation carriers in French Canada of 42:1 00,000, which 
is approximately 1.68 times the figure of Turner et al. (38). Because there are 
indications of founder effects in the French Canadian popUlation (41), we decided to 
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divide the premutation frequencies obtained by Rousseau et al. by 1.68, assuming 
that a decrease in pre mutation frequency will cause a similar decrease in full mutation 
frequency. Therefore we took a premutation frequency of 1 :435 in females. Male 
premutation prevalences were taken as half of those of females, and mosaics were not 
taken into account. For the transition from premutation in the parent to a full 
mutation in the foetus, we used the logistic model of Fisch et al. (42). In this model, 
the probability of transition to full mutation depends on the length of the mother's 
CGG repeat. For example, the risk of expansion is 20% if the mother has 60·69 CGG 
repeats, and is 71 % for 80-89 repeats. 
We assumed that all boys and 59% of the girls with a full mutation have mental 
retardation (1). The probabilities of a new premutation and a back-mutation from 
premutation size to normal size were taken to be zero. 
The prevalences at birth of serious autosomal chromosomal abnormalities and sex 
chromosome abnormalities in the general population are both 1 :500 (43). The 
recurrence risk for a chromosomal abnormality of a child, if there is a first child with a 
chromosomal abnormality, was estimated at 1.5%. 
7.2.6 Refraining, prenatal diagnosis and induced abortion decisions 
We assumed that in the preconceptional and school screening strategies, 0% of the 
non-carrier women and 15% of the carriers will refrain from a first child. Of the women 
who have not refrained from a first child, 25% will refrain from a second child if an 
abnormality or disease is found at prenatal diagnosis or birth of the first child. 
Uptake of prenatal diagnosis is set at 75% for both premutation and full mutation 
carriers, and people without a premutation or full mutation will not take prenatal 
diagnosis. If a woman has been screened and (not) had prenatal diagnosis for her first 
child, she will also (not) have prenatal diagnosis for her second child. In The 
Netherlands, 95% of foetuses with serious autosomal abnormalities, detected 
prenatally, and 75% of the foetuses with a sex chromosome abnormality were 
selectively aborted (37). We assumed that 90% of the detected males and 45% of the 
female foetuses with a full mutation would be selectively aborted; that if an induced 
abortion has been done for a first child with a given disease/abnormality, the second 
foetus will also be selectively aborted if it has the same disease/abnormality, and that 
the second foetus will not be aborted if the first foetus has not been aborted. 
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7.2.7 Spontaneous and iatrogenic abortion 
We divided the risk of spontaneous abortion into two parts: the risk of a spontaneous 
abortion occurring between the time of prenatal testing and the time of a possible 
induced abortion ('early spontaneous abortion') and a spontaneous abortion 
occurring after the time of a possible induced abortion ('late spontaneous abortion'). 
The distinction between early and late spontaneous abortions is important, both from 
a psychological and an economic point of view because if the abortion occurs in the 
first days after CVS, the woman might (falsely) ascribe a spontaneous abortion to the 
CVS procedure. On the other hand, ending an affected pregnancy by induced 
abortion when the pregnancy would otherwise have ended in a late spontaneous 
abortion is unfavourable, both because of the induced abortion-associated grief and 
because of the costs of unnecessary actions. For autosomal abnormalities, the risk for 
early and late spontaneous abortion is 21.21% and 19.70% and for sex chromosome 
abnormalities 6.15% and 2.79%, respectively (44). The risk of spontaneous abortion 
after the moment of prenatal testing in normal pregnancies is 3.5% (44) and is 
assumed the same for premutation and full mutation carriers (45). We subdivided this 
risk into 'early' and 'late' using the relative proportions of the respective early and late 
abortion risks for autosomal and sex chromosome abnormalities. In this way, we 
obtained 1.95% as the risk for early spontaneous abortion and 1.55% for the risk of 
late abortion. Furthermore, we presumed that CVS carries an attributable risk of 
iatrogenic abortion of 0.5-1.0% (46) (midpoint 0.75%). 
7.2.8 Economic factors 
The costs of screening can be divided into three categories: the costs of information 
dissemination prior to the screening - for instance by mass media and leaflets; the 
costs of testing and organisation of the screening programme, and the costs of 
aftercare. We estimated the costs from a societal point of view, the recommended 
way of analysing costs in screening programmes (47, 48), by calculating invested 
manpower, equipment and materials at relevant wages and prices. These cost 
estimates will differ from the results using a purely financial point of view. In the latter 
case, commercial prices are used including transfer payments (profits, margins, taxes, 
and royalties) (49). We regarded as economic savings, the precluded lifetime medical 
costs of patients who will be born less because of the screening programme ('avoided 
patients'). Because costs of diagnosis and treatment of fragile X syndrome occur at a 
later point in time than the actual screening, they were transformed to the (present) 
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value in the year of screening using an annual discount rate of 3%. Cost figures were 
converted from Dutch guilders (NLG) to EUROs (€) using an exchange rate of €1 = 
NLG 2.20371. 
Costs of information 
We divided the information costs into two parts: the mass information costs that 
depend on the target group-for example costs of mass media campaigns-and the 
individual information costs that are proportional to the number of individuals-for 
instance costs of leaflets. 
Fragile X syndrome is not very well known in the general population, contrary to, for 
example, breast cancer. Van der Maas et al. (50), studying the costs and effects of mass 
screening for breast cancer in The Netherlands, obtained €262,058 for mass 
information costs and €1.36 for individual information costs (costs adjusted for 
inflation). Because fragile X syndrome is less well known, we decided to take twice 
these values as baseline cost estimates for the preconceptional screening programme 
for fragile X carriers. Because of its easy integration in the existing screening 
programme, we set the mass information costs for prenatal screening at 60% of the 
value for preconceptional screening and we took the school mass information costs at 
80% because of the integration in the school setting. 
The individual information costs are likely to be highest for prenatal screening 
because of the direct consequences and emotional sequelae of the test outcome. 
Therefore, we estimated them as twice the costs of individual information for 
preconceptional screening. The individual information costs were set lowest for 
school screening at 50% of the value of preconceptional screening. 
Costs of testing 
Costs of testing can be subdivided into costs of acquisition of the blood sample by a 
general practitioner, midwife or nurse, shipment of the samples to a laboratory, DNA 
extraction, PCR analysis, Southern blot analysis, reporting of the results, and costs for 
the screenee. We estimated the so·called organisation costs of acquisition, shipment 
and administration at €17.23 per individual. The cost of DNA extraction was 
estimated at €7.96 per sample (G. Pals, personal communication). One sample 
provides enough DNA to perform the PCR analysis at €21.27 and, if necessary, the 
Southern blot at €66.68 (G. Pals, personal communication). All figures include costs 
for staff, equipment, materials, disposables and overhead. For the costs for the 
screenee, we took the costs of travelling by public transport and the costs of 
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production 1055 (1 hour for travelling back and forth to the screening, waiting time 
and the time of screening) (51), totalling €7.00. 
Costs of further diagnosis and treatment 
Aftercare consists of counselling carriers and, depending on the choice of the carrier, 
prenatal diagnosis for detected carriers and eventually, depending on the carrier's 
decision, abortion of an affected foetus. For counselling, we took the costs of a 
qualified nurse in a clinical-genetics centre, assuming that counselling a carrier takes 
3 hours. At an hourly wage of €19.06 and an overhead percentage of 40%, 
counselling costs to the clinical-genetics centre are €80.05 per carrier. For the carrier 
couple, we added to the counselling time 15 minutes of waiting time and the costs of 
public transport to the counselling costs, totalling €20.98 (51). The costs of prenatal 
diagnosis, selective abortion, early and late spontaneous abortion, and iatrogenic 
abortion were based on Dutch reimbursements: €1,270.58, €221.01, €69.23, 
€444.36, and €69.23 respectively (52, 53). These reimbursements are the prices that 
insurers pay to hospitals, general practitioners, doctors, and other health care 
providers, and are mostly settled in some form of negotiation between health care 
insurers and providers (for example, hospitals). Therefore, they do not necessarily 
equate with real costs. 
Lifetime costs of care of patients 
People with fragile X syndrome stay in institutions for people with a mental handicap 
or surrogate family units, live with their parents or are self-supporting. In The 
Netherlands, 38% of the male patients and 8% of the females stay in institutions, and 
18% of both males and females stay in surrogate family units. 35% of the male and 
38% of the female patients live with their parents, while the other 9% of males and 
36% of females are self-supporting (A.P.T. Smits, personal communication). For these 
types of services the age- and sex-specific costs of care for fragile X syndrome are 
known (54-56). We adjusted the age- and sex-specific costs for the survival figures of 
the general popUlation and with a discount percentage of 3%. In that way, the 
so-called lifetime costs of care for fragile X syndrome patients were estimated at 
€847,472 for males and €472,232 for females. These figures are somewhat lower than 
the figure of Turner et al. (57) who estimated the costs at approximately €889,000. 
Therefore, the use of our own estimates will lead to a more conservative estimate of 
the cost-savings balance. 
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We considered the costs of care of people with Down syndrome as representative for 
those of people with autosomal chromosome abnormalities, To obtain the lifetime 
costs of care for these patients, we used the methodology described above, but we 
used a survival table for Down syndrome patients (58) and assumed that the 
proportions of patients in the above-mentioned institutions are distributed evenly, In 
that way, the costs of care for (male and female) patients with an autosomal 
chromosomal abnormality were estimated at €663,854, Because people with sex 
chromosome abnormalities in general do not have many complications, we decided 
to ignore these costs, 
7.3 Results 
In Table 7,2-Table 7.4, we give the results of our analysis for prenatal and 
preconceptional screenings, The results of school screening are not described in the 
tables for the sake of clarity, Total costs of screening are lower for preconceptional 
screening than for prenatal screening (Table 7,2) because it has a low coverage of 
screening, With regard to the number of detected carriers (Table 7.3), prenatal 
screening outperforms preconceptional screening (200 detected carriers) because of 
its higher coverage, The potential number of detected carriers (maximum yield 
scenario), however, is equal for both 
strategies at 255 detected carriers, 
The baseline prenatal screening 
strategy detects 200/255 = 78% of 
the maximum number of detectable 
carriers, As for all strategies, this 
percentage can be obtained by 
taking the weighted average of the 
uptake rate of screening for the first 
child and the additional uptake rate 
of screening for the second child, 
Table 7,2 Costs per year of two fragile X 
screening programmes 
Spread ofinformation* 
Organisation and testing* 
Aftercare¥-
Screening strategy 
Prenatal Precoflceptional 
€885,OOO €820,OOO 
€6,975,OOO €5,132,OOO 
€358,OOO €198,OOO 
10tal with baseline assumptions* €8,219,OOO 
Maximum yield scenario· €10,244,OOO 
€6,151,OOO 
€10,026,OOO 
... costs and savings are rounded to €l,QOO 
When we want to carry the economic analysis of the screening programmes further, 
we need to calculate the number of avoided patients, These numbers are defined as 
the number of patients not born because the would-be parents decided to refrain 
from haVing (more) children or to have an induced abortion in case a foetus has the 
full mutation or a chromosomal abnormality, The number of avoided patients is lower 
in the preconceptional screening strategy because of its low coverage, As a 
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percentage of the maximum 
yield, prenatal screening 
avoids the birth of most 
patients (28 out of a 
maximum of 68 = 41 %). 
Table 7.3 Numbers of detected carriers, avoided 
patients and negative side effects per year of two 
fragile X screening programmes 
Screening strategy 
Prenatal Preconceptional The costs per detected C;D~et-ecc-te-;d-ca-rn-'-'e-rs-----------"==~===~ 
carrier are comparable, but Baseline assumptions 
somewhat lower for prenatal Ma~mumyield scenario 
screening, €41, 100 
(Table 7.4). The cost-
effectiveness ratio of the 
preconceptional screening 
strategy is €41 AOO per 
detected carrier, and the 
ratio for school screening is 
€39,300. The net economic 
Avoided patients 
Boy with full mutation and MR (baseline) 
Girl with full mutation and MR (baseline) 
Child with autosomal abnormality (baseline) 
Child with sex chromosome abnormality (baseline) 
Total (baseline assumptions) 
Total (maximum yield scenario) 
Negative side effects 
Avoided girls with full mulation without MR 
Avoided normal or premutation children 
Iatrogenic abortions 
200 149 
255 255 
21 14 
6 5 
0 
0 0 
28 19 
68 61 
4 3 
5 17 
1 savings (savings minus costs) 
are positive for all strategies 
at €12 million for prenatal 
screening, €8 million for Table 7.4 Cost-effectiveness measures and 
savings per year of two fragile X screening 
preconceptional screening and 
€2 million per year for school 
screening. 
To assess the stability of the 
conclusions, we varied the 
values of some assumptions 
and determined the costs per 
detected carrier and the net 
economic savings per year for 
each programme. As expected, 
varying the prevalence of 
premutation carriers has a 
large impact on the cost-
programmes 
Costs per detected carrier 
Baseline assumptions 
Maximum yield scenario 
Savings of affected children born less 
Baseline a55umptions 
Maximum yield scenario 
Net savings per year 
Baseline assumptions 
Maximum yield scenario 
Screening strategy 
Prenatal Preconceptlonal 
€41,100 
€40,200 
€lO,580,OOO 
€47,173,OOO 
€11,361,OOO 
€J6.919,OOO 
€41,400 
€39,400 
€14,OI8,OOO 
€41,219,OOO 
0.868,000 
€Jl,194,OOO 
effectiveness ratio (Figure 7.1) and on the net economic savings (Figure 7.2a). Varying 
the coverage on the other hand has less influence on the net savings (Figure 7.2b). 
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Figure 7.1 Dependency of the cost-effectiveness ratio on premutation carrier 
prevalence. Note that the costs per detected carrier are almost equal for both 
strategies so that the lines overlap. 0: baseline value of the parameter 
The costs of care play no role in the cost-effectiveness ratio, but they have a 
somewhat larger influence on the net savings than the prevalence of carriers 
(Figure 7.2c). For the other assumptions, the balance is rather insensitive to a change 
in the values. 
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Figure 7.2 Dependency of the net savings on selected assumptions. 0: baseline 
value of the parameter 
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looking at the threshold values of the parameters (the percentage increase/decrease 
of the parameter for which costs of the programme equal the savings), we can 
conclude that costs of prenatal and preconceptional screening programmes will never 
exceed savings for a wide range of assumptions (Table 7.5). For example, in these 
strategies, costs will only be higher than savings if the prevalence of premutation and 
full mutation carriers is less than 43% of the baseline values (I.e. 1/1,011 for 
premutation carriers and 1/9,287 for full mutation carriers), if information preservation 
is less than 50% of the baseline values or if the costs of care of patients are lower than 
44% of the baseline values. Although coverage has a considerable influence on the 
costs and the savings, the costs will only become higher than the savings in these 
strategies if coverage is lower than 5% (the prenatal threshold is 6% of a 75% baseline 
coverage and the preconceptional threshold is 9% of a 50% baseline). Although the 
thresholds are somewhat stricter for school screening, costs will not exceed savings 
for a wide range of assumptions also. For example, costs exceed savings only if the 
prevalence of carriers is 74% of the baseline value. 
In the multi-variable sensitivity analysis (Figure 7.3) we varied ten parameters 
simultaneously to see how sensitive the cost-savings balance is if all these parameters 
had been estimated too optimistically or too pessimistically. The conclusion of this 
multi-variable sensitivity analysis is that for prenatal and preconceptional screenings 
the parameter values can deteriorate to 86% of the baseline values before the costs of 
screening exceed the savings, while parameter values of school screening could only 
deteriorate by 5%. 
Table 7.5 Threshold values for favourable cost-savings balance of screening 
programmes (% of baseline values depicted in Table 7.1, pos = savings are 
higher than costs for all parameter values) 
Threshold (or prevalence of carriers 
Threshold fOf coverage 
Threshold (arcosts of (afe 
Threshold for information preservation 
Threshold for refraining from children 
Threshold for uptake of prenatal diagnosis 
Threshold for uptake of induced abortion 
Threshold for costs of tests 
Threshold for (osts of individual information 
Multi-variable threshold 
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Prenatal Preconceptlonal 
39% 43% 
6% 9% 
40% 44% 
49% 50% 
pas pas 
39% 28% 
37% 27% 
386% 347% 
1,304% 2,906% 
86% 86% 
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Figure 7.3 Multi-variable sensitivity analysis of the net savings per year. 
Assumptions that are simultaneously varied in favourable (+) and unfavourable 
(-) direction from their baseline value: coverage, information preservation, 
carrier prevalence, refrain percentage, uptake of prenatal diagnosis, percentage 
of induced abortions, discount percentage of the costs, costs of care, costs of the 
screening tests, costs of individual information. 0: baseline value of the 
parameter 
7.4 Discussion 
Using a decision-analytic model, we found that there are no economic objections 
against screening for carriers of the fragile X gene, since the costs of screening are 
(amply) recovered later. In a sensitivity analysis, this conclusion remained valid for a 
wide range of other plausible assumptions. 
The distinction between high-end normals and low-end premutation alleles is not 
always clear because repeats of similar size differ markedly in their intergenerational 
stability. We decided to use 55 CGG repeats as a cut-off between normals and 
premutation alleles. Using this cut-off, 1.3% of the women with 55 CGG repeats or 
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more are incorrectly classified as having a premutation allele (false-positives) (22). This 
means, for example, that of the 49 tested women with 55-59 eGG repeats in the 
prenatal screening strategy, on average one woman will be false-positive. If this 
woman chooses prenatal diagnosis, she has a 0.75% risk of iatrogenic abortion. On the 
other hand, 1 % of the women with 50-54 repeats, and perhaps a few with less than 
50 repeats, are incorrectly classified as having a normal allele (false-negatives) (22). 
Assuming a 2:1 ratio of women with 50-54 eGG repeats to women with 55-59 repeats 
(59), this means that on average one woman will have a false-negative test result. 
However, this woman has a very small probability of giving birth to a fragile X 
syndrome child. These percentages will of course be altered by changing the cut-off 
value to higher or lower values. 
The difference in intergenerational stability between normal and premutation alleles 
suggests that differences in sequence content may play an essential role in 
determining an allele's predisposition to instability. A normal fragile X eGG repeat has 
some dispersed AGG repeats, normally one AGG for every 9-10 eGGs. In unstable 
premutations, the number of AGGs is diminished or absent (60, 61). However, 
determining the number of AGGs requires expensive sequencing that will influence 
the cost-effectiveness balance. 
The full mutation creates a problem of interpretation in female foetuses because the 
intellectual outcome is so variable. For example, 41% of the females with a full 
mutation will not have mental retardation (1). At present there is no prenatal test to 
determine which of the female foetuses with the full mutation will be affected, but 
some studies indicate that the degree of methylation of the FMRl gene correlates 
with mental function in both females and males (62,63). A decision whether or not to 
terminate a pregnancy of a female foetus with a full mutation must therefore be 
based on the knowledge of a 59% likelihood of the foetus having fragile X syndrome. 
For this reason, it has been proposed to first test for the sex of the foetus and to only 
test male foetuses for the fragile X gene. Therefore we also determined the cost-
savings balance if no female foetuses with a full mutation were aborted. In this 
scenario, savings will still exceed costs by €1 to €10 million. 
In our analysis, we did not consider screening in special schools or other forms of 
large-scale cascade testing. We feel that it is inappropriate to simply compare relative 
costs because both the ethics and methodology involved in the testing process are 
different from general population screening. For example, the first step in cascade 
testing is the diagnosis of (index) cases with fragile X syndrome whose carrier-parents 
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could also have been detected by a general population screening. In case of a general 
population screening, however, these parents would have had more reproductive 
options, such as refraining from children. On the other hand, an earlier diagnosis of 
the index case is an advantage (64). Therefore we have also developed a computer 
model with which we calculate the efficiency of cascade testing (see Chapter 8). 
It should be borne in mind that, even when savings exceed costs, financing a 
screening programme for fragile X gene carriers is not straightforward because the 
screening budget has to be made available now while the savings of the programme 
will only appear (much) later. Moreover, savings may be realised in other budgets 
than where the costs of screening are made so that conflicting interests may arise. 
We used a 3% discount rate to transform the streams of future costs and savings to 
the (present) value in the year of screening. If the effects were also discounted, carriers 
detected in the future would count less than carriers detected now. Because of this 
intergenerational setting of genetic screening, we decided not to discount the effects. 
Recently, an authoritative American Panel on Cost-Effectiveness in Health and 
Medicine recommended this 3% discount rate for both costs and effects, and 
suggested to also use a 5% and 0% discount rate for comparability with other studies 
(65). The costs per detected carrier will only be slightly affected by varying discount 
rates for costs since most costs occur in the year of screening and are therefore not 
discounted. On the other hand, net savings of all screening strategies will change 
considerably since the relative importance of the costs of care of avoided patients is 
higher for lower discount rates. For example, the net savings of prenatal screening 
range from €42.1 million at 0% discounting to €12.4 million at 3% discounting and to 
€5.7 million at 5% discounting. For preconceptional screening the net savings range 
from €29.3 million at 0% discounting to €7.9 million at 3% discounting and to €3.2 
million at 5% discounting. This means that savings exceed costs regardless of the 
choice of discount factor. Only for school screening, will costs exceed savings by €1.7 
million when using a 5% discount factor. 
In The Netherlands, all chorionic villi are routinely tested for chromosomal 
abnormalities. If this routine test were not performed, the costs of aftercare would 
obViously decrease and, because foetuses with chromosomal abnormalities are not 
detected anymore, the savings of affected children born less decrease. However, the 
savings of the avoided children decrease more than the costs of screening. Therefore 
the cost-savings balance of all screening strategies deteriorates somewhat (e.g. net 
savings of preconceptional screening decrease from €7.9 million to €7.7 million). 
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The present paper focused deliberately on cost aspects. There is of course much more 
to be discussed in genetic screening than costs, see e.g. the criteria list of the Dutch 
Health Council (20). Economic considerations should never be the primary goal of any 
screening programme, but a careful cost analysis and a discussion of cost-
effectiveness measures as reported in this paper are an essential part of a full 
evaluation. When other aspects are also considered, preconceptional screening, 
which has the second-best cost-savings balance, possibly has to be preferred because 
with that strategy all reproductive options are still open for a carrier couple. Lack of 
participation will not be irreparable when prenatal screening, the optimal strategy 
from an economic point of view, is used as a 'safety net' for pregnant women who did 
not attend the preconceptional screening programme. 
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Chapter 8 
The efficacy of cascade testing for fragile X 
syndrome 
8.1 Introduction 
The cloning of the FMR1 gene and the knowledge of the inheritance pattern of the 
fragile X syndrome (1-4) have made testing programmes for fragile X carriership a 
possibility (5-12). One of these testing strategies identifies (index) cases from a high-
risk population - e.g. special schools or institutions for mentally handicapped 
persons - and offers fragile X carrier testing to relatives of the persons (13-18). Some 
authors use the term 'screening' for this strategy, but we prefer to call this cascade 
testing, as screening is generally thought to be offered to a more general target 
population (19, 20). The term cascade testing was first proposed by Super et al. (21) to 
describe a procedure for testing the extended members of families where the 
proband had cystic fibrosis. Although family testing was already being carried out, 
their suggestion was that cascade testing should be pro-active. 
Because of the genetic nature and because the probability of new mutations in the 
FMR1 gene is (close to) zero, cascade testing in fragile X syndrome families might 
seem the obvious way to detect fragile X carriers. However, some authors consider 
cascade testing not effective as it requires extensive family tracing, testing, and 
counselling (10). Moreover, since the fragile X syndrome family is identified by an 
index case with fragile X syndrome, individuals only have reproductive options for 
potential future children. 
This paper quantifies, using a simulation model, the (hypothetical) detection rate of 
fragile X syndrome patients for three levels of cascade testing: testing only first-
degree relatives, testing relatives up to the third degree, and testing relatives up to 
the fifth degree. 
8.2 Materials and methods 
We developed a micro simulation model for cascade testing using Borland Delphi 
version 3.02. With this model we simulate a number of pedigrees of five generations 
in order to obtain a population where some nuclear families are (closely) connected 
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with others and some are not. In this way we analyse how many carriers would be 
detected by cascade testing in the optimal case. 
When starting a cascade testing programme, patients of all generations are used as an 
index case. After all these families with index cases have been tested in this 'start-up 
phase', only newly diagnosed fragile X syndrome persons are used as index case (the 
stabilised 'long-term phase'). Since we are primarily interested in the long-term 
performance of a cascade testing programme we presume first that only patients of 
the current generation are used as index case. After that, we describe the start-up 
phase and determine the number of generations to be tested in order to detect a 
given percentage of carriers. 
8.2.1 Simulation of a pedigree 
The model starts by generating a first-generation couple. Using a random number 
generator, both partners of this couple are assigned a carrier status using the 
prevalences of a theoretic general population (see section '8.2.3 Prevalence and 
transition probabilities'). Next, the number of children from this couple is determined 
which depends on the carrier status of both partners (see section '8.2.5 Other 
assumptions'). For each of these children, two random numbers are generated to 
determine sex and carrier status (see '8.2.3 Prevalence and transition probabilities'), 
and a partner of this child is simulated (see '8.2.4 Carrier status of a partner'). This 
procedure is repeated for children of these children and so on until a five-generation 
pedigree is obtained. 
8.2.2 Testing strategies 
We analyse a (long-term) situation where cascade testing takes place in one (=current 
=fourth) generation (Figure 8.1). If a person in this generation is mentally retarded, 
his/her family is tested in three ways: 1. only parents and brothers/sisters of index 
cases are tested ('first-degree relatives'); 2. grandparents and cousins/nieces of index 
cases are also tested ('third-degree relatives'); and 3. great-grandparents and second 
cousins/nieces of index cases are also tested ('fifth-degree relatives'). Offspring of 
tested persons who are not carrier is not tested for fragile X syndrome carriership. 
For all three strategies, we determine the number of families with at least one index 
case in the current generation and the number of families with at least one carrier but 
no index case in the current generation. Furthermore, we calculate the number of 
children with and without fragile X syndrome that will be born in both types of 
families in the next (fifth) generation. 
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Figure 8.1 Sample pedigree. For simplicity we show two children per couple 
III. mentally retarded person (index case) ["l male with a premutation of91 CGG repeats 
[NJ 
'normal' male (no premutatlon or fulJ mutation) U first -degree relatives testing 
.- - ~ ,----1 
I ' , third-degree relatives testing , , fifth-degree relatives testing l __ , ' , 1 ____ , 
8.2.3 Prevalence and transition probabilities 
We assumed eight carrier classes: one normal class (no premutation or full mutation), 
two full mutation classes (with and without mental retardation) and five premutation 
carrier classes (eGG repeats between 55 and 59, 60-69, 70-79, 80-89 and 90-200 eGG 
repeats). We used 55 eGG repeats as a cut-off between normal alleles and 
premutation alleles (22), as no full mutation child has been identified having a mother 
with an allele size of less than 55 eGG repeats. 
For the prevalence of these classes in the absence of disturbances because of 
screening (Table 8.1), we constructed a theoretical population genetics model 
analogous to that of Kolehmainen (23) and determined the equilibrium frequencies of 
the classes using the following assumptions: 1. the prevalence of both males and 
females with a full mutation is 1 :4,000 (24); 2. a normal allele can not mutate directly 
to a full mutation; 3. the probability of a back-mutation from premutation- or full 
mutation-size to normal-size is zero; 4. the transition from premutation in the mother 
to a full mutation in the foetus is calculated with the logistic model of Fisch et al. (25); 
5. the transition probability from premutation in the father to a full mutation in the 
daughter is zero; 6. transition probabilities from a premutation mother/father to 
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Table 8.1 Prevalence of fragile X syndrome premutations and full mutations per 
100,000 in the general (theoretical) popUlation 
Female Male 
Normal 49,923 49,958 
Premutation 65 29 
o(which 55-59 repeatl 39 19 
o( which 60-69 repeatl 7 3 
o(which 70-79 repeatl 6 
o(which 80-89 repeatl 3 
o(which 90-200 repeatl 10 3 
Full mutation 12 13 
of which no menta! retardation 5 0 
of which mental retardation 13 
Total 50,000 50,000 
premutation child are given by Fu et al. (1) and Yu et al. (26); the transition probability 
from mother to child does not depend on the sex of the child (Table 8.2); 7. all boys 
and 59% of the girls with a full mutation have mental retardation (17); 8. the 
reproductive fitness of women with a full mutation and mental retardation is 0.12 (27); 
9. fathers with a full mutation and mental retardation do not reproduce. 
A cascade testing programme obViously reduces the prevalence of premutations and 
full mutations in the population, since detected carriers can decide to refrain from 
production or to have prenatal diagnosis and induced abortion of a fragile X foetus. 
The extent of this reduction is unknown. We will assume in our calculations no 
reduction of the prevalences. This assumption will lead to an upper limit on the 
detection rate offragile X syndrome carriers. 
8.2.4 Carrier status of a partner 
Individuals in the simulated pedigrees can be assumed to have a partner who is not 
part of the same pedigree. Furthermore, it can be assumed that this partner is not part 
of a family that is already identified as being a fragile X syndrome family, as he/she will 
then belong to another simulated pedigree. Therefore, the carrier prevalences of 
these partners are not the same as the general population prevalences. For this 
reason, we determined in the first run of our simulation the carrier prevalences of 
individuals who are not in a known fragile X syndrome family, and used this 
distribution of prevalences for partners of individuals in the simulated pedigrees. 
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Table 8.2 Transition probabilities of the alleles from mother to child and father 
to daughter 
Child 
Mother Normal 55-59 60-69 70-79 80-8990-200 Fuil mutallon 
Normal 1.00' 0.00* 0 0 0 0 0 
CGG 55-59 0 0.65 0.13 0.13 0 0.00 0.09 
CGG60-69 0 0 0.06 0.15 0.32 0.27 0.20 
CGG 70-79 0 0 0.14 0 0 0.42 0.44 
CGG80-89 0 0 0 0 0.05 0.24 0.71 
CGG90-2oo 0 0 0 0 0 0.05 0.95 
full mutation 0 0 0 0 0 0 1.00 
Daughter 
father Normal 55-59 60-69 70-79 80-89 90-200 full mutailon 
Normal 1.00' 0.00* 0 0 0 0 0 
CGG55-59 0 0.72 0.14 0.14 0 0 0 
CGG60-69 0 0 0.07 0.19 0.41 0.33 0 
CGG 70-79 0 0 0.24 0 0 0.76 0 
CGG80-89 0 0 0 0 0.18 0.82 0 
CGG 90-200 0 0 0 0 0 1.00 0 
Full mutation 0 0 0 0 0 1.00 0 
* parameter values determined by the model. Rounded to four decimals the figures are 0.9999 and 0.0001, respectively 
8.2.5 Other assumptions 
Because the average number of children per couple has declined over the last 
decades, we presume that first- and second-generation couples where both partners 
are not mentally retarded have four children, that those of the third generation have 
three children and that those of the fourth generation have two children. Thus, the 
number of couples in the pedigrees increase over the five generations from 1 to 4 to 
16 to 48 to 96. Couples where the male is mentally retarded do not have any children 
and couples where the female is mentally retarded have 0.12 times the baseline 
number on average since the reproductive fitness of those women is 0.12 (27). 
Furthermore, we assumed that all persons will have a partner, that there is no 
competing mortality (i.e. mortality before or during reproductive life), that all index 
patients will be diagnosed at or shortly after birth, and that test information of all 
individuals is available (best-case scenario). 
8.3 Results 
We sampled 100,000 pedigrees in which there were 723 persons with fragile X 
syndrome in the current generation who can serve as index case and 3,086 carriers 
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who are at risk to conceive children with fragile X syndrome. As a check of the 
predictions of our simulation model, we compared the prevalences in the fifth 
generation predicted by our simulation model with those of the general (theoretical) 
population denoted in Table 8.1 and concluded that the figures are rather similar. We 
will first describe the three long-term testing strategies, where we assume that there 
has been no start-up phase for cascade testing. After that, we describe the start-up 
phase of cascade testing. Only families that are not known from the start-up phase as 
fragile X syndrome family need to be tested in the long-term strategies. Although the 
absolute numbers will change when taking into account this start-up phase, the 
relative percentages will not change. 
8.3.1 First-degree testing 
When testing only relatives up to the first degree, the 723 persons with fragile X 
syndrome in the current generation appear to belong to 548 different nuclear families 
(Table 8.3). In 2,131 other nuclear families there are no persons with fragile X 
syndrome in the current generation, but there is at least one (female) carrier who is at 
risk of conceiving next-generation children with fragile X syndrome. In the remaining 
1.6 million nuclear families (16 xl 00,000) there are no carriers or persons with fragile X 
syndrome, these families are not at risk of conceiving next-generation children with 
fragile X syndrome. 
In the 548 nuclear families with a fragile X syndrome person, 66 (current generation) 
couples will have one (next-generation) child with fragile X syndrome, and 22 couples 
will have two. These 88 couples can, in principle, be detected with cascade testing 
before they conceive children, which means that they will have a reproductive choice 
with cascade testing. In the families where there are no fragile X syndrome patients 
Table 8.3 Results for first-degree testing 
Families in the current generation with: 
- at least one index case 
-at least one carrier but no index case 
(urrent-generatlon couples In these families will have •.. next-
generation Frax children 
lFraXchlld 2FraXchlldren NoFraXchlldren Total % 
66 22 460 548 0.03% 
1,021 191 919 2,131 0.13% 
- no index case or carrier -' -. 1,596,387 1,596,387 99.83% 
Total number of families 1,087 21J 1,597,766 1,599,066 100% 
% 0.07% 0.01% 99.92% 100% 
"* non-{arriet5 (an not conceive chHdren with fragile X syndrome 
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but at least one carrier in the current generation, 1,021 couples will have a (next-
generation) child with fragile X syndrome, and 191 couples will have two affected 
children. These 1,212 couples can not be detected by cascade testing, as there are no 
current-generation index cases with fragile X syndrome. 
Summarising, 88 current-generation couples (=7%) who will have at least one child 
with fragile X syndrome in the next generation can have an informed choice with first-
degree cascade testing and 1,212 (=93%) will not have an informed choice. If all the 
recognised couples at risk would have prenatal diagnosis and induced abortion of a 
fragile X syndrome foetus, 11 ° patients (=7% of all fragile X syndrome patients) will 
not be born due to cascade testing. 
8.3.2 Third-degree testing 
When testing relatives up to the third degree, the 723 fragile X syndrome patients 
appear to belong to 483 extended families (Table 8.4). In 1,817 other families, there 
are no fragile X syndrome patients but there is at least one female carrier. 
In the 483 extended families with a fragile X syndrome patient, 122 current-
generation couples will have one next-generation child with fragile X syndrome, and 
36 couples will have two fragile X syndrome children; these 1 S8 couples can be 
detected with third-degree testing. In the 1,817 families with at least one carrier and 
no index case, 965 current-generation couples will have one child with fragile X 
syndrome, and 177 couples will have two. 
This means that 158 couples (=12%) who will have at least one child with fragile X 
syndrome can have an informed choice with third-degree cascade testing, and 1,142 
couples (88%) will not have this advantage. If again all recognised couples at risk 
would choose prenatal diagnosis and induced abortion, 194 (=13% of all) fragile X 
syndrome children will not be born. 
Table 8.4 Results for third-degree testing 
Families in the current generation with: 
-at least one index case 
-at least one carrier but no index case 
- no index case or carrier 
Total number of families 
% 
Current-generatlon couples In these families will have ... next-
generation FraX ,hildren 
lFraX,hild 2FraX,hlldren NoFraX,hildren Total % 
122 36 325 483 0.12% 
965 177 675 1,817 0.45% 
- • 
-
. 397,519 397,519 99.42% 
1,087 213 398,519 399.819 100% 
0,27% 0.05% 99.67% 100% 
• non-carriers can not conceive children with (ragile X syndrome 
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8.3.3 Fifth-degree testing 
Per definition, fifth-degree cascade testing will lead to the lowest number of 
(extended) families with at least one index case (461 families) and with at least one 
carrier without an index case (1,725 families) in the current generation, but these 
families are much larger (Table 8.5). In the families with an index case, 200 current-
generation couples (~15%) will have at least one child with fragile X syndrome, while 
1,100 couples (~S5%) in the families with a carrier but no index case will have at least 
one fragile X syndrome child. This means that 244 (~16%) children with fragile X 
syndrome will not be born if all detected foetuses were aborted. 
8.3.4 The start-up phase 
In the start-up phase of a cascade testing programme, people of all generations are 
used as possible index cases. This scenario results in 576 extended families with index 
cases, and in these detected fragile X syndrome families 179 current-generation 
couples will have one fragile X syndrome child and 50 couples will have two 
(Table 8.6). In the 1,818 carrier families without an index case, 90S couples will not 
have an informed choice for one fragile X syndrome child and 163 for two. 
Consequently, 229 (18%) couples who will have at least one fragile X syndrome child 
will have an informed reproductive choice, and 1,071 couples (S2%) will not have this 
choice, and 279 fragile X syndrome patients (18%) will not be born. 
These figures are not dramatically different from those of fifth-degree testing. The 
reason for this is that fragile X syndrome males do not reproduce, and that fragile X 
syndrome females do reproduce less. Therefore, only a small percentage of fragile X 
syndrome children is born from fragile X syndrome parents. Because of this most 
parents of a fragile X syndrome child turn out to be a premutation carrier, so that the 
Table 8.5 Results for fifth-degree testing 
(urrent-generation couples In these families will have ... next-
generation FraX ,hlldren 
lFraX,hild 2FraX,hildren NoFraX,hlldren Total % 
families in the current generation with: 
-at least one index case 156 44 261 461 0.46% 
-at least one carner but no index case 931 169 625 1,725 1.73% 
- no index case or carrier -• -• 97,814 97,814 97.81% 
Total number of families 1,087 213 98,700 100,000 100% 
% 1,09% 0.21% 98.70% 100% 
* non-carriers can not conceive children with fragile X syndrome 
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Table 8.6 Results for the start-up phase 
(urrenl-jJeneration couples In Ihese families will have." next-
generation FraX children 
lFraXchiid 2FraXchlldren NoFraXchlldren Tolal % 
Families in the CUfrent generation with: 
-at least one index case 179 50 347 576 0.58% 
-at least one carrier but no index case 908 163 747 1,818 1.82% 
- no index case or carrier . • • 97,606 97,606 97.61% 
Total number of families 1,087 213 98,700 100,000 100% 
% 1.09% 0.21% 98.70% 100% 
non-carriers can not conceive children with fragile X syndrome 
probability for brothers/sisters of the index case of having fragile X syndrome is less 
than 50%. 
8.3.5 Number of generations to be tested 
Cascade testing will detect a large proportion of carriers with large premutations, but 
will detect only a small proportion of small premutations. For example, only 20.9% of 
the carriers with 60·69 CGG repeats will be detected in the start-up phase, and can 
thus be followed·up. Using the fifth·degree testing strategy, only 20.3% of the carriers 
with 60·69 CGG repeats who are not detected in the start-up phase will be detected 
so that 36.9% of the carriers with 60·69 CGG repeats are known after the combined 
effort. In the next testing round, again 20.3% of the remaining 63.1% will be detected, 
which means that 49.7% of these carriers are detected when following the start-up 
phase two generations are tested. The same calculations can be done for other 
premutation categories and for full mutations. Taking into account the relative 
prevalences of the premutations and full mutations, a weighted average of the 
carriers detected can be calculated (Figure 8.2). In this way, we predict that testing 
only the current generation with fifth-degree relatives testing, including the start-up 
phase, detects 48.1% of all carriers, testing two generations detects 59.8% and three 
generations 68.5%. This would mean that, in order to detect 90% of all pre mutation 
and full mutation carriers, one would have to keep on testing for at least eight 
generations. This can be seen as another measure for the performance of a cascade 
testing programme. 
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Figure 8.2 Percentage of carriers detected by number of generations tested 
8.4 Discussion 
Cascade testing is not very effective in detecting couples who will have a fragile X 
syndrome child in the future. For example, if only first-degree relatives are tested, 7% 
of the couples who will have a child with fragile X syndrome are detected through an 
index case and thus have a reproductive choice, while 93% of the couples are not 
detected and do not have this choice. Probably the maximally feasible testing 
scenario in practice is fifth-degree testing, although even this scenario will be difficult 
to complete as in today's society many families have lost touch with distant relatives 
so that a lot of work is needed to construct the pedigrees. In the ideal situation that in 
this scenario all persons agree to be tested, only 15% of all couples who will have a 
child with fragile X syndrome are detected. This means that still 85% of all couples 
bound to have a fragile X syndrome child do not have a reproductive choice. 
Compared to the results obtained by Holloway and Brock (28), cascade testing for 
fragile X syndrome up to the second cousin level is somewhat less effective than 
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cascade testing for cystic fibrosis where up to 24% of all carrier couples would be 
detected if cascade testing were restricted to up to the second cousin level (28). This 
higher effectiveness of cystic fibrosis cascade testing is caused by the higher 
prevalence of the cystic fibrosis gene and because of the different inheritance 
patterns of both diseases. 
Testing seventh-degree relatives will improve the percentage of couples detected 
slightly. On the other hand, it will usually not be possible to obtain samples from 
great-great-grandparents because most of them will be deceased. Because of this, 
offspring of non-carrier great-great-grandparents is also tested which makes the 
programme less effective. 
The main reason for the rather ineffectiveness in detecting carrier couples is the 
inheritance of fragile X syndrome. Brothers and sisters of an index case only have a 
50% chance of also having inherited the premutation or full mutation, while cousins 
and nieces of the index case only have a 25% probability of having inherited the 
premutation or full mutation. Furthermore, if a premutation is passed on, it does not 
always expand to a full mutation, and only 59% of all females with a full mutation 
have fragile X syndrome (17). 
We assumed that patients with fragile X syndrome do not reproduce or reproduce less 
than other people. There are however no physiologic reasons known for this. 
Therefore we also analysed a situation in which fragile X syndrome patients have the 
same number of children as individuals without fragile X syndrome. In this situation, 
the percentage of detected families bound to have a fragile X syndrome child 
increases from 7% to 19% for first-degree testing and from 15% to 31% for fifth-
degree testing. For the start-up phase, the detection rate increases from 18% to 35%. 
The effectiveness of cascade testing obviously depends on the number of children per 
couple. Therefore, we also analysed the performance of cascade testing if all people 
would have five children. In this scenario, the percentages of fragile X syndrome 
families and premutation families rise only slightly, and the percentage of detected 
families who will have a fifth-generation fragile X syndrome child rises for all three 
testing strategies. For example, 20.0% of the families who will have at least one 
fragile X syndrome child would be detected in the ideal fifth-degree testing scenario, 
while this percentage is 15.4% in the baseline scenario. In order to detect at least 90% 
of all premutation and full mutation carriers, only six generations have to be tested in 
this scenario, as opposed to eight generations in the baseline analysis. 
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A well-known efficiency measure is the number of tested individuals per case 
detected ('number needed to test'). Using a rough calculation we estimated that with 
our assumptions a maximum of approximately 130 individuals in the start-up phase 
need to be tested to detect one couple who will have a fragile X syndrome child, if all 
eligible individuals participate in the cascade testing. For general population 
screening this figure will increase to approximately 5,000 couples that have to be 
tested; thus cascade testing needs approximately a factor 35-40 times fewer tests to 
detect one carrier couple who will have a fragile X syndrome child than general 
population screening. Of course, it is much more difficult to identify couples that need 
to be screened in cascade testing than in general population screening, and relatives 
may refuse to be tested which will make cascade testing less efficient. However, even 
if these factors would have been taken into account, cascade testing will remain much 
more efficient than general population testing. 
Therefore, although general population screening is more effective in giving the 
highest number of carrier couples an informed choice concerning reproduction, 
cascade testing has a better efficiency and has the advantage that the detected carrier 
couples have in general better knowledge of the fragile X syndrome because they 
usually know the index case who has the syndrome. As economical factors may never 
be the primary factor in deciding whether or not to introduce genetic screening or 
testing, maybe the decision whether to perform general population screening or 
cascade testing should depend on whether one considers it more preferable to give 
the informed choice to a large number of carriers by general population screening 
versus giving the choice to a smaller number of carriers who are already involved in 
the disease anyhow by cascade testing. 
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Part 4 
Concluding remarks 

Chapter 9 
Combining genetic screening programmes -
the example of cystic fibrosis and fragile X 
syndrome screening 
9.1 Introduction 
Population based screening programmes have been proposed for several genetic 
diseases (l, 2). For some diseases, screening programmes have already been 
introduced in many countries, e.g. screening for Down syndrome and neural tube 
defects in pregnancy, and Tay~Sachs carrier screening in Ashkenazi Jews. For other 
diseases, possible introduction of screening programmes is being contemplated, e.g. 
for cystic fibrosis, fragile X syndrome and Duchenne muscular dystrophy. A discussion 
is taking place whether some of these separate screening programmes could better 
be combined in one single screening programme in which a panel of tests is 
performed (combined screening, or multiplex screening) (3-6). 
Combined screening is already taking place in medical care. For example, neonates 
are screened for both PKU and CHT, and screening for open neural tube defects 
(NTDs) by assessing serum alpha-foetoprotein has been extended to a screening 
programme for NTDs and Down syndrome by including serum human chorionic 
gonadotropin and serum unconjugated oestriol, taking also maternal age into 
consideration. Also, as a 'side effect' of some screening programmes, some disorders 
will be detected which are not the primary aim of the screening programme. For 
example, Becker muscular dystrophy is detected when searching for Duchenne 
muscular dystrophy. However, since these disorders are not the direct aim, we will not 
call this combined screening. 
The main advantage of combined screening programmes is that the couple or 
individual is confronted with only one screening offer instead of several, and that they 
can therefore be informed in one counselling session. Because there is some 
information to be given in common, the duration (and thus the costs) of the pre-test 
counselling session will be shorter than the combined length of the separate 
counselling sessions. Furthermore, combining screening programmes leads to lower 
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total costs because of efficiency effects in e.g. organisation, information, and the time 
and travel costs spent by the couple ('indirect costs'). 
In previous articles, we have described cost-effectiveness analyses of separate 
screening programmes for cystic fibrosis carriers and for fragile X syndrome carriers (7, 
8). These analyses show that there is a favourable economic balance for prenatal and 
preconceptional screening for carriership for these diseases, but that the economic 
feasibility of school carrier screening is less clear cut. If the two screening programmes 
would be offered and organised together, the advantages of combined screening 
would apply. In this article we estimate the costs, effects and savings of combined 
cystic fibrosis and fragile X syndrome screening programmes, in comparison to those 
of separate screening programmes. 
9.2 Materials and methods 
We developed a decision-analytic model for a combined screening programme for 
cystic fibrosis (CF) and fragile X syndrome (FraX) carriers. The structure of the model is 
similar to that of (separate) screening for CF carriers and FraX carriers (7, 8). We 
analysed the present situation in The Netherlands, where in the absence of maternal 
serum screening additional chromosome analysis is performed routinely in samples 
obtained for prenatal diagnosis of CF or FraX and presumed a 100% sensitivity and 
specificity of the prenatal diagnosis test. 
In our analysis, we used the baseline assumptions of the analyses of the separate 
screening programmes, except for assumptions that are influenced by combining the 
programmes. Furthermore, as new mutation detection methods have been 
developed, we changed the sensitivity and costs of the screening test. 
9.2.1 Screening strategies 
For general population carrier screening, three strategies are considered: prenatal, 
preconceptional, and school screening (9-11). Since Southern blot analysis (the 
second step in FraX carrier screening) can not be performed on a blood spot, neonatal 
screening can not be considered for separate FraX or combined CF-FraX carrier 
screening. For the same reason mouth washes for CF carrier screening have to be 
replaced by blood samples. 
Because CF is an autosomal recessive disease, a child with CF can only be born from a 
couple in which both parents are carriers. For this reason, (prenatal and 
preconceptiona!) CF screening is targeted towards couples (12-15). In FraX screening, 
the primary target of screening is the woman because a FraX child can only be born 
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from carrier mothers. Therefore, the best strategy for CF-FraX screening is to test the 
woman first, and if she appears to be a CF carrier, to test her partner ('single-entry 
two-step screening'). 
We assumed that the woman is tested for CF carriership with the allele-specific-
oligonucleotide hybridisation method using the reverse dot blot detection format 
using 32 mutations (ASO) (16), which has a sensitivity of 90% and costs €45.29. If 
necessary, her partner is tested with a DGGE test that screens all exons of the CF-gene 
at once on a denaturing gradient gel by two-dimensional DNA electrophoretic 
separation of polymerase chain reaction amplified exons (17) which has a sensitivity of 
98% and costs €178.07, excluding DNA extraction. (H. Scheffer, personal 
communication). 
9.2.2 Assumptions equal to the separate screening programmes 
In this section we summarise the basic assumptions made in the earlier separate cost-
effectiveness analyses of CF screening and FraX screening and we describe the 
assumptions that differ from the earlier analyses (Table 9.1). As the recommended 
discount rate for costs has changed from 5% to 3% between the time of our analysis 
of CF screening and FraX screening (18), the first assumption that differs from that of 
the CF analysis is the discount percentage of 3%. 
Table 9.1 Parameter values used in the analysis of combined screening for CF 
and FraX carriers. The parameter values denoted by' differ from those used in 
the separate analyses (7, 8) 
Probabilities 
Probability of a new FraX premutation 
Probability of a back-mutation from FraX 
premutation-size to normal-size 
Percentage offull FraX mutation boys with mental 
retardation 
Percentage of full FraX mutation girls with mental 
retardation 
0% 
0% 
100% 
59% 
Probability of a couple being unwanted childless 10% 
Probability of a couple being wanted childless 10% 
Recurrence risk of chromosome abnormalities 1.5% 
Iatrogenic abortion after chorionic villus sampling 0.75% 
Sensitivity of ASD test 90% 
Sensitivity of DGGE test 98% 
No amplification of peR 10% 
1 DNA band at peR 40% 
Southern blot fails 10% 
Prevalences 
CF-carrier prevalence 
Females with full FraX mutation 
Males with full FraX mutation 
Females with FraX premutation 
Males with FraX premutation 
Autosomal chromosome abnormalities at birth 
Sex chromosome abnormalities at birth 
1:30 
1:4.000 
1:4.000 
1:435 
1:871 
1:500 
1:500 
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DNA extraction 
PCR test For FraX 
ASa test 
DGGE test 
Southern blot 
(osts to screenee 
Counselling a fraX carrier 
Counselling a (f carrier couple 
Counselling a (+-) (ouple For CF 
Prenatal diagnosis 
Induced abortion 
farly spontaneous abortion 
Late spontaneous abortion 
Iatrogenic abortion 
Discount rate for costs 
€7.96 
€21.27 
€45.29 
€178.07 
€66.68 
€7.00 
€101.0l 
€l7.19 
€21.22 
€1,270.58 
€221.01 
€69.2l 
€444.36 
€69.2l 
3%* 
S((eenlng-de~endent ~arameters 
Target population size 
(overage of people without FraX mental retardation 
(overage of people with FraX mental retardation 
Information retention 
Mass information costs 
Personal information costs 
Organisation costs 
Parameters depending on carrier status of the screened 
Refrain from having children 
Uetake of prenatal diagnosis among eregnant women 
Parameters depending on FraXstatus 
carrier status of the Foetus 
NormorPM fMbolS 
Early spontaneous abortion 1.95% 1.95% 
late spontaneous abortion 1.55% 1.55% 
Uptake induced abortion 0% 90% 
Costs of (are of patient 
€O €847,472 
Prevalence and risk 
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Prenatal PreconceEtional School 
100,000 100,000 100,000 
75%'" 50%* 50%* 
l7~% 25% 259'0 
100% 100% 90% 
€l9l,087' €655,145' €524,116' 
€6.81' €l.W €l.W 
€17.2l €17.2l €17.2l 
Norm fraX fraX (++)forCf (+-)forCF 
~remutatlon full mutation 
0% 15% 15% 15% 0% 
0% 75% 75% 85% 0% 
CF Autosomal Sex 
abnormality chromosome ; 
fMgidl abnormalit~ 
1.95% 1.95% 21.21% 6.15% 
1.55% 1.55% 19.70% 2.79% 
45% 80% 95% 75% 
€472,2l2 €l82,8l2 €66l,854 
€O 
The prevalence of CF-gene carriers varies between popUlations; in The Netherlands it 
is one in thirty (19, 20), The prevalence of both males and females with a full mutation 
in the FraX gene has been estimated by Turner et al. as 1 :4,000 (21). Rousseau et al. 
(22) detected 41 women with a premutation (55 CGG repeats or more) in 10,624 
women, and estimated a frequency of full mutation carriers in French Canada of 
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42:10,000, which is 68% higher than the figure of Turner et al. (21). Because there are 
indications of founder effects in the French Canadian population (23), we adjusted the 
premutation prevalence obtained by Rousseau et al. by dividing their premutation 
frequency by 1.68. In this way a premutation frequency in females of 1 :435 was 
obtained. Male premutation prevalences were taken half of those of females, and 
mosaics were not taken into account. For the transition from premutation in the 
parent to a full mutation in the foetus we used the logistic model of Fisch et al. (24). 
We assumed that all boys and 59% of the girls with a full mutation have mental 
retardation (25). New pre mutations and back-mutations from premutation-size to 
normal-size were assumed not to occur. 
The prevalence at birth of serious autosomal chromosomal abnormalities and of sex 
chromosome abnormalities in the general population are both 1 :500 (26). The 
recurrence risk for a chromosomal abnormality of a child, given a first child with a 
chromosomal abnormality, was estimated at 1.5%. 
Target population and information preservation 
The target populations of screening can be derived from the number of firstborn 
children (85,792) and the number of girls of 16 years (91,782) in The Netherlands in 
1996 (if necessary corrected with a 10% probability of a couple being unwanted 
childless and a 10% probability of a couple being wanted childless) (27-29). For ease of 
interpretation, we work in our analyses with a simplified stable population of 100,000 
firstborn children and 100,000 girls of 16 years. Furthermore, we assumed that in all 
screening strategies 84.9% of the people with a firstborn child will have a second child 
after 2.9 years on average (30, 31) and we ignore in our calculations births of children 
who are third born or more. Because the time between testing and possible use of the 
carrier information is similar to that of the Tay-Sachs screening programme of 
Zeesman et al. (32), we took their ninety percent information preservation as an 
estimate of information preservation of school screening. 
9.2.3 Assumptions specific of combined screening 
Coverage in a combined screening programme needs not be the same as in separate 
screening programmes. On the one hand there will be some people who would not 
consider separate screening but will consider a combined screening. On the other 
hand some people who would consider e.g. separate testing for CF (which is a 
physical disease) will not consider combined screening that includes carrier testing for 
FraX (which is mainly a mental disorder). Because of this, we decided to take the 
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coverage equal to the coverage of FraX screening (which in our earlier analysis was 
lower than that of CF screening), and will consider other coverages in a sensitivity 
analysis. 
If screening programmes are combined, efficiency effects will occur for some costs. 
For example, information costs will be lower than the sum of the costs of the separate 
screening programmes because of the overlapping information need. We therefore 
assumed that the mass information and individual information costs of the combined 
screening programme are 25% higher than those of a separate screening programme 
for FraX. 
The DNA extraction costs for CF and FraX PCR analysis are assumed to be the same as 
the extraction costs for a separate FraX screening programme at €7.96. Since there 
exists no combined PCR for CF and FraX however, the PCR analyses for CF mutations 
and FraX premutations or full mutations can not be done in one pass. Therefore, there 
are no efficiency effects assumed in the PCR costs for a combined CF-FraX DNA 
analysis. 
9.3 Results 
In Table 9.2-Table 9.4, we give a comparison of the yearly costs, effects and savings of 
separate and combined screening programmes for three screening strategies. 
Because we assumed in the original analysis of CF screening (7) a higher coverage and 
discount rate and other screening tests, we have in this paper reanalysed CF screening 
with the new assumptions. 
Since we took all assumptions except costs equal to those of the separate screening 
programmes, the effect measures of screening (the number of detected carriers, the 
number of avoided patients and healthy persons, and the number of iatrogenic 
abortions) in the combined screening programmes are the same as the sum of the 
respective numbers in the separate screening programmes. 
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Table 9.2 Prenatal screening: comparison of the yearly costs, effects and savings 
of separate and combined CF-FraX programmes 
Separate Separate Sumot Combined 
CF FraX separate CF-FraX 
~r~ramme ~r~ramme ~rogrammes· ~rQ9ramme 
Total costs of screening 
€6.217.000 €8,219,000 €14,435,000 €9,356,000 
Detected carrier couple~ 74 200 274 274 
- (f carrier couples 74 74 74 
- f,aX carrier couples 200 200 200 
Costs per detected carrier €85,000 €41,000 €53,000 €J4,000 
Number of avoided patients 23 28 51 51 
Health (aTe savings €8,834,00 €20,580,000 €29,414,000 09,414,000 
Net economic savings €2,618,000 €12,361,000 €14,979,000 €20,058,000 
Negative side effects 
Avoided non.oiseased children (normal children, 3 9 12 12 
CF carrier children, FraX pre mutation chHdren, girls 
with FraX full mutation but no mental retardation) 
Iatrogenic abortions 1 3 
for the costs per detected curier, the figure is calculated by dividing the sum of the total costs of screening by the total 
number of detected carriers 
Because of efficiency effects, combined screening reduces total costs: while the sum 
of the costs of two separate prenatal screening programmes is €14.4 million, the 
combined programme costs 35% less with €9.4 million per year. The decrease in total 
costs of screening for preconceptional and school screening is similar with 32% and 
33%, respectively. Since the effects of combined and separate screening are the same, 
the costs per detected carrier are also 35%, 32% and 33% lower than those of the 
separate screening programmes, respectively, The health care savings obviously do 
not change since the number of avoided patients is equal. Compared to the sum of 
the net savings (savings minus costs) of the separate screening programmes, net 
savings increase by 34% for prenatal screening and by 40% for preconceptional 
screening. 
A separate school screening programme for CF carriers has €3.2 million higher costs 
than savings, and these are not completely offset by the €1.9 million net savings of a 
FraX screening programme. The savings of a combined screening programme 
however are €2.2 million higher than its costs, which is 12% higher than the net 
savings of a separate FraX screening programme. This means that there are also no 
economic objections against combined school carrier screening. 
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Table 9.3 Preconceptional screening: comparison of the yearly costs, effects and 
savings of separate and combined CF-FraX programmes 
Separate Separate Sum of Combined 
CF FraX separate CF-FraX 
~r~ramme ~rQ9ramme p:TQgrammes" p:fQgramme 
Total costs of screening 
€4.622,000 €6,151,000 €10,m,000 €7,m,000 
Detected carrier couples 49 149 198 198 
-
CF carrier couples 49 49 49 
- FraX carrier couples 149 149 149 
Costs per detected carrier €94,000 €41,000 €54,000 €37,000 
Number of avoided patients 15 20 35 35 
Health care savings €5,482,000 €14,018,OOO €19,SOO,000 €19,SOO,000 
Net economic savings €8S9,000 €7,868,000 €8,m,000 €12,m,000 
Negative side effects 
Avoided non-i:liseased children (normal children, 11 31 42 42 
CF carrier children, FraX premulation children, girls 
with FraX full mutation but no mental retardation) 
Iatrogenic abortions 0 
-l! for the costs per detected carrier, the figure is calculated by dividing the sum of the total costs of screening by the sum of 
detected carriers 
9.3.1 Sensitivity analysis 
In our baseline analysis we assumed a coverage of combined screening that is equal 
to that of the separate FraX screening programme from an earlier paper. To assess the 
influence of a higher or lower coverage on the net savings, we show in Figure 9.1 the 
net savings of combined screening for varying uptake rates, and compare these with 
the sum of net savings of the two separate programmes. For example, the sum of the 
net economic savings of two separate preconceptional screening programmes is €8.7 
million, as denoted by the open triangle in the figure, Following the dashed line 
originating from this triangle, it can be seen that these €8.7 million net savings are 
obtained in a preconceptional multiplex screening programme if the uptake of 
screening is 38%. In other words, if more than 12% of the people who would present 
themselves to separate CF or FraX carrier screening would not show up for combined 
screening, the net savings of a mUltiplex screening programme will be lower than the 
sum of the net savings for two separate screening programmes. For a prenatal 
screening programme, the uptake rate should be higher than 58% in order to have an 
efficiency effect of combined screening compared to the baseline uptake of 75%, 
while the coverage of school screening should be higher than 6%, which is 44% lower 
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Table 9.4 School screening: comparison of the yearly costs, effects and savings of 
separate and combined CF-FraX programmes 
Total costs of screening 
Detected carrier couples 
- CF carrier couples 
- FraX carrier couples 
(osts per detected carrier 
Number of avoided patients 
Health care savings 
Net economic savings 
Negative side effects 
Avoided non-diseased children (normal children, 
CF carrier children, FraX premutation children, girls 
with FraX full mutation but no mental retardation) 
Separate 
CF 
programme 
€4,508,00{) 
10 
10 
€m,OOO 
5 
€1,311,000 
-€3,196,000 
J 
Iatrogenic abortions 0 
Separate 
FraX 
programme 
€5,7J3.000 
146 
146 
€39,000 
15 
€7,669.000 
€1,936,000 
14 
Sumor 
separate 
programmes-
€10,141,OOO 
166 
10 
146 
€61,000 
10 
€8,981,OOO 
€1,260,OOO 
27 
(ombined 
(f-fraX 
programme' 
€6,81l,OOO 
166 
10 
146 
€41,000 
10 
€8,981,000 
€1,168,000 
27 
* for the costs per detected carrier, the figure is calculated by dividing the sum of the total (osts of screening by the sum of 
detected carriers 
than the baseline uptake rate. Compared to a separate FraX carrier screening 
programme however, the coverage of combined school screening can only decrease 
by 2% in order not to lose efficiency effects. 
9.4 Discussion 
People want their children to be healthy and not just free of one particular disease. 
For this reason, a multiplex screening programme for serious genetic disease might 
be more appropriate than multiple separate screening programmes. In this analysis 
we showed that a combined screening programme for CF carriers and FraX carriers 
has a better economic performance than two separate programmes. For school carrier 
screening, this would mean that the health care savings are higher than the screening 
costs for combined screening, because the net costs of a separate CF carrier screening 
programme are more than compensated by the net savings of a separate FraX carrier 
screening programme. Furthermore, the net savings of a combined school screening 
programme are also higher than those of a separate FraX school screening 
programme. In a sensitivity analysis we showed that the economic performance of 
combined screening would only be worse than the performance of the separate 
screening programmes if a (large) part of the people who would present themselves 
- lSI -
Chapter 9 
35,000,000 I 
30,000,000 I 
25,000,000 
~ 20,000,000 . 
8 
g, 15,000,000 . o 
I 
--I 
.~ 
10 
z 
10,000,000 
5,000,000 
0 
-5,000,000 
0% 25% 50% 75% 100% 
Uptake of screening 
I
I--e- prenatal standalone + pr~~~~(eptlonal standalone -e- school sta~d~IO~~~ .... 
___ ~~en_~!a! ~l~,-rti"pl-,-" ___ --A-_--,p,,-re:..:(0:.c.nc~ptional multi~I~_x __ - school multiplex ______ _ _ j 
Figure 9.1 Net savings of combined and separate screening CF-FraX programmes 
for varying uptake rates of screening. Uptake rates are weighted averages of the 
respective uptake rates of people with and without mental retardation 
for separate screening do not take up the offer of combined screening, However, we 
think that this is unlikely, as coverage of combined screening will probably be higher 
than coverage of separate screening. 
It should also be noted from Figure 9.1 that the net economic savings are largely 
determined by coverage, and that the effect of combined screening is, in this respect, 
comparable to the effect of a 10 to 15% increase in uptake. But, as said before, non-
economic considerations like persons not being exposed repeatedly to a screening 
process may even be more important considerations for combined screening. 
There is a consensus that informed consent, which requires pre-test counselling, is 
mandatory for all screening programmes. This might be a problem for combined 
screening programmes, because it may be difficult to inform the patient extensively 
about all or most diseases concerned and about the implications of the information 
from the screening tests. To avoid this information overload, 'generic consent' has 
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been proposed by Elias and Annas (3). Here broader concepts and common-
denominator issues are used in the counselling sessions and the couple or individual 
does not give informed consent for screening for a given disease but for screening for 
(offspring with) a number of diseases with serious physical and/or mental causes, as is 
done in amniocentesis and serum screening. 
How should it be decided which diseases and disorders should be included in a 
combined screening programme? First there can be a (public) negotiation debate 
between patient organisations, 'experts' such as geneticists, psychologists and 
ethicists, and government. Another way of establishing the list has been proposed by 
Biesecker (4) who suggests an analysis of resources that are required for patient 
autonomy and informed consent for each screening test and a selection of those tests 
that can be implemented given the total current and envisaged resources (both 
workload and financial) within the health sector. Even more than for separate 
screening programmes, economic considerations are no argument against a 
combined CF-FraX screening programme. An individual or couple should always have 
the right not to have a screening test for some or all diseases, which means that a 
social climate is necessary in which there is room and support for handicapped 
persons (11). 
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General discussion 
10.1 Summary of the results 
10. 1. 1 General 
Genetic carrier screening is technically feasible for both cystic fibrosis and fragile X 
syndrome. Preconceptional carrier screening has the advantage over prenatal carrier 
screening that the carriers have more reproductive possibilities (Appendix B); 
however the cost-savings balance of preconceptional screening is somewhat less 
favourable than the balance of prenatal screening, and organisational problems for 
preconceptional screening could be prohibitive for the time being (Chapter 5 and 
Chapter 7). Because school carrier screening and neonatal carrier screening involve 
testing minors and because of the long time frame between screening and possible 
use of the test results, these two screening strategies should only be considered if 
both preconceptional and prenatal screening would not be possible. 
10. 1.2 Cystic fibrosis 
The non hospital excess costs of care of patients with cystic fibrosis are relatively high 
at €9,960 per year (Chapter 3). However, many of the patients seem to have a 'normal' 
daily life since 57% of the adult patients have a job contract and only 17-18% had 
been absent from work or school during a four week period registered by us. Total 
costs of care of patients with cystic fibrosis are estimated at €16,163 per year; the 
lifetime excess costs of care are €245,901 using a five percent discount rate (Chapter 
4), and €343,613 using a three percent discount rate. 
For cystic fibrosis carrier screening, the screening costs per detected carrier couple are 
lowest for neonatal screening at €24,OOO and are much higher for the other screening 
strategies (range €66,OOO-€97,OOO). The net economic savings (savings minus costs) 
are highest for prenatal screening, but are also positive for Single-entry 
preconceptional screening. Double-entry preconceptional screening, school 
screening and neonatal screening on the other hand have higher costs than savings. 
These conclusions hold for a wide range of assumptions (Chapter 5). 
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10.1.3 Fragile X syndrome 
The screening costs per detected carrier for the fragile X syndrome screening 
programmes are much lower than their counterparts in cystic fibrosis screening 
(range €39,OOO-€41,400). The net savings of prenatal and preconceptional fragile X 
syndrome carrier screening are higher than for cystic fibrosis, and the savings of 
school screening also exceed its costs for fragile X syndrome carrier screening 
(Chapter 7). Cascade testing is not very effective in early detection of carriers who will 
have a child with fragile X syndrome, but it is more efficient than general population 
screening in the sense that less people need to be screened per carrier detected 
(Chapter 8). Therefore a good strategy might be to perform general population 
screening followed by cascade testing on all detected carriers; this should be 
confirmed by a (cost-effectiveness) analysis. 
10.1.4 Cystic fibrosis and fragile X syndrome 
A combination of cystic fibrosis and fragile X syndrome screening will have efficiency 
effects: the screening costs per detected (cystic fibrosis or fragile X syndrome) carrier 
for a combined programme are more than 30% lower than those of the separate 
screening programmes, and the net savings of prenatal and preconceptional 
screening increase by 34% and 40%, respectively (Chapter 9). While the savings of a 
separate school screening programme for CF carriers are lower than the costs, the 
savings of a combined CF-FraX school screening programme exceed costs by €2.2 
million. 
10.2 New data with respect to CF screening in The 
Netherlands 
Obviously, the results in this thesis depend on the assumptions made. Some of these 
assumptions have already changed since the chapters in this thesis have been written. 
For example, the recommended discount rate has changed from 5% to 3% during the 
time of the CF analysis. Furthermore, several new mutation detection methods have 
been developed such as allele-specific-oligonucleotide hybridisation using the 
reverse dot blot detection format for 32 mutations (ASO test) (1) and screening all 
exons of the CF-gene at once on a denaturing gradient gel by two-dimensional DNA 
electrophoretic separation of polymerase chain reaction amplified exons (DGGE test) 
(2). The sensitivities of these two methods are assumed to be 90% and 98% per 
individual, respectively (H. Scheffer, personal communication). Of course, the costs of 
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testing will also change if these tests are used since ASO costs €45.29 and DGGE costs 
€178.07 (3). In the original analysis, we presumed a sensitivity of 73.6% for the ~F508 
test and 85.5% for the seventeen mutations test while the costs were €9,47 and 
€37.89, respectively. Therefore, the analysis of Chapter 5 is redone with accordingly 
changed assumptions for four different tests or test combinations. 
As can be seen in Table 10.1 the changes in assumptions have a large impact on the 
costs and effects of screening, and the costs of some strategies become higher than 
the savings. The net economic savings of the first test combination (the ~F508 test in 
the first step and a test for 17 mutations in the second step) for single-entry two-step 
screening are even higher than in the original analysis. The savings of double-entry 
two-step screening are higher than its costs, while in the original analysis the costs 
were higher than the savings. The main reason for this is that the discount percentage 
has decreased from 5% to 3%, which primarily affects costs of care upwards. 
If only one test is used (situations 2 and 3), the effects of the SETS version and the 
DETS version are the same since the sensitivity of the first and second step are the 
same. However, the costs of screening of the DETS version are much higher than 
those of the SETS version since partners of test-negative individuals are also tested in 
the DETS version, as opposed to the SETS version. Furthermore, twice as many couples 
will be designated as being positive-negative in the DETS version than in the SETS 
version. If the sensitivity of the screening test is lower than 97%, they have an 
increased risk of having a CF child but cannot be offered prenatal diagnosis. On the 
Table 10.1 Costs, effects and savings of single-entry two-step (SETS) and double-
entry two-step (DETS) preconceptional couple screening for CF 
Test or test combination 1. M5081n l' step, 2. Only ASO test 3. Only OGGE test 
17 mut. in 2"" step 
Single-entry two-step (SETS) 
Costs of screening €2,169,000 €4,378,000 €12,765,000 
Detected carrier couples 35 45 53 
Costs per detected carrier couple €62,000 €97,000 €239,OOO 
Number of avoided patients II 15 17 
Net economic savings €1,987,OOO €902,000 - €6,548,000 
Oouble-entry two-step (OETS) 
Costs of screening 
€2,987,000 €6,936,OOO €21,m,000 
Detected carrier couples 40 45 53 
Costs per detected carrier couple €75,000 €154,000 €408,000 
Number of avoided patients 13 15 17 
Net economic savings €1,714,000 - €1,655,000 - €15,555,000 
4.ASOln l'step, 
OGGE In 2" step 
€4,623,000 
49 
€94,000 
16 
€1,105,000 
€7,059,000 
53 
€1JJ,000 
17 
- €882.000 
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other hand, the risk of having a CF child for couples in which the first partner tested 
negative in the SETS version (-? couples) is 7.5 times higher than for negative couples 
in the DETS version (-- couples). However, both risks fall in the 'very small risk' 
category, and do not warrant extensive attention by prospective parents. 
For the fourth test combination (ASO in the first step, DGGE in the second), the 
economic savings are higher than the costs for single-entry two-step screening, but 
not for double-entry two-step screening. The main reason for this is that in the first 
step a test with sensitivity of 90% is used which means that in the second step only a 
small percentage of the carriers can be detected. 
Of the programmes with higher savings than costs, the first test combination (the 
L'lFs08 test in the first step and a test for 17 mutations in the second step) has highest 
net economic savings, while the fourth test combination detects most carrier couples 
and leads to the highest number of avoided patients. Comparing the first to the fourth 
scenario, the fourth scenario has €882,000 less of net economic savings for the SETS 
version while it detects 14 carrier couples more, so that the incremental costs are 
€63,000 per detected carrier couple. This means that if one regards these incremental 
costs not to be prohibitive, one should opt for the fourth testing scenario. For the 
DETS version, the incremental costs are €197,000 per detected carrier couple, more 
than three times the incremental costs of the SETS version. 
As the coverage has a rather large influence on the net savings of a screening 
programme, we have determined the net savings for varying uptake rates 
(Figure 10.1) and we have calculated the minimum uptake rate for which savings of 
screening are higher than or equal to its costs (threshold analysis, Table 10.2). For the 
SETS version of the first test combination, the uptake rate should be higher than 10% 
for SETS in order to have higher savings than costs, and for the DETS version the 
uptake rate should be higher than 12%. For the SETS versions of the second situation 
the uptake rate should be higher than 24%, while even a 100% uptake rate for the 
Table 10.2 Threshold analysis: the threshold coverage for which costs of 
screening equal savings 
Test or test combination l.llf5081n l' nep, 2. Only ASO test 3. Only OGGE test 4. ASO in l' step, 
17 mut. in 2" ste~ OGGE In 2" ne~ 
Threshold coverage for SETS 10% 24% none 21% 
Ratio of threshold to baseline value ,0.20 ,48 none ,0.42 
Threshold coverage for OETS 12% none none none 
Ratio of threshold to baseline value ,0.23 none none none 
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Figure 10.1 Net savings of preconceptional screening for several test 
combinations and uptake rates 
DETS version of the second combination and both versions of the third combinations 
lead to higher costs than savings, The uptake rate of the fourth combination should 
be higher than 21 %, but for the DETS version of the fourth combination costs are 
always higher than savings. 
The above analysis is a more detailed version of Verheij et al. (3). For example, 
spontaneous abortions and chromosome abnormalities are modelled, and costs for 
the screenees are taken into account. 
10.3 Assessing the criteria of the Health Council 
This thesis has shown that there is a favourable economic balance for screening for 
cystic fibrosis and/or fragile X syndrome carriers under most realistic assumptions. 
However, as this is only the last subcriterion in the Health Council report (4), the 
screening programmes analysed in this thesis have been checked in Table 10.3 
against the criteria of the Health Council Committee on Genetic Screening (note that 
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economic considerations are addressed in 12j). The criteria that are not (completely) 
satisfied are: 
• criteria 3 and 5 ('awareness and informed consent'): minors are tested in school 
screening and neonatal screening, and legally they can not give informed consent. 
Therefore, preconceptional screening and prenatal screening are better methods 
of screening with regard to these criteria; 
• criterion 4 ('actions'): the value of the information from screening for carriers 
detected as newborns or school aged children lies far in the future, by which time 
they may have 'forgotten' their test results. Since preconceptional screening gives 
the carrier couple more options than prenatal screening (avoiding pregnancy, 
artificial insemination, pre-implantation diagnosis), preconceptional screening can 
be considered preferable with regard to this criterion; 
• criterion 6 ('information'): there is a debate about the amount of information to be 
given to couples in cystic fibrosis carrier screening where one partner is identified 
as carrier and the other not when the screening test does not have a 100% 
sensitivity. Since the negatively tested partner may have a mutation that is not 
detectable with currently available screening tests, these couples have a higher 
risk of an affected child than the untested general population but they do not 
have the option of prenatal diagnosis. Understanding these and other implications 
of genetic testing for CF and fragile X syndrome requires a high degree of genetic 
knowledge about test sensitivity, carrier status, patterns of inheritance, 
risk/probability and genotype-phenotype correlations (5). Given the recognised 
gaps in genetic knowledge among the general public, it is essential that any 
genetic testing programme includes educational and counselling components 
and written informed consent (6). Involvement of patient's associations is 
important for a balanced information (7); 
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Table 10.3 Check of screening programmes to the criteria of the Health Council 
Criterion, applied to (arrier screening for: CF FraX CF-FraX 
$Iralegy: Pre, $chl Pre, $,hl Pre, $,hl Pren Neon Pren Pren 
a. Absolute criteria 
1. The programme concerns a health problem or (ondition that 
can lead to a health problem + + + + + + 
2. The target population is dearly defined + + + + + + 
J. The programme enables participants to become aware of the 
+/- +/- +/-disease or carrier status + + + 
4. Practical courses of action afe open to the participants + +/- + +/- + +/-
5. Participation is voluntary and consent is based on good 
+/- +/- +/-information + + + 
6. The target group is supplied with accurate and 
+/- +/- +/- +/- +/-
comprehensible Information + 
7. A suitable test method is available + + + + + + 
8. There are sufficient facilities for every step in screening and 
+/- +/- +/- +/-diagnosis + + 
9. The personal privacy of the participants is protected + + + + + + 
10. If scientific research is carried out, participants are properly 
+ informed about this + + + + + 
11. There is continuous quality assurance regarding tests, follow-
up and participant information + + + + + + 
b. Weighing criteria, There should be information about 
12a. The prevalence of the disease or disorder Y Y N N YIN YIN 
12b. The natural course of the disorder Y Y Y Y Y Y 
12<. All pos5ible target groups and the considerations which led to 
the selection of the target group and the time in life for Y Y Y Y Y Y 
testing 
12d. The performance of the screening test, including the burden Y Y Y Y Y Y 
which testing imposes on the participants 
12e. The available courses of action after a positive test result Y Y Y Y Y Y 
12f. The time allowed for consideration and possible Y Y Y Y Y Y implementation of the courses of action 
12g. The possible psychological, social and other repercussions of 
the offer, participation and non-participation to participants N N N N N N 
and other people 
12h. The possibility and consequences of erroneous results Y Y Y Y Y Y 
12i. The guarantees to prevent participants experiencing 
unjustified impediments from obtaining employment or Y Y Y Y Y Y private insurance cover as a result of (non-)participation in 
the screening and follow-up testing 
12j. The costs which are linked to the screening and to the Y y Y Y Y Y 
attainment of the requisite infrastructure 
+: the criterion is or can be satisfied 
+/-: the criterion is not completely satisfied 
Y: there is enough knowledge with regard to this criterion 
N: there is not enough knowledge with regard to this criterion 
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• criterion 8 (,facilities'): using the assumptions of Chapter 5 for CF prenatal and 
preconceptional screening, between 33 and 63 carrier couples can be expected to 
be detected by screening in The Netherlands per year. For these carrier couples, 
there would be sufficient facilities for counselling in clinical genetic centres. This 
might not be the case for couples where one partner is identified as a carrier and 
the other is not, given that, each year, 1,355 to 3,881 of these couples may be 
identified through screening. It has been suggested that these couples could be 
counselled by trained paramedics ('project-nurses'), who might also have a role in 
testing family members of detected carriers (8). There are likely to be adequate 
facilities for performing between 40 and 99 prenatal diagnoses and between 8 and 
20 induced abortions. The same applies for fragile X syndrome screening: between 
149 and 200 carriers can be expected per year (Chapter 7), the number of prenatal 
diagnoses ranges from 147 to 263 and the number of induced abortions from 17 
to 31; 
• criteria 9, 10, 12i ('privacy, research and guarantees against impediments'): these 
criteria can only be assessed for completely specified screening programmes. 
There should be no difficulties in fulfilling these criteria in The Netherlands; 
• although criterion 11 ('continuous quality assurance') can, in principle, be satisfied 
in any CF screening programme, special attention has to be given to the quality 
control of CFTR typing. In a European concerted action on cystic fibrosis, Cuppens 
and Cassiman (9) found that only 25 of 40 (=62.5%) participating laboratories 
throughout Europe were able to type correctly all nine samples with various CFTR 
alleles, and that four laboratories (10%) typed three or more alleles incorrectly. 
However, a significantly lower error rate was observed in laboratories from the 
United Kingdom, which is believed to be a direct consequence of their 
participation in a quality control scheme. This quality control testing has been 
operational for more than three years since the time of the study of Cuppens and 
Cassiman (9); 
• criterion 12a ('prevalence'): the prevalence of fragile X syndrome pre mutations has 
not yet been determined in The Netherlands; as a matter of fact they have not yet 
been established in a large-scale study, except in the Canadian situation with 
possibly large founder effects; 
• criterion 12b ('natural course'): only about half of the female foetuses with a full 
fragile X syndrome mutation will have mental retardation. Therefore, the parents-
to-be have a difficult deciSion to make; 
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• criterion 12g ('repercussions'): insufficient knowledge is available regarding 
adverse psychological, social and other repercussions. Factors such as anticipated 
decision regret, perception of the severity of the condition as well as perception of 
risk influence the decisions to accept or decline screening (10). The complexity of 
the concept of 'carrier status' and its implications for family members may also 
make the screening decision difficult (11). Possible anxiety caused by the 
screening result appears to be short-lived, with most of those accepting the offer 
of screening expressing a preference for "certainty" over "not knowing" (12). 
Furthermore carriership could influence the self-perception and the perceptions of 
others who are no carrier. For example, in one study carriers viewed their future 
health with less optimism than people who are no carrier (13). Most CF patients 
and their families appear to have a positive attitude to carrier screening and 
termination of affected pregnancies (14, 15). For fragile X syndrome carrier 
screening, such comprehensive studies have not yet been published. No adverse 
repercussions from a medical point of view have been reported; 
• criterion 12j ('costs'): this thesis shows that there are no economic objections 
against preconceptional or prenatal carrier screening and to multiplex school 
screening but that the costs of neonatal and separate school screening exceed the 
savings. This means that if it is decided to introduce school or neonatal carrier 
screening in The Netherlands, funds have to be made available in the health care 
budget. 
10.4 Recommendations 
There are no technical, organisational or economic objections against cystic fibrosis 
carrier screening. With regard to psychological and social consequences, there might 
be some adverse effects, but these are not yet studied in The Netherlands. 
The WBO committee of the Dutch Health Council, instituted as a result of the Dutch 
Population Screening Act (WBO) to advise central government, concluded in their 
report (16) that there are no categorical arguments against a pilot preconceptional 
screening programme for cystic fibrosis carriers in The Netherlands, and that it would 
have advised the Dutch Minister of Health to grant the license if it would have 
assessed a regular license application. The KNMG (Royal Dutch Society for the 
Promotion of Medicine) also does not have moral objections against preconceptional 
screening for CF carriers if the screening is aimed at making possible an informed 
choice concerning reproduction (17). Therefore, a pilot study in The Netherlands is 
- 165-
Chapter 10 
recommended that focuses on the psychological and social consequences, and 
determines uptake rates of screening, diagnosis and therapy. As preconceptional CF 
screening will probably involve the general practitioners in the Dutch situation, 
special emphasis should be drawn on whether the general practitioners will take part 
in the study and how to inform couples that their practitioner participates in the pilot 
study. If this pilot study shows that carrier screening is feasible from these points of 
view, introduction of general population carrier screening for cystic fibrosis in The 
Netherlands should be seriously considered. 
For a fragile X syndrome screening study, the focus should presently be on 
determining the prevalence of full mutations and pre mutations in The Netherlands, 
since these are not known in the Dutch general popUlation. Furthermore, a pilot study 
should determine the attitude of Dutch women concerning fragile X syndrome 
screening in general and the problem of predicting mental retardation in female 
foetuses with a full mutation. 
A combined screening programme of cystic fibrosis and fragile X syndrome carriers 
might not seem obvious, given the diversity of information for two different disorders 
to be given to individuals. Combining two screening programmes for physical 
disorders or combining two screening programmes for mental disorders on the other 
hand might be more feasible as the information concerns two similar disorders. As 
couples will probably be seen once in the preconceptional scenario for screening, 
they may be offered the choice between screening for physical disorders or mental 
disorders or both which will obviously lead to concepts as generic consent (18). 
Summarising, the main focus of future studies regarding carrier screening in general 
should be on the psychological and social consequences of screening, and on how to 
involve general practitioners best in preconceptional screening. 
10.4. 1 Discounting 
The above recommendations follow directly from the results of this thesis. A 
methodological issue concerns discounting effects in genetic screening. The reasons 
for not discounting health effects are (19): 
• it is difficult to conceive of individuals investing in health or trading flows of 
healthy years through time; 
• discounting for example years of life gained in the future gives less weight to 
future generations in favour of the present one. This makes only sense if one 
expects future generations to have better therapeutic technologies available. 
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The reasons in favour of discounting health effects are (19): 
• discounting costs while not discounting effects will lead to inconsistencies in 
reasoning, e.g. it is better to defer spending now so that progressively less cost-
effective programs can be mounted in the future (20, 21); 
• contrary to the first reason for not discounting effects, one can conceive of 
investments in health and the trading of health through time. If this were not the 
case, people would not refrain from pleasurable but in the long run potentially 
risky actions, such as smoking, or short run relatively dangerous activities, such as 
skydiving. 
As already said in the introduction of this thesis, both the working party convened by 
the US Public Health Service (22-24) and the working party for the British Medical 
Journal (25) recommend discounting health effects by the same discount rate as 
discounting the costs, but the British party adds the suggestion to discount the health 
effect with a lower rate for preventive (screening) programmes. On top of the debate 
how to discount costs and effects for health interventions in general, genetic 
screening deals with future generations, which means that future generations can be 
discriminated if effects are discounted. For example, detecting 100 carrier couples one 
year from now is valued equal to detecting 100/(1+0.05)=95 carrier couples at this 
moment at five percent discounting. This problem also plays a role in environmental 
economics, where some alternative discounting methods are proposed (26). For 
genetic screening, these methods would be: 
• only costs should be discounted, and not the effects. In this way, detecting a 
carrier (couple) in 10 years is valued equally important as detecting a carrier 
(couple) now (we have used this method in the thesis); 
• cost-benefit ratios are weighed differently for subsequent generations. This means 
that a cost-benefit ratio is calculated per generation from the perspective of 
time 0, the moment of the investment decision. The ratios are weighed with a 
factor that can be progressive, regressive etc. The problem obviously is how to 
determine the weighing factor(s); 
• the point in time is set to 0 every time a new generation occurs. This means that 
costs and effects are discounted to the year of birth of the generation, and not to 
some point in time in the (far) history. In this method, the standard discounting 
formula of section 1.5.3 is replaced by a more complex formula (27). The problem 
with this method is that it assumes a stable population with the same number of 
persons in every age group, and every individual is assumed to die at the end of 
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the average life expectancy. A second problem is that the discounting formula is 
based on the idea that costs and effects are distributed equally in the population. 
For the costs, this is no problem, but contrary to most environmental issues, this is 
not so obvious for the effects since health effects occur in identifiable individuals 
of known ages. 
Obviously, the problems of discounting in genetic screening have not (yet) been 
resolved. Therefore more research, in particular from health economists, is necessary 
to resolve this special form of the discounting debate. 
10.4.2 Diagnosis and treatment 
Great advances in treatment and diagnosis are taking place with regard to the 
diseases described in this thesis. For example, in cystic fibrosis treatment a shift is 
taking place from hospital care to home care, (heart-)iung transplantations are 
increasingly performed, and recombinant human deoxyribonuclease (DNase) I is used 
to decrease viscosity of purulent airway secretions (28, 29). Furthermore, clinical trials 
are already performed on gene therapy for CF, although clinical widespread use may 
not be expected in the near future (30-33). These developments are aimed at giving 
patients with CF a better life expectancy and quality of life, but will also have 
repercussions on the costs of care for patients with cystic fibrosis. If the costs of care of 
patients rise, this will lead to a 'paradox' with regard to screening. On one hand will 
the savings of preventing the birth of a patient with the disease increase (an 
economic tendency in favour of screening), but on the other hand the quality and 
length of life in the absence of screening are improving (a tendency against 
screening). There is no question that carrier screening would then be a thing of the 
past, but, on the other hand, neonatal patient screening can be contemplated. Firstly, 
as suggested by the latest paper by Farrell et al. (34) describing nutritional benefits of 
neonatal patient screening, an early diagnosis probably affects the long-term 
individual health benefits. Secondly, "there are real prospects that effective, if not 
curative, treatment based on an understanding of the pathophysiology of cystic 
fibrosis at the cellular level will be available before long" (35). Thirdly, neonatal 
(patient and carrier) screening allows parents to have a reproductive option for 
subsequent pregnancies. However, the (cost)effectiveness of neonatal patient 
screening should be investigated to see whether neonatal screening is a good public 
health measure. 
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A new approach to prenatal diagnosis of fragile X syndrome was published, where the 
absence or presence of the FMRP protein in cells is used as a diagnostic tool (36, 37). 
Since this protein is responsible for the mental retardation in fragile X syndrome, 
using a rapid and simple antibody test can predict the mental status of the foetus. 
Validation studies show that this method is reliable for male foetuses (38). 
Approximately one in a million cells in maternal blood are of foetal origin (39). At the 
moment it is possible to 'harvest' these cells by labour-intensive laboratory methods, 
but less labour-intensive methods are under development (40). These cells can be 
analysed with PCR or fluorescent in situ hybridisation (FISH). Using this method 
prenatal diagnosis of trisomy 21 is already technically possible, and there are no 
technical reasons that in the future cystic fibrosis or fragile X syndrome can not be 
detected using this method. Harvesting cells from male foetuses is no problem, since 
cells in the blood originating from males per definition are of a foetus and not of the 
mother. For female foetuses, more laborious methods are needed to distinguish a 
maternal cell from a foetal cell. A second problem is that cells of previous pregnancies 
or miscarriages may remain in maternal blood and thus may complicate the diagnosis 
(41). If these complications can be resolved, invasive prenatal diagnosis by 
amniocentesis or chorionic villus sampling with its associated risk of miscarriage will 
not be necessary in the future for these diseases. 
10.4.3 Information 
It is very important that the target group receives adequate and balanced 
information. It should include at least the test characteristics, a description of the 
severity of the disease and inheritance patterns. The offer of testing should be made 
to enable couples who wish to avoid the birth of a child with CF to do so, without 
influencing those who do not. Care should be taken to ensure that the decision to 
have testing is completely voluntary (6). An important point of attention in future 
research should be how to transfer probability measures in inheritance patterns to 
individuals, as many individuals are inclined to dichotomise probabilities into "yes" or 
"no". This leads to many people accepting rather far-reaching procedures in order to 
prevent that their child has a disease, however small the probability. For example, 
Tijmstra and Bajema (42) found that many people would take part in a screening 
programme in which all three-day-old children would have to be in an incubator for 
24 hours in order to save the life of 2 out of 180,000 children with a fatal disease 
yearly. The authors conclude that there are no limits as far as the public is concerned: 
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if people have the impression that distress can be prevented by means of medico-
technical interventions, they will make use of the technology en masse (42). This 
means that the public will probably accept combined screening for a large number of 
diseases in order to rule out most of the serious diseases, so that the demand side of 
the 'health care market' does not limit the number of diseases to screen for. Therefore, 
as we already remarked in Chapter 9, a public negotiation debate between patients 
organisations, experts and government should establish a priority list of diseases to 
screen for. 
10.4.4 Computer models 
As for all evaluation analyses, the assumptions used in analysing the 
(cost)effectiveness of genetic screening are important. Computer models make these 
assumptions explicit and therefore force the user to consider what plausible value(s) 
the assumptions can have. In order to have a consistent approach in calculating 
(cost)effectiveness measures, it would be advisable to have one model that can be 
used for screening for several diseases, standalone or in a multiphasic way. The model 
should enable individuals with different backgrounds (e.g. medical doctors, 
economists, and politicians) to analyse screening programmes. Therefore, it should be 
very user-friendly and flexible. The (spreadsheet) models that were used in the 
analysis of general population screening in this thesis can, in principle, be extended 
for the analysis of several diseases, but the models become increasingly complex and 
inflexible. Therefore, a microsimulation programme comparable to the MISCAN-
programme for analysis of cancer screening (43), might be the proper way to follow. 
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Appendix A 
A short introduction to genetics 
Human genetic material is contained in the cell nucleus and outside cell nuclei, in the 
mitochondria. In the cell nucleus, it consists of 22 pairs of non-sex determining 
chromosomes (called autosomes), numbered from 1 to 22, and two sex determining 
chromosomes, called X and Y, where women have two X chromosomes and men 
one X and one Y chromosome. Each individual inherits one set of autosomes (one of 
each pair) from the mother and one set from the father. Furthermore, they inherit one 
of the two sex determining chromosomes from the mother and one from the father. 
A.1 Genes 
Each chromosome contains a number of genes, a length of DNA (deoxyribonucleic 
acid) that caries information relating to one particular function. Information is based 
on four building stones: adenine, thiamine, guanine and cytosine (abbreviated A, T, G 
and C). Most genes are unknown, and of most known genes the function is unknown. 
Each set of chromosomes inherited from a parent contains 50,000-100,000 genes (1). 
Because the paternal and maternal chromosomes have the same genes, individuals 
also have all genes in duplicate. Up to February 1999, 10,181 genes have been 
described and 7,030 of these have been located (http://www.ncbLnlm.nih.gov/omim). 
The DNA sequence of the other genes is expected to be known in the beginning of 
the next century as a consequence of the Human Genome Project (2). 
Molecular 'errors' in DNA can arise during cell division. Errors may consist of the 
substitution of one or more building blocks (point mutation), loss of (part of) a gene 
(deletion) or of rearrangements such as insertions, duplications or the repetition of a 
given sequence of building blocks. 
A.2 Disorders 
A classic distinction between hereditary disorders is chromosomal disorders, 
monogenic disorders and multifactorial disorders (3). 
A. 2. 1 Chromosomal disorders 
Chromosomal disorders are disorders in the number or structure of the chromosomes. 
An important chromosomal disorder is Down syndrome (see Appendix C). In Down 
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syndrome, there are three chromosomes 21 instead of the usual two. Most of the 
times, this is caused by a spontaneous error in one of the divisions resulting in the egg 
cell, the risk of which increases with maternal age. Most pregnancies with gross 
chromosomal disorders miscarry in pregnancy. For example, approximately 30% of all 
Down syndrome pregnancies end in miscarriage in the second or third trimester of 
pregnancy (4). 
A.2.2 Monogenic disorders 
Monogenic disorders (or Mendelian or single-gene disorders) can be distinguished in 
autosomal recessive, autosomal dominant and X-linked diseases. 
In autosomal dominant disorders individuals with one mutated gene, either the 
paternally or maternally derived one, have the disorder. This means that the child of a 
patient with an autosomal disorder has a 50% probability of being a 
(Figure A.1). Examples of autosomal dominant disorders are 
hypocholesterolemia and Huntington's disease. 
patient 
familiar 
If the disorder is autosomal recessive, offspring will have the disease only if both 
parents transmit the mutated gene (see Figure A.2). If one of the parents has 
transmitted a mutated gene and the other parent has transmitted a 'normal' gene, the 
child will not have the disease but can transmit the mutated gene to his/her offspring. 
Individuals with one mutated and one 'normal' gene are called carrier. In Chapter 2 to 
Chapter 5 the autosomal recessive disorder cystic fibrosis is described. 
Most X-linked disorders are recessive. This means that men with a single abnormal 
gene on the X chromosome have the disorder, while women usually are protected by 
the second (normal) X chromosome. A son always inherits the X chromosome from 
the mother (and the Y chromosome from the father), so if the mother has a mutated 
X chromosome the son has a 50% probability of inheriting this chromosome and thus 
having the disease (Figure A.3). Daughters inherit an X chromosome from both the 
Figure A.l Inheritance pattern of autosomal dominant disorders 
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mother and the father, so they do not have the disease but may be a carrier. In 
Chapter 6 to Chapter 8 fragile X syndrome is described. In this disease the mode of 
inheritance is very complex, this is described in Chapter 6. 
A.2.3 Multifactorial disorders 
Multifactorial disorders are disorders with a considerable genetic component, but 
with as yet no clear pattern of inheritance or detectable chromosomal abnormality. 
They result from an additive effect of several independent genes and several 
exogenous factors (environmental influences). This group includes most congenital 
disorders (e.g. neural tube defects) and major chronic diseases of later life (e.g. 
diabetes mellitus). 
Figure A.3 Inheritance pattern of X-linked disorders 
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A.3 Founder effects 
Particularly in communities that originate from the migration of small groups, a few of 
the founders of the community contribute a lot to the so-called genetic makeup of 
the next generations. If one of them has a particular genetic trait, this can lead to a 
relatively high number of people with the trait in the future generations; this is called 
founder effect. Founder effects can also occur if existing populations become first 
smaller and than larger ('bottle neck'). Founder effects exist e.g. in populations in 
Finland, South Africa, Quebec and the U.S.A. 
A.4 peR test 
With the technique of PCR (Polymerase Chain Reaction), a method of increasing the 
amount of DNA (amplification) developed in the mid-1980s (5, 6), it is possible to 
perform tests on DNA from just a few cells, or even from a single cell. This method can 
be important for prenatal testing using foetal cells isolated from the mother's blood, 
or which have been taken from an embryo produced by test tube fertilisation (50-
called pre-implantation genetic diagnosis). 
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Screening for cystic fibrosis gene carrier state: 
pros and cons of different scenarios 
B.1 Introduction 
The increasing possibilities of DNA diagnostics have given genetic testing a 
completely new dimension. For hundreds of genetic disorders the exact gene defect 
has been found already (1). Through this the possibilities for direct DNA diagnostics 
increase; for example it is possible to identify carriers of recessive inheritable 
disorders. One of these disorders is the serious autosomal recessive inheritable 
disorder cystic fibrosis (CF). The basic defect of this (still) incurable disease consists of 
mutations in the so-called 'cystic fibrosis transmembrane conductance regulator' 
(CFTR)-gene on chromosome 7. With a birth prevalence of 1 in 3,600, CF is the most 
frequent autosomal recessive inheritable disease in The Netherlands (2). Most of the 
children with CF are born in families in which this disease had not occurred earlier. 
Approximately 1 in 30 individuals in The Netherlands is carrier (heterozygote) of the 
CF gene. This means that in our country approximately half a million people are 
carrier. Carriers do not have health problems as a consequence of this carriership. 
However, if two partners are carriers, each child of them has a 25% probability of 
having CF. With the discovery in 1989 of the gene that causes CF and of the most 
occurring mutation t.F508 it is possible to detect carriers of this genetic disorder by 
direct mutation detection (3-5). In The Netherlands the t.F508 mutation occurs in 
approximately 77% of the CF chromosomes (6, 7). Furthermore, at least 13 other 
mutations have been identified in our country, so that with the present diagnostic 
tests a mutation can be detected in approximately 90% of the CF chromosomes in our 
country (DJ.J. Halley and H. Scheffer, personal communication). With this it is, in 
principle, possible to detect 90% of the carriers and 81% of the carrier couples. At this 
moment carrier detection in The Netherlands takes place mainly in CF families and in 
partners of carriers who are found in this way, but there are research projects in 
several European countries and the United States where carrier detection is also 
offered to persons without these risk-increasing factors. The advantage of this 
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screening is that it informs people about their risk. At the same time, carrier detection 
raises psychosocial, ethical and social questions (8). 
When it is decided to also offer carrier screening to persons without CF-family history 
in this country, the question arises at what moment and to what persons screening 
should be offered. As to the time of the screening offer, the following five possibilities 
can be considered: shortly after birth (neonatal screening); during secondary school 
(school screening); at the moment of child wish (preconceptional screening); during 
pregnancy (prenatal screening); early in pregnancy (embryonic screening). This article 
gives an overview of the possible scenarios for a screening offer and the advantages 
and disadvantages of each type. 
The aim of a large-scale carrier screening offer for CF is that it enables people to make 
deliberate reproductive choices on the basis of information. People should have the 
freedom to make the choice themselves. This is only possible when they are informed 
in advance of all possible implications and results of carrier screening. When weighing 
the advantages and disadvantages of the various scenarios it is more important to 
offer the possibility to people to choose for CF carrier screening themselves than to 
aim for a coverage as high as possible. 
B.2 Neonatal screening 
The large advantage of choosing neonatal screening is that it can be simply added to 
the phenylketonuria/congenital-hypothyroidism (PKU/CHT) screening so that the 
coverage can be almost 100% (9). This also means that screening for treatable 
diseases is combined with screening for a (yet) untreatable disorder. This will 
inevitably have consequences for the existing PKU/CHT screening; at least it will mean 
that the routine character of the heel pricks will no longer be natural for every 
individual. 
With neonatal screening, not only children who are carrier of the CF gene are 
detected, but also children who have the disease CF. Advocates of neonatal screening 
see this as a big advantage: an early diagnosiS makes treatment in an early stage 
possible (10). As long as the sensitivity of the test is not 100%, the diagnosis CF can 
only be made if a CF mutation is found on both chromosomes 7. If a CF mutation is 
found on one of the chromosomes, a sweat test has to determine whether the 
individual is carrier or patient: there is a chance that a non-detectable mutation is 
present on the other chromosome. 
- 182-
Screening for cystic fibrosis gene carrier state: pros and cons of different scenarios 
Table B,l Frequency of cystic fibrosis mutations in 200,000 neonates in The 
Netherlands 
Mutations on chromosome 7 
On neither chromosome 
Mutation at one chromosome (carriership) 
Mutation at both chromosomes (disease) 
frequency In % 
96.64 
l.ll 
0.03 
Absolute number 
In = 200,000) 
19l,277 
6,667 
56 
Assuming 200,000 births per year in The Netherlands, approximately 6,700 children 
will be carrier of the CF gene (Table B,l), Because of the incomplete sensitivity of the 
test not all children with a CF mutation will be detected (Table B,2), Depending on the 
test sensitivity used, approximately 5,100 children (when screened for only the 
mutation AF508) resp. 6,000 children (when screened for several mutations) in whom 
a mutation is found at one of the chromosomes will need a sweat test to determine 
whether they are CF gene carrier or CF patient. Ultimately, more than 5,000 children 
know at a very early age that they are gene carrier of a heritable disease. Clearly, there 
can be no self-determination about participation or informed consent. 
With neonatal screening, the knowledge of being a carrier will be relevant only after 
20-40 years. There is a probability that at that time the sensitivity of the test is 
increased and that neonates in whom no mutation has been detected have to be 
rescreened. Furthermore it is possible than people do not know (anymore) what the 
result of the screening is or what the significance of the result is. 
When a child is a detected CF gene carrier, both parents have to be tested for 
carriership if they want to have more children. After all there is a considerable chance 
that both are carrier. This possibility to inform parents on the basis of the test result is 
often named as one of the advantages of neonatal screening. In some cases this 
information will arise only after a child with CF has been born, Furthermore, in some at 
risk couples the risk will be undetected; after all there is a probability of 25% in each 
pregnancy that the child has no mutation on either chromosome. 
Table B,2 Detection of carriers and patients with cystic fibrosis for 200,000 
births, depending on the sensitivity of the screening test 
Senslti~ty Genecarrier Patient 
Detected Missed Detected' Missed 
77% 5,134 1,5ll 4l 13 
90% 6,000 667 50 6 
detected provided every neonate with one detected mutation has a sweat test 
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B.3 School screening 
In school screening, obtaining the samples can take place within the school situation. 
To make the time between screening and the moment of reproduction as short as 
possible, scholars in the last phase of (compulsory) education can be screened. 
From a social-genetic perspective this type of screening gives a good possibility for 
genetic education: the information can be aimed directly at the target group and 
fitted into the school system. Various studies have shown that scholars themselves 
have a positive attitude against school carrier screening (11, 12). Screening at schools 
has been especially successful in Italy for screening for carriership of thalassaemia and 
in Canada for screening for carriership ofTay-Sachs disease (13, 14). 
School screening concerns testing of minors. This means that the final decision to 
participate is with the parents, and not with the scholars themselves. Also, knowledge 
regarding carriership is not directly applicable with school screening and the chance 
exists that the individual needs to be rescreened at the time this knowledge is 
relevant. In a screening programme for carriership of Tay-Sachs disease it appeared 
that 10% of the screened secondary scholars had forgotten the test result after 8 years 
(15). 
With school screening there is a rather large probability of stigmatisation, especially 
with contemporaries. There is a possibility that, despite good information, the carriers 
are regarded as divergent. At an age where youths conform themselves especially to 
contemporaries this can have a negative consequence. 
B.4 Preconceptional screening 
Preconceptional screening concerns a screening offer to individuals and couples in 
the reproductive age with a (future) child wish. This type of screening aims at the 
group for which screening is most relevant: there is a wish for children, but there is 
not yet a pregnancy. This means that there is enough time for information and 
preparation for the screening. When, after screening, there appears to be an increased 
risk to have a child with CF, all reproductive options are open for the persons involved: 
accepting the increased risk; primary prevention by refraining from offspring; having 
prenatal diagnosis, possibly followed by selective abortion in case of a foetus with CF; 
adoption; reproduction by means of artificial insemination with donor sperm; egg cell 
donation or pre-implantation diagnostics. The target group of this type of screening 
can not be reached without a special effort. A possible offer could therefore be 
announced without obligation via the media and primary care. The way in which this 
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will be done will be of decisive importance for the extent of interest of the intended 
target group. In a pilot study in London, aimed at people in the reproductive age, the 
average participation was 17% for those who received a written invitation. With a 
personal offer by a member of the research team, where screening was directly 
possible, the participation was a lot higher (70%). With the same offer, where first an 
appointment for taking the research material at another day was planned, the 
participation was 25% (15). A possibility for such an aimed offer in our country would 
be to set up a preconceptional consultation system. 
Preconceptional screening can be offered both to individuals and to couples. Because 
the probability of having a child with CF is only present when both partners are carrier 
of the CF gene, there is a reason to let the couple be the object of screening, and not 
the individual. A positive result of an individual test means a risk of 1 in 120 for a child 
with CF. In more than 97% of the cases screening of the partner will reduce this 
estimated risk. Screening aimed at couples not only gives a more realistic picture of 
the risk, but also has the advantage that, if desired, both partners can be approached 
simultaneously. In couple screening namely, there are two strategies possible: 
stepwise screening or simultaneous screening (16). Stepwise screening means that 
first one partner is tested. Only with a positive test result the other partner is tested. In 
simultaneous screening both partners are tested directly. If screened for only the 
llF508 mutation the test material of the second partner can be tested for more 
mutations if one of the partners has a positive test result. The advantage of 
simultaneous screening is that couples are given more certainty about their risk. The 
number of couples where one partner has a positive test result and the other a 
negative result is twice as large in simultaneous screening as in stepwise screening 
(Table B.3). A disadvantage however is that with the current test sensitivities the 
Table B,3 Hypothetical results of carrier screening for cystic fibrosis for 200,000 
couples in The Netherlands, assuming a carrierfrequency of 1:30 
Number of persons (%) screened with a test of 
Incomplete senslti~ty' (omplete sensitivityt 
Carrier status of the (ouple Stepwise screenlngt Simultaneous screening 
Negative/negative 194,867 (97.43) 189.865 (94.93) 186.889 (93.44) 
Positive/unknown or positive/negative 4,979 (2.49) 9.959 (4.98) 12,889 (6.44) 
Positive/positive 154 (0.08) 176 (0.09) m (0.11) 
assuming a test sensitivity of 77% for screening of the first partner and of 90% for screening of the second partner 
t assuming a not (yet) existing test sensitivity of 100% 
t one partner is tested first; ifhe/she is positive, the second partner is also tested 
- 185-
AppendixB 
estimated risk is not reduced for positive-negative couples (Table BA); without 
screening the risk is 1 :3,600. This disadvantage is present in all strategies, but is most 
prominent with an offer aimed at couples. Only with a detection rate of approximately 
97% screening will also reduce the estimated risk for these couples. 
Considering the problems that screening gives to couples with a positive-negative 
result some institutes have chosen a policy where a couple is only informed about 
carriership if both partners are carrier (16, 17). This prevents in many cases 
unnecessary anxiety and has furthermore the advantage that counselling can aim 
completely at couples with a high risk. Results of a pilot study show that this type of 
selective information has no effect on the participation (18). Selective information 
however deprives some people of the possibility to make a choice regarding 
procreation on the basis of information. This is in conflict with the starting point of the 
screening offer. 
B.5 Prenatal screening 
Prenatal screening is aimed at those for whom the need for information about 
possible congenital abnormalities is most actual. Therefore the participation can be 
high. The advantage of prenatal screening is that it is easy to integrate in the existing 
health care system. At the first contact in relation to pregnancy, women can be 
informed about screening by general practitioner, gynaecologist or midwife. An 
important disadvantage of the offer of prenatal screening is that not all options are 
possible for participating couples: there is already a pregnancy. With an increased risk 
there is a large possibility that, considering the time pressure, decisions are made too 
qUickly. This can later lead to feelings of regret and blame. To decrease the time 
pressure, the offer of screening should be made as soon as possible in pregnancy. 
Table B.4 Estimated probability that a couple in The Netherlands will have a 
child with cystic fibrosis after carrier screening 
S<le<nlng result" 
Mutations detected One partner tested Both partners tested 
by screening Negative Positive Both negative One positive and Both positive 
one negative 
77% 1:15,250 1:120 1:64,604 1:508 1:4 
90% 1:35,076 1:120 1:338,724 1:1,164 1:4 
96% 1:87,690 1:120 1:2,108,304 1:2,904 1:4 
97% 1:116,920 1:120 1:3,745,515 1:3,871 1:4 
the frequency of carriers in The Netherlands is 1:30, so the probability of a child with cystic fibrosis without screening is 
1:3,600. 
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Results of a pilot project in Manchester show that such an offer is experienced 
positively (19). More than 80% of the participating women had the opinion that they 
had enough time to decide whether or not to have screening after having been 
informed. This does not remove the fact that pregnant women prefer screening 
before pregnancy to screening during pregnancy (20). The results of carrier screening 
programmes for other recessive inheritable disorders show that screening during 
pregnancy is most common. From a report published in 1989 in the U.S.A. regarding 
carrier screening for Tay-Sachs disease, 80% of the participants had screening only 
during pregnancy (21). In Sardinia there is a shift in thalassaemia screening: interest 
increases in couples for preconceptional screening (22). 
Also with prenatal screening there is the question whether to offer screening stepwise 
or simultaneously. With stepwise screening it seems logical to first screen the 
pregnant woman since she already has medical help. For couples where the woman is 
identified as carrier, this means however a large burden to wait for the test result of 
the male. Results of a pilot study in the United Kingdom indicate that this stress 
decreases quite quickly after the negative test result of the partner becomes known 
(23). However, with a negative result for the partner there is still a risk that is 
approximately 5 times as high as the general risk. This indicates that for 
understanding and interpreting risk figures all kinds of psychological mechanisms 
playa role independent of the quantitative risk. 
When all future parents make use of the possibility of prenatal screening, 
approximately 97.4% (stepwise screening) and 94.9% (simultaneous screening) of the 
couples will have a negative-negative test result (Table B.3). They have a very small 
probability of haVing a child with CF. For the other couples the test brings about that 
they are confronted with an increased probability of having a child with CF. Table B.3 
shows that with the still incomplete test sensitivity not all couples at risk are detected 
who have a 2S% probability of having a child with CF. Furthermore, a relatively large 
number of the positive-negative couples is missed, especially with stepwise screening. 
For the positive-positive couples there is a possibility for prenatal diagnosis (chorionic 
villus sampling, amniocentesis). With this diagnostic test there is a 100% guarantee 
whether the foetus is affected or not. Despite their increased risk, the positive-
negative couples can not have prenatal diagnosis, because at most it can be 
demonstrated that the foetus is a carrier. This disadvantage obviously applies to all 
screening scenarios, but is the most relevant for prenatal screening. 
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B.6 Embryonic screening 
A fifth possibility of carrier screening is embryonic screening. Only recently this form 
of diagnosis has been published. In The Lancet of September 1993 Brambati et al. 
describe a screening programme performed by them in Italy of embryonic screening 
in women who qualified for chorionic villus sampling because of the increased risk of 
having a child with chromosomal abnormalities (24). Villi obtained by the CVS were 
screened for the presence of the CF gene. In this type of screening, both foetuses with 
the CF gene on one chromosome as affected foetuses with the CF gene on both 
chromosomes are detected. In the screening programme one affected foetus was 
detected; this pregnancy was terminated because of the test result. In 12 of the more 
than 880 screened foetuses the AFS08 mutation was present at one chromosome. 
Because not all mutations are detectable, these foetuses have an increased risk of CF. 
Two couples decided for this reason to terminate the pregnancy. In a comparable 
screening programme in the United States none of the participating couples broke off 
the pregnancy when only one CF mutation was detected. In some cases a sweat test 
was performed shortly after birth at the request of the parents (2S). 
Probably the advocates of embryonic screening point out that it is important to 
extract as much information from the villi as possible on an indication of CVS (26). 
B.7 Discussion 
Technological developments offer new possibilities to people. This is also true for 
carrier detection: it enables an informed choice with regard to reproduction and with 
this the prevention of distress. The discovery of the CF gene and the most common 
mutations enables screening not only within CF families but also outside the families. 
A complicating factor is the still incomplete sensitivity as a result of the large number 
of mutations that can cause the disorder. If it is decided to offer carrier screening 
outside CF families, the question is how this should happen. Screening of neonates is 
possible. The objections to neonatal screening are so large however that this type of 
screening seems no serious possibility. This also applies to screening of scholars. 
Although in this case the target group can be informed well, there are large 
objections: the information is not directly relevant and minor scholars can not decide 
completely themselves about participation. It seems logical to choose as a target 
group people in the reproductive age. Knowledge about carriership after all becomes 
relevant when reproduction is possible. When the advantages and disadvantages of 
preconceptional and prenatal screening are weighed, an offer of preconceptional 
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screening is preferred. In this type of screening the most relevant target group is 
reached. This group has, contrary to the target group of prenatal screening, still all 
reproductive options open after screening. Many people however turn out to need 
screening during pregnancy. A preconceptional screening offer where screening can 
happen before and during pregnancy would give in most to the wishes. 
A discussion point with regard to an offer of preconceptional screening constitutes 
the question whether this offer should be aimed in a stepwise or simultaneous way. 
The advantage of simultaneous screening is that a more realistic image is obtained of 
the risk. If both partners are tested simultaneously, more certainty can be given about 
the risk also. Simultaneous screening however leads to twice as many positive-
negative couples as stepwise screening. With the present still incomplete test 
sensitivity, screening will not reduce the risk for these couples. Furthermore, these 
couples do not have the possibility of prenatal diagnosis. A second important 
consequence of the still incomplete test sensitivity is that not all couples at risk are 
detected. In The Netherlands, approximately 60% of the carrier couples can be 
detected if screened for the most occurring mutation LlFS08. When screened for the 
mutation LlFS08 and for 13 other mutations 81% of the carrier couples can be 
detected. The gain of screening with a larger test sensitivity is that more carrier 
couples can be informed about their risk of having a child with CF. 
The primary problem in an offer of embryonic screening is the impossibility to 
distinguish with another test (such as the sweat test in neonatal screening) carriers 
from patients. Furthermore this type of screening can only be used if for some other 
reason foetal material is collected. An offer of embryonic screening to all pregnant 
women would bring about a too large risk, given the probability of a spontaneous 
miscarriage after CVS. In our opinion embryonic screening can not be regarded as a 
serious possibility of carrier screening. This type of screening is not aimed at 
identifying carriers, but at detecting affected foetuses. In this sense embryonic 
screening should rather be seen as a form of prenatal diagnosis. 
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Serum screening for Down syndrome and 
open neural tube d~fects in the second 
trimester of pregnancy - does it satisfy the 
criteria of the Committee Genetic Screening of 
the Dutch Health Council? 
C.1 Introduction 
Serum screening for Down syndrome and open neural tube defects in the unborn 
child is carried out on a large scale in several countries. In The Netherlands there is 
debate whether the present programme for detection of Down syndrome in 
pregnancy by diagnostic amniocentesis or chorionic villus sampling, which is limited 
to women over 35, should be replaced by a serum screening offer to all pregnant 
women (1-4). 
The Dutch Population Screening Act (WBO) requires that central government 
approves certain screening programmes before they are implemented. Because 
genetic screening has some special implications, a committee of the Health Council 
(hereafter called 'the committee') has issued a report on genetic screening (5). In this 
report, the committee formulated eleven absolute criteria and ten weighing criteria 
for the admission of genetic screening programmes, taking the criteria of Wilson and 
Jungner (6) as a starting point. In this article we assess serum screening for Down 
syndrome and open neural tube defects in the unborn child against the criteria of the 
committee and indicate gaps in knowledge for making decisions in The Netherlands. 
We address screening for both Down syndrome and open neural tube defects, unless 
explicitly noted otherwise. 
C.2 Assessing the criteria of the Health Council Committee 
According to the Health Council Committee, genetic screening has to meet three 
groups of criteria. The first group (1-5) consists of absolute criteria that do not depend 
on the particularities such as design and organisation of a specific screening 
programme. The second group (6-11) has to be assessed for a specific screening 
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programme, and the third group (12a-j) is composed of ten weighing criteria where 
the overall balance should be directed towards the benefits. We discuss the criteria 
groupwise. 
C.2.1 Absolute criteria, independent of the specific screening programme 
1. The genetic screening programme must concern a health problem or a condition that 
can lead to a health problem in those being tested, or in their descendants., 
Down syndrome and neural tube defects are serious health problems for the persons 
involved and theirfamily. 
2. The target population of the screening programme must be clearly defined. 
Serum screening targets pregnant women with a gestational age of 15-18 weeks. 
3. The screening programme should enable participants to become aware of the 
presence or risk of a disorder or carrier status, and to take a decision based on that 
information. 
The individual risk of a Down syndrome child or a child with an open neural tube 
defect can be calculated by an algorithm using the concentration of serum markers 
and maternal age. Above a cut-off risk defined beforehand, the couple can choose for 
a diagnostic test such as ultrasound examination and/or amniocentesis. In case of a 
serious abnormality, the parents can opt for termination of pregnancy or for 
continuation of pregnancy, preparing themselves for the birth of the child. In the 
latter case, adequate care around delivery can be agreed on and organised in an 
earlier stage. 
4. Practical courses of action must be open to the participants. 
See discussion of criterion 3. The Dutch abortion law allows termination of pregnancy 
until neonatal viability. Reckoning with possible inaccuracies in calculating gestational 
age (GA) this means until 22-24 weeks depending on the way of determining GA. The 
time schedule of serum screening allows decisions to be taken before that time (see 
also criterion 12f). 
5. A test method should be available which is suited to the objective of the screening. 
Serum screening is currently based on the measurement of alpha-foetoprotein (aFP), 
unconjugated oestriol (uE3), and (free-f}) human chorionic gonadotropin (hCG) levels 
in maternal blood. In combination with maternal age, the concentration of these 
analytes predicts the individual risk for a Down syndrome or open neural tube foetus 
in that pregnancy. The test characteristics of serum screening are expected to 
improve with the introduction of new markers. Also screening in the first trimester will 
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eventually become possible, with as most promISing candidate serum markers 
free-~hCG and Pregnancy Associated Plasma Protein A (PAPP-A) (7). 
C.2.2 Conclusion with regard to the independent absolute criteria 
Serum screening for Down syndrome and neural tube defects fulfils the absolute 
criteria set by the committee. 
C.2.3 Absolute criteria that have to be met in a specific programme 
6. Participation in the genetic screening programme should be voluntary and 
conditional on consent based on good information. 
Voluntary and well informed participation has to be realised in the screening 
programme itself; whether counselling has been comprehensible and non-directive 
can only be checked afterwards. High uptake rates of prenatal blood tests suggest 
passive acceptance, while uptake is lower in case more non-directive information is 
passed on to the woman (8). The way in which routine prenatal screening is presented 
will not always lead to well-informed decisions; health care providers should be well 
trained in how to inform people about the advantages and disadvantages of serum 
screening (9). 
7. The target group should be supplied with accurate, comprehensible information. 
The information given before the screening should at least discuss the conditions 
possibly detected by the screening (Down syndrome and open neural tube defects), 
the likelihood of detection, the test method, the significance of low-risk and high-risk 
test results including diagnostic tests, the options after a diagnosis 'Down syndrome' 
or 'open neural tube defect', and how further information can be obtained (10). At this 
moment there is considerable debate in the British literature whether this information 
should be detailed or simple (8, 11-14). 
8. There should be sufficient facilities for follow-up diagnostics, for carrying out the 
chosen courses of action and for informing and supporting the participants. 
Using a risk cut-off of 1 in 250 for Down syndrome or open neural tube defects, 4.5% 
of the pregnancies will be classified as high risk for Down syndrome (cf. criterion 12d) 
and 1.9% as high risk for open neural tube defects (1 S). Using uptake rates from 
literature (16-26), 5,500-10,200 amniocenteses would be performed annually if serum 
screening were to replace maternal age screening in The Netherlands (±200,000 
pregnancies per year). In 1993 more than 7,000 invasive prenatal diagnoses were 
done for advanced maternal age reasons in The Netherlands. The potential number of 
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amniocenteses as a consequence of serum screening is thus in the same order as the 
number of amniocenteses for advanced maternal age currently done. 
The most recent number of induced abortions of Down syndrome foetuses for all 
indications in The Netherlands was 86 (=92% of all detected foetuses) (27). If the age 
indication would be replaced by serum screening, between 55 and 165 extra induced 
abortions would be performed. Annually 30,242 legal abortions are done in The 
Netherlands (28). Therefore no more resources are required in case age-based 
screening by amniocentesis is replaced by serum screening. 
Facilities for performing the amniocenteses indicated through results of serum 
screening and terminations when requested are sufficient. However, a major problem 
are the facilities required for informing pregnant women adequately before and after 
the test, and for assisting those ending with a termination of pregnancy because of 
foetal anomaly. 
9. Provision should be made for continuous quality assurance of the effectiveness, 
efficiency and safety of the test procedure, and all follow-up procedures, as well as 
information and support given to the participants. 
The laboratories have to continuously evaluate the serum determinations by means of 
quality standards. In The Netherlands invasive prenatal diagnosis is regulated by law 
and can only be done in authorised centres. These have the obligation to keep quality 
standards and report annually. Evaluation of information and counselling demands 
labour-intensive psychosocial research and can therefore only be performed in a 
research framework. 
10. If scientific research is carried out within the framework of screening, the participants 
should be properly informed about this in advance. 
Because the conserved sera may be traced to the individual woman, consent of the 
participants has to be obtained if additional research is done that exceeds evaluation 
of the test characteristics (29). 
11. The procedures used for the storage of medical information and cellular material must 
incorporate adequate measures to protect both the personal privacy of the 
participants and their rights regarding their personal data and cellular material. 
The Dutch Data Protection Act (,Wet Persoonsregistratie') and the ministerial order 
about sensitive data ('Besluit Gevoelige Gegevens') state that only data that are 
essential to the treatment of the patient can be filed conditional on the patient's 
approval. Rules on use of registered data, blood, storage periods and procedures for 
file clearing have to be made for this purpose and transmitted to the patient. 
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C.2.4 Conclusion with regard to the programme-dependent absolute criteria 
Facilities for follow-up diagnostic tests and for different courses of action will be no 
problem in The Netherlands. When serum screening becomes a large scale event, a 
huge effort will be needed to inform and train health care providers, to adequately 
inform the patients, and to evaluate both the screening performance and the social 
and psychological impact. The question whether to give detailed or simple 
information to the participants has to be answered. The other absolute programme-
dependent criteria have to be assessed in the specific screening programme by 
continuous evaluation. 
C.2.5 Weighing criteria 
12. The benefits for the participants in the programme should outweigh the 
disadvantages. To support this evaluation, those proposing a screening programme 
must provide information about: 
a. The prevalence of the disease or disorder in the target group. 
Approximately 1.2-1.3 per 1,000 births are affected by Down syndrome, making it the 
most common congenital cause of mental handicap (10, 30). The incidence of Down 
syndrome rises steeply with increasing maternal age (30) and hence depends on the 
age distribution of the target popUlation in The Netherlands. Approximately 9 percent 
of all pregnancies (maternal age higher or equal to 36 years at 18 weeks gestation) is 
'responsible' for the birth of 35 percent of the children with Down syndrome (32). 
The birth incidence of a child with a neural tube defect for the years 1980-1986 was 
1.4 per 1,000 in the northern part of The Netherlands (0.66/1,000 anencephaly and 
0.5811,000 spina bifid a) and 3.2/1,000 in the United Kingdom (1.28/1,000 anencephaly 
and 1.5811,000 spina bifid a) (33). The risk for neural tube defects is not age-
dependent. 
b. The natural course of the disorder, and the variation in degrees of severity. 
Of all liveborn Down syndrome patients, thirty percent has a congenital heart disease. 
A quarter of the patients with congenital heart disease dies within a year after birth, 
while fifty percent reaches the age of thirty. Of the Down syndrome patients without 
congenital heart disease, nine percent dies within the first year of life and 80 percent 
reaches the age of thirty (34). In the majority of patients there are age-dependent 
degenerative changes in the brain which are typical of Alzheimer's disease. 
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Anencephaly is not compatible with life. Children with spina bifida can be kept alive 
through a variety of operations, both shortly after birth and later in life. They are 
almost always physically -and frequently also mentally - handicapped (35). 
c. The target group and the considerations which led to the choice of the proposed 
target group and the proposed time of testing. 
Down syndrome occurs in pregnant women of all ages. Because the predictive value 
of the test is much lower for younger women than for older women (Table c.1). some 
people advocate restricting serum screening to older age categories. On the other 
hand a serum screening programme only for women younger than 35 years of age 
has been proposed in the United States of America, to be used complementary to 
direct amniocentesis or chorionic villus sampling in women older than 35 years (36). 
Strategies and risk cut-offs will depend on current national policies and resources and 
on preferences in society. 
Ideally, screening should be performed as early as possible in pregnancy. At present 
there is sufficient information for making a good risk estimation for screening in the 
second trimester of pregnancy, but not for screening in the first trimester. 
d. The specificity, sensitivity and predictive value of the test method Qlld the burden 
which testing imposes on participants. 
Ten projects have shown a combined sensitivity (detection percentage) of 67 percent 
for Down syndrome (Table C.2). Assuming a 100% uptake of screening, 4.5 percent of 
the women who are not pregnant of a child with Down syndrome will be offered 
amniocentesis because of a high-risk test result (false positive), that is a specificity of 
95.5 percent. For comparison: a risk estimation on the basis of maternal age (36 years 
or older at 18 weeks gestation) with a 100 percent uptake detects 35 percent of Down 
syndrome foetuses with a specificity of 91 percent. The predictive value of a high-risk 
Table C.1 Calculation of the number of false-positive serum test results per 
detected Down ~yndrome foetus 
Maternal P(evalence at Detection False positive Number of Number of true- Numberof 
age prenatal diagnosis percentage'" percentage"* false positive pOlitive telt (TPI FP resultl 
(per 1,000 women) (sensitivity) (1-lpecificity) test (FP) relultl relultl (per per TP result 
(per 1,000 lVomen) 1.000 women} 
(a).(30) (b).(3l) (,).(3l) d - (1-a)" e-a"b f-d/e 
35 3.8 72% 11% 110 3 40.1 
40 13.3 90% 33% 326 12 27.2 
45 45.3 98% 68% 649 44 14.6 
cut-off risk 1:250, gestational age determined with ultrasound 
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test result (cut-off 1 :250) is 1 :68 if the gestational age is based on the last menstrual 
period and 1 :53 for a gestational age determined through ultrasound (31). 
For open spina bifida the detection percentage of the aFP-test for a risk cut-off of 
2.5 MoM (multiples of the normal median) is 75 if the gestational age is based on the 
last menstrual period and 90% for an ultrasonically detected gestational age. The 
percentages of women with a false-positive test result are 3.3 and 2.8 respectively. 
Some of them have a child with another abnormality such as exomphalos and 
gastroschisis. The predictive value for open spina bifida of a high-risk test result after 
ultrasound dating is 1:31 for a birth prevalence of 1/1,000 and 1:16 for a birth 
prevalence of 2/1,000 (31). For anencephaly the detection percentage is at least 90 
percent with a predictive value of about 1 :23 (35). The burden for the participants is 
discussed under criterion 12g. 
e. The available courses of action if a health problem or carrier status is revealed. 
See also criterion 3. Furthermore it should be noted that pregnancies with a high aFP-
andlor high hCG-concentration that can not be explained by the presence of a Down 
syndrome or neural tube defect foetus have a higher risk of obstetric complications 
(37-40). These pregnancies should therefore be labelled as high-risk pregnancies. 
Research should clarify which cut-off value is optimal and whether the findings have 
clinically useful consequences. This finding of an enhanced obstetric risk has special 
significance in the organisation of prenatal care in The Netherlands where in 70% of 
pregnant women, prenatal care is initially provided by GP's or midwives. 
f. The time allowed by the procedure for consideration and possible implementation of 
the selected course of action. 
Serum analysis can be performed daily if there are more than 50 samples a day, so that 
the time between blood sampling and the availability of the test result for the woman 
is 3-5 days. In case of a high-risk test result, prenatal diagnosis can be performed 
within seven days, depending on the time the woman needs to make her decision. 
The result of ultrasound examination is known immediately, while the result of the 
amniocentesis is known within 10-14 days. Consequently, if blood sampling is 
performed between 15 and 18 weeks, the result of amniocentesis can be known 
between 17 and 22 weeks. Because the Dutch abortion law states that termination of 
pregnancy has to be performed before 22 weeks gestation (see above), the woman 
has between a few days and five weeks to decide whether or not to terminate the 
pregnancy. 
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Table C.2 Results of ten pilot studies of second-trimester serum screening 
No. of Mean age Risk Downls Detected Detection False-positive Positive Amniocentesis Partidpation 
pregnancies (range) cut-off pregnancies Down's percentage percentage predictive uptake 
in stud~ t 
* 
Q~nandes ; (sensitiv!!l:) (100-seecffid~1 value 
Haddowetal. (17) 25,207 27.0 (16-41) 1:190m 36 21 58 3.8 1:38 79 not given 
Phillips et al. (18) 9,530 24.5 (12-34) 1:274m 7 4 57 3.2 1:77 68 not given 
Wald et al. (19) 12,603 not given 1:250 b 25 12 48 4.1 1:43 75 74% :.. 
Burton et al. (20) 8,233 28.1 (lH8)' 1:270m 12 10 83 5.9 1:48 81 not given "0 
"0 
Cheng et al. (21) 7,718 28.7 1:195 m 22 20 91 6.0 1:23 69 not given 
'" 
'" Wenstrom et a1.(22) 18;12 not given 1:190m 27 13 48 3.6 1:51 78 not given ~ Goodburn et al. (23) 25,359 27.0 (15-53)' 1:200 b 48 36 75 4.0 1:28 85 77% 
" Piggott et al. (24) 6,990 not given 1:250 b 11 8 73 3.0 1:26 76 67% 
Benn et al. (25) 11,434 not given 1:270m 20 14 70 5.9 1:48 67 not given 
Kellner et al. (26) 10,605 29.7 (14-44) 1:270b 16 12 75 7.2 1:64 90 not given 
All 136,391 224 150 67 4.5 1:40 80 
.. median age 
t b=at birth, m=mid-trimester 
* detected and undetected 
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g. The possible psychological, social and other repercussions (bot/] positive and 
negative) of an offer and of participation or non-participation in the screening for the 
person to be tested and for members of their family or for groups within the 
community. 
Adverse psychological consequences are to be expected during the decision process 
whether or not to have serum screening, during the waiting for the screening results, 
and after a high-risk test result. The consequences of a high-risk test result for a non-
Down syndrome pregnancy are mainly short-term: the anxiety generated by the 
serum screening results generally subsides rapidly when diagnostic tests are 
reassuring (41-46). There has not been research on psychological consequences of 
having a Down syndrome child after low-risk test results. Positive psychological 
effects of serum screening are the autonomy and self-determination allowed to the 
patient and consequently her enhanced possibilities to detect or exclude some of the 
most serious foetal abnormalities. 
Amniocentesis causes iatrogenic loss of pregnancy in about 0.3 percent of cases (47). 
If amniocentesis detects a serious abnormality, the woman can choose to terminate 
the pregnancy, which has a risk of 1-2 percent of medical complications (47) and 
induces a long period of perinatal grief (48). 
h. The likelihood of erroneous results, the possible consequences of this for participants 
and the measures taken to limit any harm which such an error might couse. 
See also criteria 12d and 12g. In order to reach a uniformly high standard of serum 
screening, the sera should be examined in a limited number of laboratories. These 
laboratories have to communicate intensively with the departments of obstetrics in 
which the counselling is done and the invasive prenatal diagnosis is performed. 
Centres for prenatal diagnosis have a pivot role as advisors and instructors for other 
pregnancy care providers. 
i. The safeguards for participants against unjustified impediments (as a result of their 
participation or non-participation in the screening programme or follow-up testing) 
to obtain employment or private insurance cover. 
The insurance implications of genetic testing are more and more a concern (49). We 
are not aware of any cases in the world literature where difficulties in getting insured 
have occurred because people opted out of prenatal screening, prenatal diagnosis, or 
termination of pregnancy of a foetus with severe illness. 
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j. The costs of the screening and of the necessary infrastructure. 
Several studies have estimated the costs of serum screening for Down syndrome 
andlor open neural tube defects prospectively and retrospectively for various 
countries and various situations (19, 50-59). Per 100,000 pregnant women these costs 
have been estimated between €2,097,000 and €3,835,000 for Great Britain (19, 55, 56, 
59). For the situation in the United States of America, which we regard less 
comparable with the Continental European situation, much higher costs have been 
estimated (57). For the Dutch situation no calculations are available. 
C.2.6 Discussion of weighing criteria 
For the Dutch situation data are available for most (12a-12f, 12h-12i), but not all 
criteria (12g, 12j). The psychological, social and other repercussions to the tested 
people andlor their family (criterion 12g) as well as the costs of a screening 
programme (criterion 12j) have been studied in the UK. Part of the data is probably 
valid for the Dutch situation. Ideally Dutch studies should be conducted to make the 
final weighing. 
C.3 General discussion 
Insofar they can be checked, the absolute criteria for genetic screening of the Health 
Council Committee are fulfilled. Contrary to researchers in other countries we cannot 
yet assess the weighing criteria for The Netherlands because the individual 
psychological and social consequences of serum screening and the costs of a 
programme have not yet been examined. One of the reasons of this gap in knowledge 
is that there is no tradition of aFP-screening for open neural tube defects in The 
Netherlands, as opposed to for example Great Britain (1-4). Before we contemplate to 
introduce a larger-scale serum screening programme in The Netherlands, we should 
investigate a number of issues, amongst others optimal ways of informing the patient 
and psycho-emotional consequences as well on the individual level as on society as a 
whole (8, 11-14). 
If the introduction of serum screening is considered, we propose the following 
preparatory steps: 
• diffusion of knowledge through the departments of obstetrics where invasive 
prenatal diagnosis is performed (the 'centres for prenatal diagnosis'); 
• training of current health care providers andlor special counsellors who can assist 
(individually or on a group basis) patients with their choices concerning screening 
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(not only for Down syndrome but for example also for cystic fibrosis) and 
diagnostic procedures; 
• uniform information (written or on tape) in various languages; 
• close collaboration between laboratories analysing sera, centres for prenatal 
diagnosis, and health care providers. 
Once introduced, the quality of the programme should be monitored by a committee 
installed for that purpose. Training of health care providers and development of 
information material should be a continuing effort. We are ultimately in favour of: 
• individual information and reporting of results through general practitioner, 
midwife or gynaecologist; 
• follow-up of the course of pregnancy and outcome of all patients for instance 
through the nationwide obstetric registration. 
These steps ask for a large logistic and financial effort and a long time of preparation. 
The success of such a programme depends on the Willingness to make these efforts 
and requires a dedication of the persons involved. Because screening for disease takes 
a growing share of the health care (for example cystic fibrosis) such a restructuring of 
information and follow-up has to be done anyway. 
Counselling should contain only comprehensible information and should never be 
directive or coercive. In order to really make decisions in freedom, a social climate is 
necessary in which there is room and support for handicapped persons. The 
committee of the Health Council duly gives this strong emphasis in her report. 
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Comparison of single-entry and double-entry 
two-step couple screening for cystic fibrosis 
carriers 
0.1 Introduction 
Cystic fibrosis (CF) is the most common life-shortening recessive disorder affecting 
people of European descent (1). For instance, in the United States of America alone, 
1,700-2,000 babies are born with CF annually (1). Disregarding rare instances of 
uniparental disomy (2) or pseudodominance, both parents of CF patients are carriers 
of one mutated copy of the so-called CFTR gene (3). The number of Americans who 
are CF carriers is estimated to be 8 million (1). However, only children of couples 
where both partners are carriers are at a high l-in-4 risk of being affected with CF. In 
the United States, 1 in every 625 couples is supposed to have this l-in-4 risk with each 
pregnancy (l).lf couples with such a high risk are identified before birth or conception 
of a CF child, they can be informed about their high risk and consider all options, 
including prenatal diagnosis. In theory, the identification of all at risk couples can be 
achieved by population screening programmes, and many pilot studies are currently 
undertaken (4-9). The number of Americans of reproductive age who could 
theoretically be involved in CF carrier screening amounts to 125 million (1). With such 
high numbers, all possible strategies need to be carefully considered. 
One of the main technical problems with CF carrier screening is that there is no single 
screening method that detects all carriers. Screening is performed through mutation 
detection by DNA technology. Several hundred different mutations have been 
identified so far (10). One mutation, M508, has a particular high frequency in most 
white popUlations, representing 60-80% of all mutated CFTR genes (11). Some other 
mutations, each with an individual frequency of 1 to a few percent, together make up 
10-15% of mutated CFTR genes. So, in most populations, 5-30% of all CFTR mutations 
cannot be detected easily because they are either rare or still unknown. Several 
strategies have been proposed to minimise the disadvantages associated with the 
incomplete sensitivity of present screening methods. 
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In this paper we will compare the arithmetic consequences of two types of couple 
screening: single-entry two-step screening (SETS) and double-entry two-step 
screening (DETS). In SETS, one starts with testing one member of the couple first (first 
step), and proceeds to test the other member (second step) only if the first member is 
identified as a carrier. In view of the large number of possible mutations, one might 
choose for economic reasons to employ a test with a lower sensitivity in testing the 
first member than in testing the second member. For instance, one could screen only 
for the L'lFS08 mutation in the first member of the couple, and screen for L'lFS08 and as 
many mutations as possible in the second member. In DETS, both members of the 
couple are tested initially for one or a few mutations (first step) and partners of 
identified carriers, who themselves are not identified as carriers in the first step, are 
tested for more mutations (second step). 
The differences between SETS and DETS are the following. In SETS, only one member 
(singl~-entry) and in DETS both members (double-entry) of the couple are involved in 
the first step of the procedure. In SETS, the sensitivity of the second test may be 
chosen to be the same as the sensitivity of the first test, although a higher-sensitivity 
second test has potential advantages. In DETS, a second test always aims to increase 
the number of mutations for which the partner of an already identified carrier is 
tested. SETS and DETS have in common that the couple rather than the individual is 
the target of the screening, but in SETS one member of the couple will usually remain 
untested. 
SETS and DETS will be compared here with regard to the frequency of identified 
carrier couples and resulting detection rate, the frequency of couples with one 
identified carrier and their (remaining) risk for CF in a child, and the frequency of 
couples without an identified carrier and their (remaining) risk. 
0.2 Methods 
Figure D.l and Figure D.2 depict schematically the possible outcomes of SETS and 
DETS, respectively. The areas in each figure are separated from each other by lines 
representing carrier frequency (cfr), sensitivity of the first step (sensl) or sensitivity of 
the second step (sens2). In Figure D.l (concerning SETS) area a represents couples 
with both partners identified as carriers (++ couples). Couples with one identified 
carrier (+- couples) are included in areas d and i, and couples without identified 
carriers (-? couples) are contained in areas b, c, e, f, g and h. However, couples 
included in areas b, c and d are in fact not-identified couples with both partners 
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carrier non-carrier 
--HI------> 
e r 9 
i~ I-- h i 
carrier frequency 
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Partner 2 
I 
I 
I 
I h • 
Figure 0.1 Diagram showing all possible outcomes in SETS couple screening. 
Sens1 = sensitivity of the first screening step; sens2 = sensitivity of the second 
screening step. Partner 1 is the first partner of the couple to be tested. Partner 2 
is tested only if the first partner tests positive. For the pictorial presentation the 
carrier frequency has been inflated. See text for full explanation 
carriers. In Figure D.2 (concerning DETS), ++ couples are found in area~ a, band d, 
+- couples in areas e, i, k and q and -- couples in areas c, f, g, h, I, m, n, 0 and p. Here 
couples included in areas c, e, f, g, hand i are not-identified couples with both 
partners carriers. From inspection of the figures the following formulae can be 
derived. 
For SETS: 
prevalence of ++ couples = a= sensl* sensl' err; 
2 detection rate of ++ couples = a sensl' sens2; 
a+b+c+d 
3 prevalence of +- couples = d+ i=sensl* err * (1- sens2* err); 
4 residual risk in +- couples = 0.2S*~=0.2S*(1-sens2)* err 
0+1 l-sem2*di 
5 prevalence of -? couples = b+(+e+f + g+h=l- sensl* (If; 
6 residual risk in -? couples = 0.2S* b+c 0.2S*(1-sens1)* efr' ; 
b+(+e+f+g+h l-sensl* err 
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Figure 0.2 Diagram showing all possible outcomes in DETS couple screening. 
Sens1 = sensitivity of the first screening step; sens2 = cumulative sensitivity of 
the first and second screening step. Partners 1 and 2 are both tested in the first 
screening step. Partners of identified carriers who test negative in the first test 
are tested for more mutations in a second step. For the pictorial presentation the 
carrier frequency has been inflated. See text for full explanation 
For DETS: 
7 prevalence of ++couples = a+b+d=(sens2' -(sens2- sens1)')* ef?; 
d · f I a+b+d , ( )' 8 etectlon rate 0 ++ coup es = sens2 - sens2-sens1 ; 
a+b+c+d+e+f+g+h+i 
9 prevalence of +- couples = e+i+k+q=2* sens1* dr*(1- sens2* efr); 
10 residual risk in +- couples = 0.25* e+i 0.25*(1- sens2) * dr ; 
e+i+k+q 1-sens2*dr 
11 prevalence of -- couples = c+f+g+h+i+m+n+o+ p=(1- sens1* dr)' 
12 residual risk in __ couples = 0.25* c+f+g+h 0.25* ((1-sens1) * elr)' . 
c+f+ g+h+ i+nJ+n+o+p (1- sens1* dr)' 
0.3 Results 
Results of calculations with a carrier frequency of 0.04 and several sensitivities for the 
first and second test, starting at 75%, are shown in Table 0.1 For DETS, the sensitivity 
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Table D.1 Results of SETS and DETS couple screening at different combinations 
offirst- and second-test sensitivities 
SETS DETS 
Detection ++ +- -1 Detection ++ +-
Sensl Sens2 rate fieq fieq nsk fieq nsk rate freq fieq nsk freq nsk 
(In%) lin lin lin (In%) lin (In%) lin lin lin (In%) lin 
0.75 0.75 56.25% 1,111 34.4 388 97.00% 9,700 56.25% 1,111 17.2 388 94.09% 37,636 
0.80 60.00% 1,042 34.4 484 97.00% 9,700 63.75% 980 17.2 484 94.09% 37,636 
0.85 63.75% 980 34.5 644 97.00% 9,700 71.25% 877 17.3 644 94.09% 37,636 
0.90 67.50% 926 34.6 964 97.00% 9,700 78.75% 794 17.3 964 94.09% 37,636 
0.95 71.25% 877 34.7 1,924 97.00% 9,700 86.25% 725 17.3 1,924 94.09% 37,636 
0.99 74.25% 842 34.7 9,604 97.00% 9,700 92.25% 678 17.4 9.604 94.09% 37,636 
1.00 75.00% 833 34.7 97.00% 9,700 93.75% 667 17.4 94.09% 37,636 
0.80 0.80 64.00% 977 32.3 484 96.80% 12,100 64.00% 977 16.1 484 93.70% 58,564 
0.85 68.00% 919 32.3 644 96.80% 12,100 72.00% 868 16.2 644 93.70% 58,564 
0.90 72.00% 868 32.4 964 96.80% 12,100 80.00% 781 16.2 964 93.70% 58,564 
0.95 76.00% 822 32.5 1,924 96.80% 12,100 88.00% 710 16.2 1,924 93.70% 58,564 
0.99 79.20% 789 32.5 9,604 96.80% 12,100 94.40% 662 16.3 9,604 93.70% 58,564 
1.00 80.00% 781 32.6 96.80% 12,100 96.00% 651 16.3 = 93.70% 58,564 
0.85 0.85 72,25% 865 30.4 644 96.60% 16,100 72.25% 865 15.2 644 93.32% 103,684 
0.90 76.50% 817 30.5 964 96.60% 16,100 80.75% 774 15.3 964 93.32% 103,684 
0.95 80.75% 774 30.6 1,924 96.60% 16,100 89.25% 700 15.3 1,924 9332% 103,684 
0.99 84.15% 743 30.6 9,604 96.60% 16,100 96.05% 651 15.3 9,604 93.32% 103,684 
1.00 85,00% 735 30.6 96.60% 16,100 97.75% 639 15.3 93.32% 103,684 
0.90 0.90 81.00% 772 28.8 964 96.40% 24,100 81.00% 772 14.4 964 92.93% 232,324 
0.95 85.50% 731 28.9 1,924 96.40% 24,100 90.00% 694 14.4 1,924 92.93% 232,324 
0.99 89.10% 701 28.9 9,604 96.40% 24,100 97.20% 643 14.5 9,604 92.93% 232,324 
1.00 90.00% 694 28.9 96.40% 24,100 99.00% 631 14.5 = 92.93% 232,324 
0.95 0.95 90.25% 693 27.4 1,924 96.20% 48,100 90.25% 693 ll.7 1,924 92.54% 925,444 
0.99 94.05% 665 27.4 9,604 96.20% 48,100 97.85% 639 ll.7 9,604 92.54% 925,444 
1.00 95.00% 658 27.4 96.20% 48,100 99.75% 627 13.7 92.54% 925,444 
0.99 0.99 98.01% 638 26.3 9,604 96.04% 240,100 98.01% 638 13.1 9,604 92.24% 23.059,204 
1.00 99.00% 631 26.3 96.04% 240,100 99.99% 625 13.2 = 92.24% 23,059,204 
1.00 1.00 100.00% 625 26.0 96.00% 100.00% 625 ll.O 92.16% 
of the second test is represented as the cumulative sensitivity of the first and second 
tests. Inspection of the table reveals the following. 
As expected, the proportion of ++ couples (couples with both partners identified as 
carriers) is the same for SETS with similar first- and second-test sensitivities and DETS 
with a similar first-test sensitivity and no second test. To obtain this result almost 
twice as many tests have to be performed in DETS than in SETS. 
The proportion of ++ couples and with it the detection rate of couples with both 
members carriers increases with increasing sensitivity of the first and second tests, but 
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the increase with increasing sensitivity of the second test is sharper in DETS than in 
SETS. 
The proportion of +- couples (couples with one identified carrier) varies primarily with 
the screening strategy (SETS or DETS), to some extent with the sensitivity of the first 
test and only marginally with the sensitivity of the second test. The proportion of 
+- couples is twice as large in DETS as in SETS. 
The remaining risk of CF in a child of a +- couple is determined by the sensitivity of the 
second test. For sensitivities less than l/(1+cfr), which equals approximately (1-cfr), 
the after-testing risk is higher than the before-testing risk. With a 99% sensitivity of 
the second test, the remaining risk of +- couples does not decrease further than to 
about one quarter of the initial frequency. 
As expected, the proportion of -? SETS couples and -- DETS couples (couples without 
identified carriers) varies with the screening strategy and the sensitivity of the first 
test. 
The remaining risk in -- and -? couples varies with the sensitivity of the first test. This 
risk is significantly lower in DETS than in SETS. 
D.4 Discussion 
In trying to devise efficient and economical methods for carrier screening, Beaudet 
and O'Brien (12) have advocated a two-step laboratory strategy for testing couples, in 
which both partners are tested for fewer mutations in a first step and only partners of 
identified carriers are tested for additional mutations. They demonstrated that the 
detection rate of carrier couples is very little affected by studYing fewer mutations in 
the first step. This can also be illustrated by our calculations on DETS. For instance, 
testing both members of a couple with one test with a 85% sensitivity yields an only 
1 % increase in detection rate over a two-step procedure in which the first test has a 
sensitivity of 75% and the second test a sensitivity of 85%. 
With regard to the detection rate in DETS, we thus agree with the conclusion of 
Beaudet and O'Brien (12) that it is far more efficient and economic to test more 
mutations on samples of partners of known carriers thanto test an increasing number 
of mutations on all samples. However, with regard to the remaining risk in couples 
without identified carriers, it is far more beneficial to test both member of the couple 
for as many mutations as possible in one step than to start with a first step with a 
lower sensitivity and proceed to a second step with a higher sensitivity. In the 
example given above, the remaining risk for these couples in a one-test procedure 
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with 85% sensitivity is about Hold lower than in a two-step procedure with 75% 
sensitivity in the first test and 85% sensitivity in the second test. 
If one compares DETS to SETS, other disadvantages of DETS emerge. The most 
important disadvantage of DETS over SETS is the doubling of the proportion of 
+- couples (couples with one identified carrier) in DETS, while the remaining risk of 
such couples is the same in SETS and DETS (we do not go into the possibility of 
withholding the +- result as suggested by Brock (13)). Another disadvantage of DETS 
over SETS seems to be that DETS requires twice as many tests as SETS. However, 
savings obtained by DETS may be greater than by SETS (see Chapter 5). 
Comparing all the pros and cons of the different strategies does not in itself reveal the 
most optimal procedure. Preceding decisions are needed with regard to desirable 
detection rate, proportion of +- couples and their remaining risk, and the remaining 
risk in -- couples. For instance, one could regard carrier screening only justified when 
the detection is 80% of greater, when the number of +- couples is as low as possible, 
when the remaining risk of such couples does not exceed 1 in 1,000 and when the 
remaining risk of -- couples is less than 1 in 25,000. As Table D.l shows, these 
conditions can best be met by SETS with a high sensitivity (91 % or more) of the first 
test. The calculations presented here can also be used as a basis for cost and savings 
considerations, if costs of screening, cost of care of CF patients, uptake rate and the 
distribution of reproductive decisions of carrier couples found by screening are 
known (see Chapter 5). 
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Summary 
In this thesis the costs, effects and savings of genetic screening programmes for 
carriers of cystic fibrosis and fragile X syndrome are studied. In chapter 1 genetic 
screening in general is described focussing on the points in time where genetic 
screening can be offered: prenatal screening (screening of pregnant women), 
preconceptional screening (screening of non-pregnant women with a child wish), 
school screening (screening of 16-year old scholars in the last year of compulsory 
education) and neonatal screening (screening of newborns). Furthermore, this 
chapter discusses criteria that in the view of the Committee Genetic Screening of the 
Dutch Health Council have to be fulfilled by a genetic screening programme. In the 
last part of the chapter several types of economic evaluation are presented. 
Chapter 2 gives an introduction to the disease cystic fibrosis, a genetic disorder with 
recurrent pneumonia, disturbances of the digestive tract, high sweat sodium 
concentration, malnutrition and fertility problems. Cystic fibrosis is an autosomal 
recessive disorder, which means that only couples where both partners have an 
affected gene are at risk to have a child with cystic fibrosis. Because approximately 1 in 
30 persons in The Netherlands have an affected gene, about 1 in 3,600 Dutch 
newborns have cystic fibrosis. Most patients have daily physiotherapy and often use 
antibiotics to fight respiratory infections. In the period 1985-1990 the median life 
expectancy of patients was 27 years. Because of the cloning of the affected gene in 
1989 and the development of simple technical methods to detect the most prevalent 
mutations in the gene, screening for (carriers of) cystic fibrosis has become a 
possibility. In the last part of the chapter possibilities and impossibilities of such a 
programme are described. 
Chapter 3 describes a questionnaire aimed at the costs outside the hospital of patients 
with cystic fibrosis. Questionnaires were sent to 73 patients with cystic fibrosis who 
were seen in two Dutch hospitals: the Leyenburg hospital in The Hague and the 
Beatrix Children's Clinic in Groningen. In total 14 (parents of) children and 33 adults 
returned the questionnaire. The average costs outside the hospital amount to €6,944 
per child per year (range €1,065-€19,852) and €1 S,322 for adults (range 
€2,473-€39,751). Medical care outside the hospital is responsible for 8% of these 
costs for children and 5% for adults, domestic help for 15% and 9% respectively, diet 
for 10% and 7%, travelling costs because of the disease for 4% and 8%, medication for 
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63% and 67%, and devices and special facilities at home, work or school for 1 % and 
4%. The conclusion of the analysis is that costs outside the hospital are very high for 
patients with cystic fibrosis, and that these add up to almost half of the total (medical 
and nonmedical) costs of cystic fibrosis during the life of a patient. 
In chapter 4 the total costs of care of Dutch patients with cystic fibrosis in 1990 and 
1991 are described. The age-specific medical consumption is estimated by an 
examination of medical records and the questionnaire described in chapter 3. A 
distinction is made between costs of hospital care, medication in and outside the 
hospital, and home care. The costs per year are calculated by mUltiplying the yearly 
amount of care by the costs per unit. The average yearly costs in 1991 were €16,319 
(hospital care 42%, medication 37%, home care 20%). The costs of cystic fibrosis in The 
Netherlands, with about 1,000 patients, are estimated at more than €16 million per 
year; this is 0.07% of the total health care budget. When the survival is taken into 
account and the costs are discounted at 5% per year to the birth year of the patient, 
the costs during the life of a patient are about €250,000. 
The results of chapters 3 and 4 are used in the analysis of the costs, effects and savings 
of a screening programme for carriers of the cystic fibrosis gene presented in 
chapter 5. A general computer model was constructed with which prenatal, 
preconceptional, school, and neonatal carrier screening is evaluated. For prenatal and 
preconceptional screening two strategies are analysed: single-entry and double-entry 
screening of couples. In singe-entry screening one partner is tested for carriership, 
and only if he/she is carrier the second partner is tested; in double-entry screening 
both partners are tested for carriership. Of all screening strategies, neonatal screening 
gives most carrier couples (112 couples) the possibility of an informed choice 
concerning reproduction, followed by prenatal screening (63 couples). Prenatal and 
single-entry preconceptional screening for carriers of the cystic fibrosis gene have a 
favourable cost-savings balance in The Netherlands for a wide variety of assumptions, 
and single-entry prenatal screening has highest savings (€1.5 million per year). For 
double-entry and neonatal screening relatively favourable assumptions concerning 
coverage and, uptake of prenatal diagnosis and induced abortions are necessary to 
have a favourable cost-savings balance, while carrier screening of scholars has an 
unfavourable balance for a wide range of assumptions (in the baseline analysis the 
costs of school screening are €2 million higher than the savings). The conclusion of 
the analysis is that costs will not form an obstacle for prenatal or single-entry 
preconceptional screening. 
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Chapter 6 discusses fragile X syndrome, the most common single-gene cause of 
mental retardation. Many patients with fragile X syndrome have one or more of the 
following physical symptoms or behavioural abnormalities: high forehead, large 
prominent ears, enlarged testicles, hyperactivity, excessive shyness and autistic 
features. The symptoms are milder in women with fragile X syndrome than in men. In 
most cases the cause of fragile X syndrome is a large expansion of the number of CGG 
repeats in a part of the fragile X gene (full mutation). Persons with a smaller number of 
repeats in the gene (so-called premutation) have no symptoms, but women with a 
pre mutation run the risk of having a child with fragile X syndrome because the 
premutation 'grows' to a full mutation. Men with a premutation can give this 
premutation to their child, but it will never grow to a full mutation. This means that 
men with a premutation do not run the risk of having a child with fragile X syndrome. 
Moreover, as (almost) no men with fragile X syndrome do conceive children, only 
women have to be tested in a screening programme. In the last part of the chapter 
screening for carriers of the fragile X gene is described. 
The costs, effects and savings of a screening programme for the fragile X gene is 
discussed in chapter 7. Prenatal screening detects the highest number of carriers (200 
carriers) and prevents the highest number of births of patients (28 patients). The costs 
per detected carrier are almost equal for all screening strategies (€40,000), and all 
screening strategies have a favourable cost-savings balance: €12 million for prenatal 
screening, €8 million for preconceptional screening and €2 million for school 
screening. This means that from an economical point of view there are no obstacles to 
fragile X syndrome carrier screening, and that the decision whether or not to screen 
can concentrate on medical, social, psychological and ethical aspects. 
Another strategy to detect carriers, described in chapter 8, is cascade testing (testing 
of relatives of a patient) for fragile X syndrome. With a computer-simulation model 
100,000 five-generation pedigrees are constructed and the maximal number of 
detected carriers is calculated for three scenarios: 1. only first-degree relatives of the 
patients are tested; 2. relatives up to the third degree are tested; 3. relatives up to the 
fifth degree are tested. In the start-up phase of a cascade testing programme, 19% of 
the couples that will have a child with fragile X syndrome are detected. After this start-
up phase, a cascade testing programme will detect 8% of the undetected couples 
who will have a child with fragile X syndrome if only first-degree relatives are tested, 
13% if relatives up to the third degree are tested, and 16% if relatives up to the fifth 
degree are tested. This means that at least eight generations have to be tested in 
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order to find 90% of all carriers. The results of the analysis show that the effectiveness 
of cascade testing is not high, but the cost-effectiveness probably is favourable. 
Questions can be raised whether separate genetic screening programmes can and 
should be combined (chapter 9). The advantages of a combined programme are that 
the couples is confronted with only one screening offer and one counselling session, 
and that there will be efficiency effects in the costs of for example organisation and 
information. Therefore the combination of screening programmes for carriers of cystic 
fibrosis and fragile X syndrome is analysed. Because all assumptions, except for some 
costs, are taken the same as the assumptions in the analyses of chapter 5 and 7, the 
effect measures (like the number of detected couples and the number of prevented 
patients) of a combined screening programme are the same as those of the separate 
screening programmes. The conclusion of this analysis is that indeed considerable 
gains can be obtained when combining screening programmes for cystic fibrosis and 
fragile X syndrome carriers. 
In chapter 10 the research results are summarised and an updated analysis of the 
costs, effects and savings of preconceptional screening for carriers of the cystic 
fibrosis gene is presented. For example, the recommended discount rate is reduced 
from 5% to 3% and new screening tests are analysed. In the updated analysis 
preconceptional screening is cost-saving for three out of four test combinations, but 
double-entry preconceptional screening is only cost-saving for one of the test 
combinations. Considering the criteria of the Committee Genetic Screening of the 
Health Council a number of gaps in knowledge are noticed, for example the 
psychological and social consequences of screening in The Netherlands are not 
examined sufficiently. In the last part of the chapter recommendations for further 
research are made. A pilot study for preconceptional screening in The Netherlands is 
proposed in which the psychosocial aspects of screening should be investigated. 
Because the knowledge of screening for carriers of the fragile X syndrome gene is not 
sufficient to consider a screening programme, a pilot study is proposed in which the 
prevalence of carriers is examined and in which the attitude of Dutch women towards 
fragile X syndrome screening is analysed. Furthermore, the development of a general 
computer model for analysing both separate and combined genetic screening 
programmes is proposed so that a standardised and comparable way of performing 
cost-effectiveness analysis is possible. 
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In dit proefschrift worden de kosten, effecten en besparingen van genetische 
bevolkingsonderzoeken (screening) naar dragerschap van cystische fibrose en het 
fragiele X syndroom bestudeerd. In hoofdstuk 1 wordt genetische screening in het 
algemeen beschreven waarbij aandacht geschonken wordt aan de verschillende 
tijdstippen in het leven waarop genetische screening uitgevoerd kan worden: 
prenatale screening (screening van zwangere vrouwen), preconceptionele screening 
(screening van niet-zwangere vrouwen met een kinderwens), scholieren screening 
(screening van 16-jarige scholieren in het laatste jaar van het verplichte onderwijs) en 
neonatale screening (screening van pasgeborenen). Verder worden in dit hoofdstuk 
criteria besproken waaraan een genetisch bevolkingsonderzoek in de ogen van de 
Commissie Genetische Screening van de Gezondheidsraad moet voldoen, en wordt in 
het laatste deel verschillende vormen van economische evaluatie gepresenteerd. 
Hoofdstuk 2 geeft een inleiding tot de ziekte cystische fibrose, een genetische 
aandoening met onder andere steeds terugkerende longontstekingen, problemen 
met het spijsverteringskanaal, een hoog zoutgehalte in het zweet, ondervoeding en 
fertiliteitproblemen. Cystische fibrose is een autosomaal recessieve aandoening, wat 
betekent dat aileen paren waarin beide partners een aangedaan gen hebben het 
risico lopen op een kind met cystische fibrose. Omdat ongeveer 1 op de 30 personen 
in Nederland het aangedane gen hebben, heeft ongeveer 1 op de 3.600 
pasgeborenen in Nederland cystische fibrose. De meeste patienten krijgen dagelijks 
fysiotherapie en gebruiken vaak een antibioticakuur om longinfecties te bestrijden. In 
de peri ode 1985-1990 werd meer dan 50% van aile patienten ouder dan 27 jaar. Door 
de ontdekking van het aangedane gen in 1989 en de ontwikkeling van simpele 
technische methoden om de meest voorkomende mutaties in het gen te detecteren is 
bevolkingsonderzoek op (dragerschap van) cystische fibrose mogelijk geworden. In 
het laatste deel van het hoofdstuk worden de mogelijkheden en onmogelijkheden 
van zo'n bevolkingsonderzoek beschreven. 
Hoofdstuk 3 beschrijft een dagboekenquete naar de ziektekosten van patienten met 
cystische fibrose buiten het ziekenhuis. Dagboeken werden verzonden naar 
73 patienten met cystische fibrose die onder controle waren in twee Nederlandse 
ziekenhuizen: het Leyenburg ziekenhuis in's Gravenhage en het Beatrix 
Kinderziekenhuis in Groningen. In totaal 14 (ouders van) kinderen en 33 volwassenen 
- 221-
Samenvatting 
vulden de vragenlijst in. De gemiddelde kosten buiten het ziekenhuis bedragen 
€6.944 per kind per jaar (bereik €1.065-19.852) en €15.322 per volwassene (bereik 
€2.473-39.751). Medische zorg buiten het ziekenhuis is verantwoordelijk voor 8% van 
deze kosten voor kinderen en 5% voor volwassenen, hUishoudelijke hulp voor 
respectievelijk 15% en 9%, dieet voor 10% en 7%, reiskosten wegens de ziekte voor 
4% en 8%, medicatie voor 63% en 67%, en hulpmiddelen en speciale voorzieningen 
thuis, ophet werk of op school voor 1% en 4%. De conclusie van de analyse luidt dat 
kosten van ziekte buiten het ziekenhuis erg hoog zijn voor patienten met cystische 
fibrose, en dat deze ongeveer de helft uitmaken van de totale (medische en niet-
medische) kosten van cystische fibrose gedurende het leven van een patient. 
In hoofdstuk 4 worden de totale kosten van zorg van Nederlandse patienten met 
cystische fibrose in 1990 en 1991 besproken. De leeftijdspecifieke medische 
consumptie is geschat met behulp van een statusonderzoek en de enquete die 
besproken is in hoofdstuk 3. Onderscheid is gemaakt tussen kosten van 
ziekenhuiszorg, medicatie in en buiten het ziekenhuis, en thuiszorg. De kosten per 
jaar zijn berekend door de jaarlijkse hoeveelheid zorg te vermenigvuldigen met de 
kosten per eenheid zorg. Gemiddeld waren de jaarlijkse kosten in 1991 gelijk aan 
€16.319 (ziekenhuiszorg 42%, medicatie 37%, thuiszorg 20%). De kosten van 
cystische fibrose in Nederland, met ongeveer 1.000 patienten, zijn geschat op ruim 
€16 miljoen per jaar; dit is 0,07% van het totale gezondheidszorgbudget. Ais de 
overleving in beschouwing wordt genomen en de kosten met 5% per jaar worden 
verdisconteerd naar het geboortejaar van een patient, zijn de kosten gedurende het 
hele leven van een patient gelijk aan een kleine €250.000. 
De resultaten van de hoofdstukken 3 en 4 worden gebruikt in de in hoafdstuk 5 
gepresenteerde analyse naar de kosten, effecten en besparingen van een 
bevolkingsonderzoek op dragerschap van het cystische fibrose-gen. Hiertoe is een 
algemeen computermodel geconstrueerd waarmee prenatale, preconceptionele, 
scholieren, en neonatale dragerschapsscreening wordt geevalueerd. Voor de 
prenatale en preconceptionele screening zijn twee strategieen bekeken: stapsgewijs 
en gelijktijdig screenen van paren. In de stapsgewijze strategie wordt eerst een 
partner getest op dragerschap, en aileen als deze drager is wordt de tweede partner 
getest; in de gelijktijdige strategie worden beide partners getest op dragerschap. Van 
aile screeningsstrategieen geeft neonatale screening de meeste dragerschapsparen 
(112 paren) de mogelijkheid van een gernformeerde keuze omtrent reproductie, met 
op de tweede plaats prenatale screening met 63 paren. Prenatale en stapsgewijze 
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preconceptionele screening op dragerschap van het cystische fibrose-gen hebben in 
Nederland een gunstige kosten-besparingsbalans onder wijd uiteenlopende 
aannames, waarbij stapsgewijze prenatale screening het meest bespaart (€1,5 
miljoen per jaar). Voor gelijktijdige preconceptionele screening en neonatale 
screening zijn relatief gunstige aannames over opkomst bij screening, keuze voor 
prenatale diagnostiek en ge'induceerde abortus nodig om een gunstige kosten-
besparingsbalans te verkrijgen, terwijl dragerschapsscreening van scholieren een 
ongunstige balans heeft onder uiteenlopende aannames (in de basisvariant zijn de 
kosten van scholierenscreening €2 miljoen hoger dan de besparingen). De conclusie 
van de analyse luidt dat kosten geen obstakel zullen vormen voor prenatale of 
stapsgewijze preconceptionele screening. 
Hoofdstuk 6 bespreekt het fragiele X syndroom, de meest voorkomende oorzaak van 
mentale retardatie waarbij een enkel gen betrokken is. Veel patienten met het 
fragiele X syndroom hebben fysieke symptomen of gedragsstoornissen zoals een 
hoog voorhoofd, grote vooruitstekende oren, vergrote testikels, hyperactiviteit, 
overmatige verlegenheid en autistische kenmerken. De symptomen zijn milder bij 
vrouwen met het fragiele X syndroom dan in mannen. In de meeste gevallen is een 
grote verhoging van het aantal CGG-herhalingen in een deel van het fragiele X gen 
(volle mutatie) de oorzaak van het fragiele X syndroom. Mensen met een kleiner 
aantal herhalingen in het gen (zogenaamde premutaties) hebben geen symptomen, 
maar vrouwen met een premutatie hebben wei kans op een kind met het fragiele X 
syndroom doordat de premutatie 'groeit' tot een volle mutatie. Mannen met een 
premutatie kunnen de premutatie wei doorgeven aan hun kind, maar deze zal niet 
doorgroeien naar een volle mutatie. Dit betekent dat mannen met een premutatie 
geen kans hebben op een kind met het fragiele X syndroom. Omdat mannen met het 
fragiele X syndroom bovendien (bijna) geen kinderen krijgen, hoeven in een 
eventlleel screeningsprogramma aileen vrouwen getest te worden. In het laatste deel 
van het hoofdstllk wordt screening op dragers van het fragiele X gen beschreven. 
De kosten, effecten en besparingen van een bevolkingsonderzoek op het fragiele X 
gen worden besproken in hoofdstuk 7. Prenatale screening detecteert het hoogste 
aantal dragers en voorkomt de geboorte van de meeste patienten met het fragiele X 
syndroom. De kosten per gedetecteerde drager zijn ongeveer gelijk voor aile 
screeningsstrategieen (€40.000), en aile screeningsstrategieen hebben een gunstige 
kosten-besparingsbalans: €12 miljoen voor prenatale screening, €8 miljoen voor 
preconceptionele screening en €2 miljoen voor screening van scholieren. Dit 
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betekent dat er vanuit het gezichtspunt van kosten geen obstakels zijn voor fragiele X 
syndroom dragerschapsscreening, en dat de beslissing om wei of niet te screenen 
zich kan concentreren op medische, socia Ie, psychologische en ethische aspecten. 
Een andere strategie om dragers te detecteren, beschreven in hoofdstuk 8, is cascade 
testen (testen van familieleden van een patient) op het fragiele X syndroom. Met een 
computer-simulatiemodel zijn 100.000 stambomen van vijf generaties geconstrueerd 
en is gekeken wat het maximaal aantal gedetecteerde dragers is voor drie scenario's: 
1. aileen eerstegraads verwanten van de patient worden getest; 2. verwanten tot in de 
derde graad worden getest; 3. verwanten tot in de vijfde graad worden getest. In de 
opstartfase van een cascade-programma worden 19% van de paren die een kind met 
het fragiele X syndroom zullen krijgen gedetecteerd. Na deze opstartfase zal een 
cascade-programma 8% Van de nog niet gedetecteerde paren die een kind met het 
fragiele X syndroom zullen krijgen opsporen als aileen eerstegraads verwanten 
worden getest, 13% als eerste- tot derdegraads verwanten worden getest, en 16% als 
eerste- tot vijfdegraads verwanten worden getest. Dit betekent dat minimaal acht 
generaties getest moeten worden om 90% van aile dragers te vinden. De resultaten 
van de analyse laten zien dat de effectiviteit van cascade testen niet groot is, maar 
waarschijnlijk is de kosteneffectiviteit wei gunstig. 
De vraag is of aflOnderlijke genetische screeningsprogramma's gecombineerd 
lOuden kunnen en moeten worden (hoofdstuk 9). De voordelen van een 
gecombineerd programma zijn dat het paar met slechts een screeningsaanbod en 
een counselingsessie wordt geconfronteerd, en dat er efficientie-effecten in de kosten 
van bijvoorbeeld organisatie en informatie zullen optreden. Daarom is gekeken naar 
een combinatie van een screeningsprogramma op dragerschap van cystische fibrose 
en het fragiele X syndroom. Omdat, uitgezonderd enkele kosten, aile aannames gelijk 
zijn genomen aan de aannames in de analyses van hoofdstuk 5 en 7, verschillen de 
effectmaten (zoals het aantal gedetecteerde paren en het aantal voorkomen 
patienten) van een gecombineerd programma niet met die van afzonderlijke 
screeningsprogramma's. De conclusie van deze analyse is dat er inderdaad 
aanzienlijke voordelen behaald kunnen worden bij het combineren van 
screeningsprogramma's op dragerschap van cystische fibrose en het fragiele X 
syndroom; 
In hoofdstuk 10 tenslotte worden de onderzoeksresultaten samengevat waarna een 
geactualiseerde analyse van de kosten, effecten en besparingen van 
preconceptionele screening op dragerschap van het cystische fibrose-gen wordt 
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gepresenteerd. Zo is bijvoorbeeld het aanbevolen verdisconteringpercentage 
verlaagd van 5% naar 3% en zijn er nieuwe screeningstesten geanalyseerd. Bij de 
geactualiseerde analyse is preconceptionele screening kostenbesparend voor drie van 
de vier onderzochte testcombinaties, maar is gelijktijdige preconceptionele aileen 
kostenbesparend voor een van de vier testcombinaties. Bij het nalopen van de criteria 
van de Commissie Genetische Screening van de Gezondheidsraad worden een aantal 
leemtes in kennis geconstateerd, waarbij vooral de psychologische en sociale 
gevolgen van screening in Nederland nog niet voldoende zijn onderzocht. In het 
laatste deel van het hoofdstuk worden onderzoeksaanbevelingen gedaan. Zo wordt 
onder meer gepleit voor een vooronderzoek in Nederland naar preconceptionele 
screening op dragerschap van het cystische fibrose-gen waarin vooral de 
psychosociale aspecten van screening onderzocht moeten worden. Aangezien de 
kennis van screening op dragerschap van het fragiele X syndroom nog niet 
toereikend is om een screeningsprogramma nu reeds te overwegen wordt 
voorgesteld eerst een vooronderzoek uit te voeren waarin de prevalentie van 
dragerschap wordt onderzocht, en waarin de houding van de Nederlandse vrouwen 
jegens fragiele X syndroom screening wordt bekeken. Tevens wordt voorgesteld een 
algemeen computermodel te ontwikkelen voor zowel afzonderlijke als 
gecombineerde genetische screeningsprogramma's zodat een gestandaardiseerde en 
daardoor onderling vergelijkbare manier van kosteneffectiviteitsanalyse voor diverse 
genetische screeningsprogramma's kan worden bereikt. 
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Dankwoord 
Een proefschrift is een hele bevalling, maar gelukkig waren er vele preconceptionele 
hulpen. Ais eerste zou ik mijn promotoren willen bedanken. Dik, jouw deur stond 
letterlijk en figuurlijk altijd voor me open. Je gaf me de vrijheid om zelf mijn weg in de 
wetenschap te zoeken, maar als ik een gids nodig had kon ik bij je binnenvallen en 
maakte je tijd voor me vrij. Mijn tweede promotor bracht mij in contact met de 
boeiende wereld van de genetica. Beste leo, bedankt voor je nauwgezette, zinnige, 
zinvolle en op tijd ingestuurde commentaar op aile stukken en manuscripten. 
De derde persoon die ik wi! bedanken is Dr. Christiaens. Beste lieve, bedankt voor je 
aanstekelijke enthousiasme en voor het feit dat jij me hebt laten inzien dat er ook nog 
gezonde kindertjes geboren worden, wat steeds minder vanzelfsprekend wordt als je 
aileen maar zieke kinderen geboren laat worden in je computer. 
Fijne en gezellige kamergenoten zijn belangrijk. Peter en Petra, hoewel jullie andere 
ziektes bestudeerden dan ik hebben we vaak lekker kunnen praten, roddelen en 
lachen over werk en prive. Juist dit soort praatjes maken het verschi! tussen 
kamergenoten en fijne kamergenoten. 
Ook de verschillende coauteurs en de mensen die een bijdrage hebben geleverd in de 
vorm van een persoonlijke mededeling in de artikelen moeten genoemd worden. 
Zonder jullie op- en aanmerkingen zouden de meeste artikelen in dit proefschrift niet 
tot stand kunnen zijn gekomen, en zou in ieder geval de kwaliteit veel minder 
geweest zijn. Ook jullie hebben ervoor gezorgd dat de computermensen in mijn 
model in mijn gedachte tot leven hebben kunnen komen. 
Rob, Harry en Paul moet ik bedanken voor de gelegenheid die ze mij hebben gegeven 
om mijn proefschrift af te maken. Inderdaad heeft het prostaatproject niet altijd mijn 
volledige aandacht gekregen doordat het afronden van mijn proefschrift meer tijd en 
energie kostte dan verwacht, maar al het werk kan nu ingehaald worden. 
Mijn voedertijdmaatjes Ivar, Michel, Roel, Ton, Yolande en Daniella verdienen een 
bedankje voor de gezellige praatjes onder het eten. Het is zo belangrijk om onder het 
eten even niet aan werk te den ken. Misschien kwam het niet altijd zo over, maar al die 
plagerijen waren ook echt als grap bedoeld. 
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Twee maatjes verdienen een extra vermelding: mijn paranimfen Barry en Hans. Barry, 
steeds weer weet je alles in korte tijd gedaan te krijgen als de ambtelijke molens te 
langzaam draaien. Volgens mij kan jij zo promoveren in de organisatiekunst. Hans, je 
luisterde altijd aandachtig als ik weer eens een nieuwe computer of 
computerprogramma wilde hebben, en meestal kreeg ik het dan ook nog. Ik hoop dat 
ik niet al te lastig ben geweest met al mijn computer-betweterigheid. 
Lieve Rien en Coby, dit proefschrift is voor een groot deel ook jullie werk. Jullie zijn er 
altijd als ikjullie nodig heb, en niets was te moeilijk of te lastig. Jullie hebben me erg 
verwend, maar ik hoop dat ik me niet zo gedraag. Ik weet dat jullie trots op me zijn, en 
ik ben trots op jullie. 
Tot slot wil ik mijn steun en toeverlaat bedanken. Lieve Anita, je weet hoe belangrijk 
het is een goede mix te vinden tussen hard werken en ontspannen. Vooral voor de 
laatste Was jij onontbeerlijk voor mij. Bovendien herinnerde je me er ook vaak aan dat 
er ook nog zoiets als een proefschrift bestond als ik weer eens te veel tijd had besteed 
aan MISCAN. Maar je weet het: computeren is voor mij altijd leuker dan het schrijven 
van een laatste hoofdstuk van een proefschrift. Bedankt voor je onvoorwaardelijke 
liefde en steun. 
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